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Sequence variation in gene promoters is often associated with disease risk. In this study, a 1,418 
bp sequence of the 5´-flanking region of the APOH (encoding for β2-glycoprotein I) has been 
functionally characterized by in vitro analysis.  Associations of APOH promoter SNPs with 
systemic lupus erythematosus (SLE) risk and related phenotypes along with their effect on 
human plasma β2GPI levels were examined. Transient transfections, dual-luciferase reporter 
gene assays were performed in COS-1 and HepG2 cells. HepG2 nuclear extracts was used for 
electrophoretic mobility shift assay (EMSA). A case-control design and genotyped 345 SLE 
women and 454 healthy control women for 12 APOH promoter single nucleotide polymorphisms 
(SNPs) (-1284C>G, -1219G>A, -1190G>C, -1076G>A, -1055T>G, -759A>G, - 700C>A, -
643T>C, -627A>C, -581A>C, -363C>T -38G>A, and -32C>A). Haplotype analyses were 
performed using EH (Estimate Haplotype-frequencies) and Haploview programs. Deletion 
analysis localized the core promoter of APOH ~160 bp upstream of ATG codon with the 
presence of critical cis-acting elements between -166 and -65. Functional relevance for three 
SNPs (-1219G>A, -643T>C and -32C>A) that resulted in lower promoter activity (51%, 40% 
and 37%, respectively) as compared to the wild-type alleles in COS-1 cells. EMSA demonstrated 
HepG2 nuclear protein(s) bind to the elements located in the regions of the three SNPs. Overall 
haplotype distribution of the APOH promoter SNPs was significantly different between cases 
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and controls (P = 0.009). The -643C allele was found to be protective against carotid plaque 
formation (adjusted OR = 0.37, P = 0.013) among SLE patients. Three-site haplotype analysis 
revealed one haplotype carrying -32A to be significantly associated with decreased plasma β2GPI 
levels (P < 0.001) and another haplotype harboring the minor allele for -1219A showed a 
significant albeit less pronounced association (P = 0.046). Our data indicate that APOH promoter 
variants may be involved in the etiology of SLE, especially the risk for autoimmune-mediated 
cardiovascular disease.  
Public Health Significance: Cardiovascular disease is the leading cause of death in the U.S. and 
other developed nations. Understanding its pathogenesis will help in formulating newer 
therapeutic strategies and treatment that may decrease the adverse consequences of accelerated 
atherosclerosis in SLE patients. 
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1.0  INTRODUCTION 
1.1 SYSTEMIC LUPUS ERYTHEMATOSUS 
Systemic lupus erythematosus (SLE) is a prototypic autoimmune inflammatory disease that can 
affect virtually any organ system. It primarily affects premenopausal women (female:male ratio 
= 9:1) and is characterized by a plethora of clinical manifestations, including glomerulonephritis, 
arthritis, pleuritis, pericarditis and vasculitis [1]. Many theories have been advanced as 
explanations for the gender imbalance in SLE prevalence, including genetic factors, differential 
environmental and occupational exposures, and hormonal effects [2]. There is a bimodal pattern 
of mortality in SLE, with early deaths from active disease, that included renal insufficiency, 
infection, and sepsis and late deaths from cardiovascular origin [3]. Active lupus is also 
characterized serologically by high titers of circulating antibodies directed against native DNA 
(anti-DNA antibodies), and the presence of these antibodies could pre-date disease 
manifestations by many years [4]. Nephritis is a predictor of poor prognosis and a major cause of 
death in patients with active SLE [5]. 
1.1.1 Autoantibodies in SLE 
The serological hallmark of SLE is the production of autoantibodies directed against components 
of the cellular nucleus. Autoantibodies are typically present several years prior to diagnosis of 
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SLE and serve as markers for future disease in otherwise normal individuals [6]. Antinuclear 
antibodies (ANA) refer to a diverse group of antibodies that target nuclear and cytoplasmic 
antigens and have a role in transcription or translation, in the cell cycle or as structural proteins. 
The ANA test is the most common screening test used in the laboratory diagnosis of SLE. 
Virtually all patients with SLE have ANA while most patients with ANA do not have SLE. 
Antibodies to double-stranded DNA (anti-dsDNA) are of great importance in SLE and 
nephritis, since presence of anti-dsDNA and its titer have been correlated with SLE activity [7]. 
These are among the most specific autoantibodies in SLE. However, it is not particularly 
sensitive owing to the fact that it may be present transiently, occurring in only 50–60% of lupus 
patients at some point in the course of their disease [6]. Among the other autoantibodies are anti-
histone and antibodies to extractable nuclear antigens (ENA) [RNP, Sm, SS-A (Ro), or SS-B 
(La)].  
Antiphospholipid antibodies (APA) are autoantibodies associated with thrombophilic 
disorder named antiphospholipid syndrome (APS), defined by arterial and/or venous thrombosis, 
recurrent fetal loss, and neurologic disorders. APA represent a group of heterogeneous antibodies 
[anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), and anti-β2-glycoprotein I (anti-
β2GPI)] which are detected in a variety of conditions, including SLE. APA are found in ~ 1-10% 
of a general Caucasian US population versus (vs.) 30-70% in patients with SLE and APS [8-10]. 
 
1.1.2 Diagnosis of SLE 
Diagnosis is not easy as there is no single set of symptoms that are uniformly specific to SLE and 
no laboratory tests conclusively prove that a person has or does not have SLE. For an early 
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diagnosis, a complete systems review, analysis of the urine for blood and protein, a complete 
blood count that can reveal cytopenia or anaemia, liver and kidney function, ANA testing, testing 
for autoantibodies to dsDNA, Ro (SS-A), La (SS-B), nRNP, Sm autoantigens, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) levels (a high ESR with normal CRP 
levels can indicate SLE) needs to be carried out. APA should be evaluated in women with 
thrombotic events or with a history of morbidity in pregnancy. Correct diagnosis of SLE, 
whether affecting an adult or a child, requires an integration of a patient’s symptoms, physical 
examination findings and the results of diagnostic testing. The revised American College of 
Rheumatology (ACR) classification criteria is commonly used by rheumatologists to diagnose 
SLE (Table 1). In these classification criteria, a person is said to have lupus if they have 4 or 
more of the 11 criteria, either simultaneously or over time. The 1982 criteria were further revised 
in 1997 by the Diagnostic and Therapeutic Criteria Committee of the ACR to delete the lupus 
erythematosus (LE) cell preparation, which was not frequently used, and add changes in the 
immunologic disorder category. 
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Table 1. ACR Criteria for Classification of SLE 
ACR 1982 criteria ACR 1997 revised criteria 
Malar Rash Malar Rash 
Discoid Rash Discoid Rash 
Photosensitivity Photosensitivity 
Oral or nasal ulcerations Oral or nasal ulcerations 
Nonerosive Arthritis Nonerosive Arthritis 
Pleuritis or Pericarditis Pleuritis or Pericarditis 
Nephritis/Renal Disorder - Proteinuria > 
0.5g/day, or > 3+ or Cellular casts 
Nephritis/Renal Disorder - Proteinuria > 
0.5g/day, or > 3+ or Cellular casts 
Neurologic Disorder – Seizures or Psychosis Neurologic Disorder – Seizures or Psychosis 
Hematologic Disorder - Hemolytic anemia or 
Leukopenia or Lyphopenia or Thrombocytopenia 
 
Hematologic Disorder - Hemolytic anemia 
or Leukopenia or Lyphopenia or 
Thrombocytopenia 
 
Immunologic Disorder - Anti-DNA: antibody to 
native DNA or Anti-Sm: antibody to Sm nuclear 
antigen or Positive LE cell preparation or 
Biologically false-positive test for Syphilis 
 
Immunologic Disorder - Anti-DNA: 
antibody to native DNA or Anti-Sm: 
antibody to Sm nuclear antigen or Positive 
finding of antiphospholipid antibodies on: 
1. an abnormal serum level of IgG or IgM 
anticardiolipin antibodies, 
2. a positive test results for lupus 
anticoagulant using a standard method, or 
3. a false-positive test for at least 6 months 
confirmed by Treponema pallidum 
Immobilization or fluorescent treponemal 
antibody absorption test 
 
Positive Antinuclear Antibody Positive Antinuclear Antibody 
 
Adapted from Tucker, 2007 [11] 
 
1.1.3 Clinical Features of SLE 
Skin disease is the second most frequent clinical manifestation of SLE [12]. The current ACR 
classification criteria for SLE include four somewhat overlapping dermatologic criteria, butterfly 
rash, discoid lupus, photosensitivity, and oral ulcers and thus patients can be classified as having 
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SLE with only skin manifestations (cutaneous lupus erythematosus). 50–100% of SLE patients 
have fatigue, weight loss or fever in the absence of infection. Musculoskeletal problems 
(arthritis, myositis or arthralgia) and renal problems are found in SLE patients (proteinuria, 
haematuria). Haematological problems include thrombocytopenia, anaemia or leucopenia. 
Among the other complications include reticuloendothelial anomalies (splenomegaly, 
hepatomegaly); neuropsychiatric problems (seizures, psychosis); and gastrointestinal problems 
(vomiting, nausea or abdominal pain). Cardiac abnormalities are seen in 15% of patients 
(endocarditis, pericarditis or myocarditis). Pulmonary problems are seen in 2–12% of the 
affected (pulmonary hypertension). Both clinically and scientifically, the variable organ 
manifestations of SLE pose a particular challenge to rheumatologists. Validated scores for 
disease activity of SLE include British Isles Lupus Assessment Group (BILAG) index, the 
European Consensus Lupus Activity Measurement (ECLAM), the Systemic Lupus Activity 
Measure (SLAM), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the 
Lupus Activity Index (LAI). In addition to the assessment of disease activity, the evaluation of 
damage using the validated SLICC/ACR damage index and health-related quality of life (MOS 
SF-36) is also advised for clinical research [13]. 
 
1.1.4 SLE and Cardiovascular Risk 
A large body of evidence indicates that aCL are significantly associated with thrombotic events 
in patients with SLE [14]. Several subsequent reports have supported an increased cardiovascular 
risk among SLE patients. Cohort studies have shown that the increased cardiovascular risk in 
SLE patients cannot be fully explained by the higher prevalence of traditional risk factors such as 
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hypertension and dyslipidemia and that disease-specific factors play an additional role [15-17]. 
Several studies have recently demonstrated that risk factors for cardiovascular disease (CVD) in 
SLE are both traditional and nontraditional risk factors acting in concert [18]. Traditional risk 
factors implicated in SLE include, for example, dyslipidemia (especially high triglycerides), 
hypertension, and renal disease. While non-traditional risk factors such as inflammation, APA 
and low-density lipoprotein (LDL) oxidation are also associated with CVD in SLE. Many reports 
have been published that have assessed the prevalence and risk factors for the development of 
accelerated atherosclerosis in SLE patients [19]. Case-control studies confirmed that 
atherosclerosis develops prematurely, independently of traditional risk factors for CVD [20, 21]. 
Premature coronary heart disease (CHD) is a major cause of morbidity and mortality in SLE 
patients; more pronounced in younger women (35-44 years) for whom the estimated risk is more 
than 50 fold [22]. Although the pathogenesis of vascular disease in SLE is unknown, it is thought 
to be multifactorial and of atherosclerotic origin. Atherosclerosis involves both atherosis (fatty 
degeneration) and sclerosis (vessel stiffening). Both of these processes can be evaluated with 
noninvasive ultrasound imaging techniques. Atherosis in the carotid arteries is evaluated using 
B-mode ultrasound, which measures the degree of focal plaque and intima-media wall thickness 
(IMT). Vascular stiffness is evaluated using pulse-wave velocity (PWV), which measures the 
rate at which arterial pulse waves move along the vessel. Plaque and IMT are measures of the 
structural properties of the arterial wall, whereas vascular stiffness is a measure of the functional 
properties. Longitudinal studies have shown that all three of these subclinical measures of CVD 
are significant predictors of future cardiovascular events and mortality [23]. Both carotid IMT 
and plaque progression can be measured using B-mode ultrasound in women with SLE. Using 
these modalities, increased rates of carotid focal plaque (37.1% vs. 15.2%) [20] and coronary 
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calcium (30.7% vs. 8.7%) [24] have been reported in women with SLE compared with controls. 
Plaque progression appears to be greater in women with SLE than in healthy women, and 
monitoring its progression may be more useful than monitoring IMT in women with SLE. Rates 
of progression of both IMT and plaque have been related to both SLE-associated and traditional 
risk factors, and these may work together to increase CVD risk [23]. To date, IMT and plaque 
assessment have not been used in longitudinal studies of women with SLE to evaluate rates of 
progression and the factors that predict change in subclinical atherosclerosis. Recently, 
Thompson et al (2008) [25] have reported the use of carotid B-mode ultrasound as a surrogate 
end point in future clinical trial to examine the efficacy of CVD prevention strategies in SLE 
patients. The three major steps to SLE-related atherogenesis are illustrated in Figure 1: (A) 
Endothelial injury and leukocyte recruitment, (B) Foam cell formation and progression to the 
fibrous plaque, and (C) Plaque rupture and thrombosis. Endothelial injury and leukocyte 
recruitment that can act as autoantigens promote local inflammation, foam cell formation and 
development of fibrous plaque [26]. This unchecked inflammatory response can lead to 
increased vulnerability of the plaque to rupture and to form an acute occlusive thrombus. 
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 Figure 1. Three major steps involved in the vascular biology of atherogenesis seen in SLE 
From Kao et al. 2003 [26] 
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1.1.5 SLE and Lupus Nephritis 
Lupus nephritis is a serious manifestation in SLE, which affects over half of the SLE population, 
and could result in either acute or chronic renal failure. Cardinal features of lupus nephritis 
include the deposition of immunoglobulins within the glomerular and tubular basement 
membranes and amplification of local inflammatory responses, leading ultimately to renal 
fibrosis. Renal involvement in SLE is an important cause of morbidity and mortality, reaching a 
prevalence of 39% during the course of the disease [5] . Kidney involvement in patients with 
SLE is a common and serious complication that is often associated with a poor long-term 
prognosis. Aggressive immunosuppression is effective in controlling renal lupus flares and has 
improved disease outcomes, but is associated with significant morbidity (infection, malignancy, 
metabolic disturbances, infertility) and mortality [27]. While many different immunologic and 
non-immunologic factors contribute to disease expression in lupus nephritis, a large body of 
evidence suggests that the production of anti-DNA antibodies and the formation of glomerular 
immune deposits are important initial events in the pathogenesis of the disease [28]. The 
diversity of clinical presentations of lupus nephritis parallels the diversity of pathologic lesions 
seen in the kidneys of patients with SLE [29]. Renal manifestations range from asymptomatic 
hematuria (presence of red blood cells in urine) or proteinuria (presence of excess serum proteins 
in urine) to overt nephritic and nephrotic syndromes, rapidly progressive glomerulonephritis, and 
chronic renal failure. The criterion for diagnosis of a renal disorder includes the presence of: a) 
persistent proteinuria of greater than 0.5 g per day (or greater than 3+ urine dipstick reaction for 
albumin), or b) cellular casts, including red blood cell, hemoglobin, granular, renal tubular cell, 
or mixed. Urinalysis is one of the most important and effective methods to detect and monitor 
the activity of lupus nephritis [30]. Depression of classic complement pathway components and 
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high titers of anti-DNA, anti-nucleosome, or anti-C1q antibodies identify patients are increased 
risk of renal involvement or flares of nephritis [29]. Compelling evidence suggests that anti-
DNA antibodies, in addition to being an important diagnostic marker, are also actively involved 
in the pathogenesis of lupus nephritis through their ability to bind to cell surface antigens or 
components of the glomerular basement membrane either directly (cross-reactivity) or indirectly 
(via chromatin material) [31]. 
 
1.1.6 Epidemiology of SLE 
SLE is a heterogeneous disease with a multifactorial aetiology. There is now enough evidence to 
support ethnic and geographical variations in the manifestations of SLE including disease 
frequency, serological changes, organ involvement and overall prognosis. There are several 
studies of SLE prevalence and incidence in different areas of the world. Danchenko et al. (2006) 
[32] have summarized the results of over 60 such studies. A number of studies carried out in 
North America have shown Hispanics and American Blacks to have an excess morbidity from 
SLE and a younger age of onset than Caucasians [33-35]. Similar studies have also shown 
evidence for an excess in the prevalence of SLE among Orientals as compared to Caucasians 
[33]. The lowest incidences of SLE were seen among Caucasian Americans, Canadians and 
Spaniards with incidences of 1.4, 1.6 and 2.2 cases per 100,000 people respectively. Throughout 
Europe, the highest incidences were found in France (5 cases/100,000), Sweden (4.7 
cases/100,000), and in Asian (10 cases/100,000) and Afro-Caribbean (21.9 cases/100,000) 
residents of the UK. The prevalence patterns summarized by Danchenko et al. (2006) [32] were 
similar to those of incidence, but no clear north–south or east–west pattern emerged. A higher 
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prevalence of SLE among people of sub-Saharan African descent living in North America, the 
Caribbean and Europe, compared with residents of sub-Saharan Africa, was summarized by Bae 
et al. (1998) [36]. Whether these variations are secondary to genetic differences or environmental 
changes such as socioeconomic status, availability of healthcare facilities, certain toxins, and 
dietary habits is not fully understood. However, it is likely to be due to interplay of these known, 
and other yet unrecognized factors.  
 
1.1.7 Childhood SLE 
SLE is a relatively rare disease in childhood, with estimated incidence ranging from 10 to 20 per 
100,000 children, depending on the ethnic population [11]. Approximately 15% of individuals 
with SLE will have the onset of their disease prior to the age of 18 years; children and 
adolescents generally have a more severe disease presentation, develop disease damage more 
quickly than adults with SLE and have a higher overall burden of disease over their lifetimes 
[37]. The 1997 ACR classification criteria for SLE, which are, in general, used as diagnostic 
criteria among adult rheumatologists, are appropriate for use in children and adolescents. The 
pattern of clinical and serologic presenting features in children and adolescents with SLE is 
different in general from the adult SLE population, with a more severe disease onset in general. 
Early and accurate diagnosis of SLE in children and adolescents is crucial for initiating treatment 
to prevent damage. 
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1.1.8 Genetic Model of SLE 
Genetic factors play an important role in SLE susceptibility, as reflected by heritability of up to 
66% [38] and a 20-80 times greater risk for family members [39]. Concordance rates in twin 
studies range from 2% to 5% for dizygotic twins and 24–60% for monozygotic twins [40-42]. 
The current model for the development of autoimmune disease such as SLE involves multiple 
different susceptibility genes interacting with a variety of potential environmental exposures 
(Figure 2). Several environmental (or non-genetic) factors have been discussed in SLE 
susceptibility, including viruses, hormones, smoking, alcohol intake, exposure to aromatic 
amines, pesticides, silica, organic solvents, heavy metals and ultraviolet light, as well as dietary 
factors such as alfalfa sprouts and saturated fats [43]. Environmental exposures may lead to the 
production of autoreactive T cells and autoantibodies, the stimulation of pro- and anti-
inflammatory cytokines, and target end-organ damage, but are not very convincing as agents 
causing SLE. Hormones have multiple influences on the regulation of the immune system and 
profound effects in murine models of lupus [44]. Menopausal factors such as menopausal status, 
age at menopause and postmenopausal hormone (PMH) therapy also have been evaluated as risk 
factors for SLE. The association of hair dyes with the risk of lupus has been examined in several 
other case-control studies in a variety of settings [45] and none or only a very weak association 
was found. Ultraviolet light is a well-known factor capable of eliciting a flare in SLE patients 
[46]. This is thought to be dependent on the capacity of particularly ultraviolet B (UVB) to 
induce apoptosis in keratinocytes due to formation of reactive oxygen species (ROS) and by 
direct DNA damage, but may also be related to altered cytokine expression patterns or effects of 
vitamin D production [47]. The anti-SS-A/Ro antibody is the most closely associated with 
photosensitivity in SLE patients. Studies exploring the role of socioeconomic factors as risk 
 12 
factors for SLE are limited, although poorer outcomes and higher disease activity have been 
associated with measures of socioeconomic status [48]. In SLE, epigenetic mechanisms has been 
proposed as important, possibly being the target for drugs and environmental factors thus 
mediating the interaction between genes and the environment [49]. 
 
 
Figure 2. Role of Environment in the pathogenesis of SLE 
From Sarzi-Puttini et al. 2005 [46] 
 
1.1.9 Genetics of SLE 
To date, two high-density case-control genome-wide association analyses have been published 
for SLE that have provided further support for several existing SLE susceptibility genes and have 
also helped to identify novel candidate genes [50, 51]. One study by The International 
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Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) used a cohort of 720 SLE 
cases and 2337 controls. Genotyping was performed using the Illumina HumanHap 300 
BeadChip, resulting in the successful genotyping of over 300 000 SNPs [50]. The second study 
used a cohort of 1311 cases and 1783 controls [51]. This study used the Illumina HumanHap550 
bead chip, resulting in over 500 000 SNPs successfully genotyped. Both studies confirmed strong 
genome-wide significance for the established susceptibility genes, the major histocompatibility 
complex (MHC) locus, interferon regulatory factor 5 (IRF5) and signal transducer and activator 
of transcription 4 (STAT4). Additional risk loci were identified for SLE susceptibility including B 
cell receptor signaling (B-lymphoid tyrosine kinase), BLK–C8orf13 on chromosome 8 and 
integrin, alpha M complement component 3 receptor 3 subunit (ITGAM) and integrin, alpha X 
complement component 3 receptor 4 subunit (ITGAX) on chromosome 16. 
 
1.1.10 Current SLE Candidate Genes  
Linkage has proven a rather poor way to actually identify candidate genes in lupus. True 
candidates have been identified by a variety of other methods including association studies, 
mouse work, expression data and studies in other diseases. The human MHC on chromosome 
6p11-21 has shown the most consistent and significant linkage and association of all the lupus 
susceptibility genes [52]. The SLEGEN genome wide association analysis has now provided 
evidence of independent signals arising from both human leukocyte antigen (HLA) Class II and 
Class III regions [50]. Even before the genome-wide association studies, there was growing 
evidence to implicate IRF5 as an important SLE susceptibility gene. The type I interferon (IFN-α 
and -ß) system has been proposed as having a pivotal role in the development and maintenance 
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of the disease process in SLE [53]. Three functional polymorphisms have been identified  in 
IRF5 that are associated with SLE susceptibility; SNP rs2004640 where the associated T allele 
creates a donor splice site allowing expression of several unique IRF5 isoforms [54-56], a second 
mutation rs10954213 located in the 3´untranslated region (3´UTR) that creates a functional 
polyadenylation site and hence a shorter and more stable gene transcript [55], and an 
insertion/deletion in the 6th exon that defines the isoforms of IRF5 that are translated into protein 
[57].The best current genetic model for IRF5 is a SLE risk haplotype carrying functional 
mutations that is associated with higher serum IFNα activity in SLE patients positive for either 
anti-RNA binding protein or anti-dsDNA autoantibodies [58]. The broad range of immunological 
function of candidate genes highlights the complexity of lupus pathogenesis. To some extent 
they may be grouped into functional categories. Complement component C1q, mannose binding 
lectin (MBL) and C- reactive protein (CRP) may affect availability of nuclear antigens [59]; 
tyrosine kinase (TYK2) [54] and toll-like receptors (Tlr7) (mouse) [60] are involved in the 
activation of innate immune mechanisms; cytotoxic T lymphocyte antigen-4 (CTLA4) [61], 
programmed cell death 1 (PDCD1) [62, 63], protein tyrosine phosphatase nonreceptor 22 
(PTPN22) [64] and the signaling lymphocyte activation molecule (SLAM) genes (mouse) [65] 
affect the activity and survival of potentially autoreactive B- and T-cells; while the 
immunoglobulin Fc γ receptor genes [66] play an important role in the regulation of the humoral 
induced-immune response. Among the other candidate genes included are ITGAM [67], STAT4 
[68], BLK [51], B-cell scaffold protein with ankyrin repeats (BANK1) [69], and tumor necrosis 
factor superfamily 4 (TNFSF4) [70]. Recent reports have identified SNPs in the tumor necrosis 
factor alpha–induced protein 3 (TNFAIP3) region to be associated in the etiology of SLE among 
individuals of European ancestry [71]. The TNFAIP3 encodes an ubiquitin editing enzyme, A20 
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that restricts NF-KB–dependent signaling and prevents inflammation. Recently, a ‘genetic 
hypothesis’ was postulated elucidating the role of key SLE candidate genes in the immunological 
mechanisms associated with SLE disease pathogenesis (Figure 3) [72].  
 
 
  
Figure 3. Proposed mechanism for the role of key candidate genes in the SLE pathogenesis 
From Rhodes and Vyes, 2008 [72]. Genes are italicized within cells that are sites of their 
primary expression 
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1.1.11 Prognosis and Preventive strategies in SLE 
The prognosis of patients with SLE has improved tremendously in the past few decades. While 
the 5-year survival of SLE was below 50% in the 1950s, recent studies report survival of 85% at 
10 years and 75% at 20 years [73]. The main reasons for this improvement are the efficacy of 
current treatment protocol and the development of laboratory tests to detect ANA, which has 
made the early diagnosis of SLE easier in a great amount of cases. Despite the improvement of 
SLE short- and medium term survival observed in the last decades, the long-term prognosis of 
these patients remains poor, mainly due to complications of the disease and/or of its treatment. 
Therefore, long-term prognosis in SLE can be improved by adopting strategies early in the 
disease course that can contribute to reducing long-term complications, including screening for 
and prophylaxis against infections, control of  risk factors for atherosclerosis, and cancer 
surveillance [74]. Infections are an important cause of hospitalization and death in SLE. All 
types of infections have been reported: bacterial, viral and opportunistic [46]. Among the main 
risks factors for infections in SLE, there are severe disease manifestations, particularly 
glomerulonephritis, and corticosteroid and immunosuppressant use. All patients should be 
screened for Mycobacterium tuberculosis and for viral infections, including human 
immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV), before 
starting treatment with corticosteroids and immunosuppressants. Regular surveillance and 
control of traditional risk factors is mandatory, and so is the appropriate use of the statins, anti-
malarial agents, anti-platelet agents, and anti-coagulation for primary and secondary prevention 
of arterial thromboembolism in SLE patients [75]. Control of disease activity and/or severity 
using the lowest effective dosage of corticosteroids is also recommended. For prevention and/or 
early diagnosis of malignancies, it is important that SLE patients regularly undergo the age-
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related specific cancer screening recommended for the general population. Moreover, strategies 
directed at preventing clinical manifestations in asymptomatic ANA–positive individuals or in 
APA–positive SLE patients, as well as at preventing severe manifestations in patients with mild 
SLE at the time of the diagnosis should be considered [74]. To date; there have been only few 
high quality randomized controlled trails (RCTs) in SLE, particularly for manifestations other 
than nephritis and thus, several important issues have not been adequately addressed. 
Importantly, end-points currently used in SLE trials have not been validated in clinical trials. 
These findings underscore the need to establish international networks to facilitate clinical trials 
addressing these issues and testing new therapies. Recently, the European League Against 
Rheumatism (EULAR), have developed recommendations for the management of SLE and for 
points to consider in the design of SLE trials [76]. 
1.2 APOLIPOPROTEIN H 
Human apolipoprotein H (APOH), also known as β2-glycoprotein I (β2GPI), is a plasma 
glycoprotein first discovered in 1961 [77] (in this study, we will use APOH to refer to the gene 
as used in human genome databases and β2GPI to refer to the protein as commonly used in the 
rheumatology literature). β2GPI is a major autoantigen recognized by predominant APA found in 
sera of many autoimmune diseases such as primary antiphospholipid syndrome (PAPS) and SLE. 
The plasma concentration of this glycoprotein is approximately 20 mg/dL of which 40% is 
bound to very low-density lipoprotein (VLDL), high-density lipoprotein (HDL), and 
chylomicrons [78]. β2GPI is expressed primarily in the liver and sporadically in intestinal cell 
lines and tissues [79]. β2GPI is a major urinary protein excreted in patients with renal tubular 
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diseases such as adult Fanconi syndrome [80]. The level of APOH mRNA expressed by HepG2 
cells is downregulated when incubated with inflammatory mediators, implying that β2GPI is a 
negative acute-phase protein [81]. 
1.2.1 Structural Characterization of Apolipoprotein H 
1.2.1.1 5'-Upstream Region  
 
Primer extensions determined alternate transcription start sites (TSSs) at 31 base pairs (bp) and 
21 bp upstream of the translation start codon [82]. TSS 31 bp upstream agreed completely with 
the consensus for an initiator element (Inr) known to sustain transcription initiation. Wang and 
Chiang (2004) [83] have initially characterized the 5′-flanking region and proximal promoter of 
APOH using transient transfection assays in hepatoma cell lines. Serial deletion analysis of 
APOH 5´-flanking sequence revealed strong promoter activity in the regions between -197 to +7 
in hepatoma cells but not in HeLa cells. Several consensus sequence elements relevant for 
regulation of transcription in the liver were determined in the 5′ upstream region of APOH. Gene 
expression of APOH is governed by distinct liver-specific transcriptional regulation involving an 
atypical TATA box (TATTTA), located between positions -97 and -92 and a hepatic nuclear 
factor-1α (HNF-1α) element binding between regions -65 to -51, that play an essential role in the 
transcriptional initiation of the APOH promoter. Co-transfection of APOH promoter-luciferase 
vector with HNF-1α expression vector in Huh7 and HNF-1-deficient HeLa cells demonstrated 
the transactivation effect of HNF-1α on APOH promoter activity. In addition, overexpression of 
HNF-1α also enhanced the endogenous β2GPI expression. These results indicated that both the 
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atypical TATA box and HNF-1α cis-element are critical for APOH transcription and the HNF-
1α maybe mediating cell type-specific transcriptional regulation leading to differential 
expression of APOH in humans. 
 
1.2.1.2 Gene Structure of Apolipoprotein H  
 
The human APOH locus has been mapped to chromosome 17q23-qter using somatic cell hybrids 
[84] and was localized to chromosome 17q23–24 using fluorescent in situ hybridization [82]. 
APOH spans 18 kilobases (kb) on chromosome 17q23-24 and is comprised of eight exons that 
encode for a mature protein of 345 amino acid (aa) residues, including 19 aa in the signal peptide 
which is cleaved in the mature protein [81, 84, 85]. The 326 amino acid sequence was originally 
determined by sequencing the purified protein and was found to be one of the most proline-rich 
eukaryotic proteins with a frequent occurrence of cysteine-proline linkages at regular intervals 
[82]. APOH cDNA has been cloned and sequenced from human hepatic cells and the hepatoma 
cell line HepG2 that are major sites of biosynthesis for β2GPI [81, 84]. β2GPI is a single chain 
glycoprotein of 326 amino acid residues containing 22 cysteine (Cys) residues that form 11 
disulfide bridges and four N-linked glycosylation sites [84, 85] The positions of all 11 disulfide 
bonds in human β2GPI are identical to those seen in bovine β2GPI [86]. The amino acid sequence 
can be divided into four contiguous homologous regions of about 60 aa residues known as short 
consensus repeats (SCRs) and an additional fifth C-terminal domain. The SCRs, also known as 
GP–1 domains, sushi domains, and complement control protein (CCP) repeats are widely 
distributed in the proteins of the complement system and also in some non-complement proteins 
such as the interleukin-2 receptor and the selectin family of endothelial leukocyte adhesion 
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molecules [84]. Each β2GPI SCRs contain four invariant Cys residues that form two disulfide 
bridges in a conserved pattern of Cys-1 bound to Cys-3 and Cys-2 to Cys-4 [82]. In contrast to 
the first four SCR domains, the fifth and most C-terminal domain has six Cys residues resulting 
in three disulfide bonds that have been mapped with the disulfide linkage pattern shown to be as 
Cys 1-4, Cys 2-5, and Cys 3-6 [84].The cDNA consists of eight exons (  1.2 kb), separated by 
large introns (  16.2 kb) [82]. Exon 1 codes for the 5′-UTR and the signal peptide, SCRs 1, 3, 
and 4 are encoded by a single exon while SCRs 2 and 5 are encoded by two exons and exon eight 
also codes for the C-terminus and 3′-UTR (Figure 4).  
 
 
Exons 1               2              3                 4              5                           6                      7      8
95              177              97                 77                     189                           180       198                     155
(1-42)          (43-161)            (162-238)               (239-271)               (272-326)ATG TAA
CCP I    CCP II       CCP III         CCP IV         CCP V
NH2 COOHSig
 
Figure 4. Schematic representation of human APOH showing the intron-exon organization 
 
The positions of exons are shown as blue boxes, and introns are shown as lines connecting the 
exons. CCP repeat modules are shown below as connected rectangles. Position of translation 
initiation codon (ATG) and termination codon (TAA) are also shown. 
 
1.2.1.3 Crystal Structure of β2-glycoprotein I 
 
Crystal model of β2GPI containing 326 aa and four glycans revealed four CCP modules and a 
distinctly folded fifth C-terminal domain arranged like beads on a string to form an elongated J-
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shaped molecule [87, 88]. The four N-terminal CCP modules are arranged along their long axis 
in a slight right-handed spiral to join the distinct fifth domain (Figure 5). The secondary structure 
of each module is comprised of several short, anti-parallel β-strands wrapped around a well 
defined hydrophobic core. The structure is stabilized by two disulfide bonds that are N- and C-
terminally disposed at opposite poles of the module. The β-strands run approximately parallel 
and anti-parallel to the long axis, with the first and third turns located close to the C-terminus and 
second and fourth turns near the N-terminus. The fifth domain folds into a central β-spiral 
composed of four anti-parallel β –sheets and one short α-helix that are held together by three 
disulfide bridges in a 1–4, 2–5, 3–6 pattern. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Crystal (secondary) structures of β2GPI 
From Schwarzenbacher et al. 1999 [88] 
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1.2.1.4 Fifth Domain of β2-glycoprotein I 
 
The first four GP-I domains (~60 aa each) of β2GPI are all structurally related, while the fifth 
domain (84 aa) is the most variable and includes a cluster of lysine residues (282–287), four 
highly conserved hydrophobic amino acids (313–316), and three disulfide bonds instead of two, 
as present in each of the preceding four domains. This variable configuration of the fifth domain 
of β2GPI is essential for the binding of β2GPI to anionic phospholipids (Figure 6) [89]. 
 
 
Figure 6. Schematic diagram of the domains of β2GPI 
From de Groot and Derksen, 2005 [90]. Domain V is involved in the binding to anionic 
phospholipids while domain I contains the binding epitope for anti- β2GPI antibodies. 
 
 
 
Two common structural mutations at codon 306 and codon 316 present in the fifth 
domain directly affect the binding of β2GPI to anionic phospholipids [86, 91]. Missense mutation 
at codon 316 affects the integrity of a potential protein-lipid interaction site defined by the highly 
conserved (evolutionarily conserved in bovine, rat, mouse, dog, and human β2GPI) hydrophobic 
 23 
loop at positions 313-316 that is composed of residues leucine-alanine-phenylalanine-tryptophan, 
respectively [89]. The missense mutation at codon 306 disrupts the disulfide bond between Cys 
306 and Cys 281, which plays a key role in clustering the positively charged amino acid 
sequence motif (position 281-288) in the fifth domain. Homozygosity of 316 mutations and 
compound heterozygozity of codons 306 and 316 abolished complete binding capacity of β2GPI 
to phosphatidylserine [86]. Crystal structure of human β2GPI has confirmed that the positive 
charge cluster (281-288), the hydrophobic loop (313-316), and integrity of disulfide bonds of the 
fifth domain are all essential for the lipid-binding of β2GPI [88]. In domain V of the β2GPI, the 
substitution at position 247 of Leu to Val is correlated with anti- β2GPI antibody production in 
patients with primary APS. The Val247 allele of the Val247Leu polymorphism was significantly 
more frequent in primary APS patients with anti- β2GPI antibodies than in controls or in primary 
APS patients without anti- β2GPI antibodies in a British APS cohort [8]. Val247 allele was found 
to be associated with higher frequency as well as stronger reactivity with anti- β2GPI antibodies, 
when compared with the Leu247 allele in Asian APS patients indicating it to be a major risk 
factor for APS in Asians [9]. Val247 allele was shown to be a genetic risk factor for development 
of APS and important in the formation of β2GPI antigenicity [92]. Similarly, in a pediatric cohort 
study an association has been demonstrated for the Val247Leu substitution and both the 
development of APA, and APA-associated clinical manifestations in patients [93]. The 
significance of the position of Val247Leu polymorphism that is located between the 
phospholipid binding site in domain V and the potential epitopes of anti- β2GPI antibodies in 
domain IV was analyzed by conformational optimization [92]. Results showed that the 
replacement of Leu247 by Val247 led to a significant alteration in the tertiary structure of domain 
V and/or the domain IV-V interaction. The VV genotype at position 247 in Mexican subjects 
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was found to be significantly higher frequencies in anti- β2GPI-positive patients and in patients 
with arterial thrombosis than in anti- β2GPI-negative patients or donors [10]. Recent reports have 
shown that the Val247Leu and Trp316Ser polymorphisms in exons 7 and 8, respectively, were 
not related to the presence of anti- β2GPI antibodies in unselected Chilean patients with venous 
and arterial thrombosis, but they were significantly associated with venous and arterial 
thrombosis [94]. β2GPI could have a potential role in the pathogenesis of HBV infection in 
humans. Indeed, the binding of β2GPI to the HBV surface antigen has been reported [95, 96]. It 
was demonstrated that the β2GPI cDNA transfected COS-1 cells expressed and secreted full-
length recombinant β2GPI (rβ2GPI) into its culture medium that exhibits normal binding to 
recombinant hepatitis B surface antigen (rHBsAg) [95]. The authors speculated that the mode of 
entry for HBV into the human hepatocytes might take place when infectious HBV binds to 
β2GPI complexed with chylomicrons or HDL followed by uptake through LDL receptor or the 
α2-macroglobulin receptor. The binding of β2GPI with rHBsAg was disrupted by reducing the 
intramolecular disulfide bonds of β2GPI and chemical modification of as few as three positively 
charged lysine residues of β2GPI located in the fifth domain [96]. It was therefore, recently 
predicted that the binding region for rHBsAg on β2GPI is located in the fifth domain of β2GPI 
and is the same as the phospholipid binding region on β2GPI [97]. 
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1.2.2 Phylogenetic Analysis of Mammalian β2-glycoprotein I Sequences 
β2GPI has been extensively characterized both at the protein and nucleotide levels from a number 
of other species including rat, bovine, canine, mouse and chimpanzee. Significant structural 
homology of β2GPI across these several mammalian species indicates conserved regions in the 
protein with natural evolution that may be critical for its function. Studies have observed a high 
degree of similarity of human β2GPI sequence with other mammalian species; rat - 83% [98], 
bovine - 83% [99, 100] mouse - 73.6% [101-103], canine - 82.5% [104], and chimpanzee - 
99.4% [105]. The mature protein is composed entirely of 5 contiguous SCR domains among all 
species. SCRs 1-4 are approximately 60 aa residues in length and contain four conserved Cys 
residues, whereas SCR 5 (C-terminal) contains six Cys residues, two of which are not conserved. 
Interestingly, the position of Cys residues and the 11-disulphide bonds were homologous among 
all species. Phylogenetic analysis (Figure. 7) established the mouse β2GPI sequence to be the 
most divergent species overall, reported to date. It is most similar to human (73.6%) and least 
similar to bovine sequence (72%) indicating that mouse β2GPI has accumulated more mutations 
and hence is a faster evolving species than others. Chromosomal location of mouse β2GPI was 
mapped to chromosome 11 and the TSS was identified by primer extension 44 nucleotides 
upstream of the initiator AUG codon. In contrast to human and canine β2GPI, the mouse β2GPI is 
not an acute phase reactant, since there was no down regulation of β2GPI mRNA levels in 
response to pro-inflammatory cytokines. The nucleotide sequences between human and 
chimpanzee APOH were 99.6% identical between the two species, whereas at the protein level 
there was 99.4% identity between human and chimpanzee β2GPI. The prevalence of anti- β2GPI 
antibodies in chimpanzees (64%) was found to be unusually high as compared to humans.  
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Figure 7. Phylogenetic tree of mammalian β2GPI proteins 
From Sellar et al. 1994 [102]. Human (H. sapiens); bovine (B. taurus and B. bovis); canine (C. 
domesticus) and mouse (M. musculus). The branch lengths indicate the evolutionary distances 
between the different. 
 
 
1.2.3 APOH Polymorphisms 
Complete DNA sequence variation in APOH has been reported recently in 46 Caucasian 
Americans and 48 African Americans chromosomes and a larger Pittsburgh cohort of Caucasian 
Americans (n = 452) and African blacks (n = 81) [106]. A total of 150 SNPs, including 146 from 
the SeattleSNPs Program for Genome Application (University of Washington-Fred Hutchinson 
Cancer Research Center Variation Discovery Resource website - 
http://pga.gs.washington.edu/data/apoh/) and one tri-allelic polymorphism were identified. Eight 
of them were present in the coding region (Exon 3 Æ Ser88Asn; Exon 5 Æ Ile122Thr, 
Arg135His, Ser140Ser, Ala141Asp; Exon 7Æ Val247Leu, Cys306Gly; Exon 8 Æ Trp316Ser), 
14 in the 5´-region and two in the 3´-region (17273T>C and 17314T>C). Of these, 16 were 
unique to Caucasian Americans, 62 to African Americans, and 68 were present in both groups. 
The observed number of SNPs (130 vs. 84), SNP density (6.5 SNPs per kb vs. 4.2 SNPs per kb) 
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and inferred haplotypes (34 vs. 16), were higher among African Americans than Caucasian 
Americans. Race-specific linkage disequilibrium (LD) pattern of SNPs identified 17 informative 
tagSNPs among Caucasian Americans and 35 in African Americans. The present study is 
focused on the 14 SNPs present in the 5´- region, five of which are found only in African 
American or black population (Table 2). The -1284 C>G polymorphism is present only in the 
Caucasian Americans or white population.  
 
Table 2. Positions and minor allele frequencies of APOH Promoter SNPs 
SNP ID 
Ethnicity       
(W = Whites    
B = Blacks) SNP
African 
Americans  
(N = 24)
African 
Blacks      
(N = 81)
Caucasian 
Americans   
(N = 23) 
American 
Whites     
(N = 425)
-1284 (rs8178818) W C>G 0 0 0.02 0.001 
-1219 (rs8178819) W/B G>A 0.02 0.07 0.04 0.1 
-1190 (rs3760290) W/B G>C 0.43 0.34 0.28 0.38 
-1076 (rs8178896) B G>A 0.02 NA 0 NA 
-1055 (rs8178897) B T>G 0.02 NA 0 NA 
 -759 (rs8178820) W/B A>G 0.12 0.09 0.2 0.24 
 -742 (rs8178821) W/B delT 0.11 NA 0.2 NA
 -700 (rs3760291) W/B C>A 0.11 0.08 0.2 0.24 
 -643 (rs3760292) W/B T>C 0.17 0.1 0.17 0.13 
 -627 (rs8178898) B A>C 0.07 NA 0 NA 
 -581 (rs8178899) B A>C 0.02 NA 0 NA 
 -363 (rs8178900) B C>T 0.12 NA 0 NA
-38 W/B G>A 0 NA 0 NA 
  -32 (rs8178822) W/B C>A 0.05 NA 0.07 NA 
  
From Chen & Kamboh, 2006 [106].  The A of the ATG of the initiator methionine codon is 
denoted nucleotide +1, the nucleotide 5´ to +1 is numbered −1.NA = not applicable 
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1.2.4 APOH Protein Polymorphisms 
1.2.4.1 Quantitative Polymorphisms of β2-glycoprotein I 
 
The normal concentration of ß2GPI in serum is ~20mg/100ml. Early studies by Cleve et al. 
(1968) [107] proposed that the variation in the ß2GPI concentration values as observed in family 
and population data was controlled by two autosomal codominantly expressed alleles, BgN 
(normal) and BgD (deficiency). BgN BgN homozygous individuals had a ß2GPI concentration 
between 16-30mg/100ml; BgN BgD heterozygous individuals were intermediate between 6-14 
mg/100ml; and BgD BgD homozygous individuals had the lowest at <5 mg/100ml. Furthermore, 
the frequency of the BgD deficiency allele was found to be much higher in mongoloid and black 
populations (>20%) as compared with whites (~6%) [108]. 
1.2.4.2 Qualitative Polymorphisms of β2-glycoprotein I 
 
Genetically determined structural polymorphism of ß2GPI as detected by isoelectric focusing 
(IEF) and immunoblotting provided evidence for two kinds of ß2GPI variation [108]. The first is 
the variation in sialic acid moieties which serves as a major determinant of intraindividual 
glycoprotein microheterogeneity. The second kind of variation has been observed among 
individuals plasma samples and reveals structurally different isoforms with different isoelectric 
points, presumably representing an altered polypeptide chain owing to amino acid substitution 
resulting in a given variant isoform. The four primary isoforms, therefore, can be accounted for 
by the presence of three altered polypeptide chains resulting from the substitutions of three aa 
residues on different positions on the normal chain. As originally revealed by IEF APOH 
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structural locus has three common alleles namely, APOH* 1, APOH* 2 (most common or wild-
type) and APOH* 3 and a fourth rare allele, APOH* 4, that was hypothesized to explain the 
qualitative ß2GPI variation (Figure 8). The distribution pattern of APOH allele frequencies 
revealed (1) identical frequencies of the APOH* 1 and APOH* 3 alleles in U.S. Whites, (2) a 
lower frequency of the APOH* 1 allele in U.S. Blacks as a consequence of admixture, and (3) 
the polymorphic occurrence of the APOH* 4 as a unique marker present only in the black 
population.  
 
Figure 8. Schematic representation of ß2GPI phenotypes detected by IEF 
From Kamboh et al. 1988 [108] 
 
 
Three IgG monoclonal antibodies (mAb) to human ß2GPI, designated 3G9, 1B4, and 
3D11, have been produced. In contrast to mAbs 3G9 and 1B4 which recognize both free and 
phospholipid-bound ß2GPI and react with all ß2GPI allelic isoforms, the 3D11 was specific only 
for one form of the APOH*3 allele, called APOH*3W, that does not bind to anionic 
phospholipids [109]. IEF and immunoblotting results provided evidence for the equal reactivity 
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with all four APOH allelic products for the 3G9 and 1B4 mAbs, whereas the 3D11 recognized 
only the APOH*3 allele product [110]. The APOH* 3 allele was also found to be heterogeneous 
and could be distinguished into APOH* 3W (reactive) and APOH* 3B (non-reactive) based on its 
differential reactivity with monoclonal 3D11 antibody [110].  The APOH* 3W allele product that 
reacted with 3D11 did not bind to anionic phospholipid precluding the production of APA. This 
suggests that the 3D11 epitope lies within the lipid binding site and is unavailable when ß2GPI 
binds to phospholipids. Since the 3D11 reacted only with APOH*3 allele present mostly in 
Whites and Chinese, but not in Blacks, this variant plays a significant role in the ethnic-specific 
variation in the cofactor activity of ß2GPI. Molecular basis of ß2GPI protein polymorphisms, 
APOH* 1 and APOH* 3W alleles has been reported .due to two missense mutations, G341A 
(Ser88Asn) in exon 3 and Trp316Ser in exon 8, respectively [111]. The IEF pattern of the most 
common phenotype in chimpanzees was identical to the human APOH*3B polymorphism [105]. 
Another phenotype which was distinct from any reported human isoforms was designated as 
APOH*4 allele, which corresponded to a missense mutation at codon Lys210Glu (A>G) in exon 
6 that did not affect the binding of β2GPI to cardiolipin. The correlation between SNPs in the 
coding region of APOH and protein polymorphisms have been reported by comparing human 
and chimpanzee ß2GPI amino acid sequences [112]. The human and chimpanzee protein 
sequence difference lie in the coding regions, involving three samesense mutations at codons 57, 
75, and 130, and two missense mutations at codons 122 and 135. The wild-type human β2GPI 
protein consists of isoleucine and arginine at codons 122 and 135, respectively, but the 
chimpanzee β2GPI has threonine and histidine at the two respective sites. An evolutionary 
pathway of observed APOH haplotypes was suggested by screening a large African population 
(n = 755), wherein the APOH* 3 allele comprising the five-site haplotype (122Thr-135His-
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141Ala-247Val-316Trp) was the ancestral haplotype from which all subsequent allelic isoforms 
(APOH*1: 88Asn; APOH*2: 122Ile-135Arg-141Ala-247Leu-316Trp; APOH*3W: 122Thr-
135His-141Ala-247Val-316Ser; APOH*3B: 122Thr-135His-141Asp-247Val-316Trp) were 
derived (Figure 9). A revised nomenclature was proposed based on the evolutionary pathway 
wherein the previously identified APOH* 4 allele was designated as APOH* 3B (122Thr-135His-
141Asp-247Val-316Trp) seen in Blacks only, and the APOH* 3W (122Thr-135His-141Ala-
247Val-316Ser) seen mainly in Whites, remained the same. Association of APOH protein 
polymorphisms with prevalence of anti-ß2GPI antibodies revealed a gender-specific genotypic 
effects of APOH* 3 and APOH* 3B polymorphisms associated with higher anti-ß2GPI levels only 
in males. Evidence for the third domain of ß2GPI to be involved in binding with cardiolipin, as 
revealed by the binding abilities of the naturally occurring haplotypes (carrying mutations at 
codons 122 and 135) of APOH* 3 and APOH* 3B has been established. 
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Figure 9. Evolutionary pathways of APOH haplotypes 
From Kamboh et al. 2004 [112]. The evolutionary steps that may have led to the formation of 
present day haplotypes are numbered in sequential order from 1 to 6. Crosses between two 
haplotypes indicate possible recombinant events. Bold letter amino acids (Thr, His, Asp, Ser) 
indicate the characteristic amino acids of the APOH*3, APOH*3B and APOH*3W haplotypes. 
 
 
1.2.5 Effect of APOH Polymorphisms on Plasma β2-glycoprotein I levels  
There is a wide range of interindividual variation in ß2GPI plasma levels, ranging from 
immunologically undetectable to as high as 35 mg/dL with a mean value of 20 mg/dL in 
Caucasians and 15 mg/dL in AA, which may have clinical relevance in ß2GPI-related pathways 
[113]. Family and heritability data have provided strong support that ß2GPI plasma variation is 
under genetic control but the exact molecular basis of this variation remains largely unknown. A 
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low level of plasma ß2GPI is thought to be a risk factor for thrombosis [114] and it may also 
affect the production of APA, therefore it is important to determine the molecular basis of ß2GPI 
plasma variation. Population-based genetic association studies in non-Hispanic Whites from 
Colorado indicated a significant association of APOH protein polymorphisms with plasma ß2GPI 
levels in both men and women (P < 0.0001) that accounted for 11.4% and 13.6% of the variation 
seen in men and women, respectively. Compared with the APOH*1 and APOH*2 alleles, the 
APOH*3 allele was associated with significantly lower plasma ß2GPI levels. More specifically, 
the APOH*3W form which is defined by the codon Cys316Gly polymorphism explained about 
10% of the variation in plasma ß2GPI levels, indicating that this polymorphism is a major 
determinant of plasma ß2GPI levels [115]. Previous studies in 222 white SLE women have also 
confirmed that the codon 306 and codon 316 polymorphisms show significant (P < 0.0001) 
gene-dosage effects on plasma ß2GPI levels accounting for about 30% and 13% of the variation, 
respectively [113]. The variant alleles of Gly306 and Ser 316 were associated with lower levels 
of ß2GPI than their corresponding wild-type alleles. Apart from common genetic variation in 
APOH coding sequences, a functionally  important point mutation (-32C>A) was identified in 
the 5´-flanking region at the transcription initiation site of APOH that was associated with 
significantly lower ß2GPI plasma levels (P < 0.0001) in a sample population consisting of 232 
lupus patients [116]. Functional relevance was also reported by in vitro studies that showed two-
fold lower luciferase reporter gene expression (a 696-bp long fragment of 5´ region of APOH 
from nucleotide -622 to +74 was tagged to pGL3 - Basic luciferase constructs) in COS-1 cells 
associated with the -32A minor allele and northern blot results that revealed this SNP affects 
APOH transcription. Consistent with the luciferase results, the two-fold difference observed 
between the -32C and -32A alleles was similar also between the AA (9.4 mg/dL) and CC 
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(18.5mg/dL) genotypes for plasma ß2GPI levels. Further evidence for its effect on ß2GPI 
transcription was demonstrated by EMSA results indicating an allele specific (-32A having lower 
affinity than -32C) binding to transcription initiation factor (TFIID) and also to transcription 
factors in mouse liver nuclear extracts. The plasma ß2GPI concentrations were found to be 
significantly higher in patients positive for APA than in patients negative for APA (18.5±4.0 
mg/dl vs 17.1+3.8 mg/dl; P = 0.02) [113]. The distribution of the Trp3l6Ser polymorphism was 
significantly different between the APA-positive and APA-negative groups. The frequency of the 
mutant allele (Ser316) was significantly lower in the APA-positive group than the APA-negative 
group (3.1% vs. 12.1% P < 0.04), indicating that the Ser316 mutation is protective against the 
production of phospholipid- ß2GPI dependent APA. Due to the almost complete LD between 
SNPs -32C>A and Trp316Ser, the -32C>A SNP also showed a similar significant protective 
effect against the occurrence of APA. The carrier frequency of the -32A allele was almost four-
fold lower in the APA-positive group than the APA-negative group (4.8% vs. 16.6%; P = 0.019). 
In univariate analysis, both the -32C>A and Trp316Ser SNPs showed significant association 
with ß2GPI plasma levels. However, in multivariate analysis, the effect of the Trp316Ser was 
lost, indicating that the -32C>A is the functional variant. The Cys306Gly SNP, however, 
exhibited an independent significant effect on ß2GPI plasma levels in both univariate and 
multivariate analyses. 
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1.2.6 Functions of β2GPI 
1.2.6.1  β2GPI and Lipid Metabolism 
 
Although a role for β2GPI has been implicated in a variety of physiological pathways, no precise 
metabolic function has yet been assigned to it. Approximately 35% by weight plasma β2GPI  is 
associated with various lipoprotein classes (very low-density lipoproteins (VLDL - 16%), high-
density lipoproteins (HDL - 17%), low-density lipoprotein (LDL - 2%) and chylomicrons), and 
the remaining 65% is present in the lipid-free 1.21 density fraction [78, 117]. Being a constituent 
of these lipoprotein particles, its function in lipid metabolism has been investigated in detail 
[118]. β2GPI was first thought to be involved mainly in triglyceride metabolism since much of 
the circulating protein is bound to lipoproteins, and it was postulated that when stimulated by 
apoC-II, β2GPI activates lipoprotein lipase (LPL) and increases its enzymatic activity about 45% 
in triglyceride metabolism [119]. The association of APOH polymorphisms in relation to serum 
lipoprotein concentrations exhibited a sex-specific effect with females having higher triglyceride 
levels [120]. A recent study comprehensively investigated the association of variation in APOH 
with lipid traits in hepatic cholesterol transport (HCT), dietary cholesterol transport (DCT), and 
reverse cholesterol transport (RCT) [121]. The study population consisted of families from the 
Genetic Epidemiology Network of Arteriopathy (GENOA) multicenter study that includes 
African Americans, Mexican Americans, and European Americans. The strongest associations 
were found for DCT traits (triglyceride and apoE levels) in Mexican Americans with a 
nonsynonymous variant (SNP 14917, Cys306Gly) that may alter β2GPI protein folding in a 
region involved in phospholipid binding.  
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1.2.6.2 β2GPI and Atherosclerosis 
 
Oxidative stress and low-density lipoprotein (LDL) modification (oxidized low-density 
lipoprotein; oxLDL) are early pro-atherogenic events [122-124]. The oxidation products of LDL 
are cytotoxic, chemotactic, and proinflammatory, and promote the formation of macrophage-
derived foam cells. Increased cardiovascular morbidity and mortality due to the premature or 
accelerated development of atherosclerosis has been reported in patients with systemic 
autoimmune diseases such as SLE and APS [125]. A growing body of data has implicated 
β2GPI-mediated immune response in the pathogenesis of atherosclerosis. β2GPI binds 
significantly to oxLDL than to native LDL [126] to form oxLDL/β2GPI complexes (Figure 10). 
The nature of the binding has been further characterized and the oxLDL-derived ligands specific 
for β2GPI have been identified and synthesized.  
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Figure 10. OxLDL/β2GPI complex formation 
From Matsuura et al. 2006 [127]. β2GPI interacts with oxLDL in a two-step reaction that is 
calcium independent. Initially, β2GPI binds to oxLDL via the specific, high affinity ligands 
oxLig-1 and -2. Stable complexes between the protein and oxidized lipid form at neutral pH. The 
latter complexes are non-dissociable at the neutral pH, but can be dissociated with Mg2+ or 
heparin at pH 10. 
 
 
 
Circulating oxLDL/β2GPI complexes are significantly elevated in sera of patients with 
systemic autoimmune and/or atherosclerotic disease such as APS, SLE, and type 2 diabetes 
mellitus as compared to healthy controls [128]. However, these complexes were not associated 
with either SLE disease activity or any major clinical manifestation of APS. Circulating 
oxLDL/β2GPI complexes have been implicated as atherogenic autoantigens, and their presence 
might represent a risk factor or an indirect but significant contributor to thrombosis (chronic 
inflammation of the vasculature) and atherosclerosis (oxidative stress) that occurs in autoimmune 
patients. SLE and APS patients produce autoantibodies (anti-β2GPI) to this complex and the 
resulting circulating immune complexes are etiologically important in the development of 
atherosclerosis in these patients [129]. Studies have reported IgG anti-oxLDL/β2GPI antibodies 
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to be significantly higher in SLE and systemic sclerosis (SSc) patients when compared to the 
control population [130]. A positive predictive value (PPV) of IgG anti-oxLDL/ β2GPI 
antibodies for total thrombosis (arterial and venous) in patients with secondary APS was 92% 
and for arterial thrombosis 89%. These observations provided concrete explanation for the 
accelerated (premature) development of atherosclerosis in autoimmune patients. IgG anti-
oxLDL/β2GPI antibodies seem to represent a distinct subset of APA (i.e., anti-β2GPI) that appear 
to be useful serologic markers for atherothrombotic risk in autoimmune patients with high 
specificity for APS [127]. The physiologic relevance of these findings was demonstrated in vitro 
by the enhanced macrophage uptake of IgG immune complexes of oxLDL/β2GPI (Figure 11). 
The participation of macrophage FcγRI receptors in the uptake of oxLDL-containing complexes 
seems to be particularly important to explain the development of foam cells and autoimmune-
mediated atherosclerotic plaques. Circulating IgG anti- β2GPI antibodies facilitate the antigen 
presentation by macrophages to specific T cells. Interestingly, in vitro stimulation of 
macrophages by oxLDL/β2GPI complexes together with anti-β2GPI antibodies led to the 
expression of membrane CD36 as well as FcγRI  [131]. These observations suggest that IgG 
immune complexes containing oxLDL/β2GPI provide not only FcγRI- but also scavenger 
receptor-mediated uptake of oxLDL/β2GPI complexes by macrophages. Thus, oxLDL/β2GPI 
complexes represent a major atherogenic autoantigen, and IgG anti-β2GPI autoantibodies may 
facilitate antigen presentation and foam cell formation in APS.  
Interestingly, β2GPI could play a dual role in the regulation of uptake of oxLDL by 
macrophages [126]. β2GPI is primarily anti-atherogenic but the immune response against β2GPI 
converts it to proatherogenic. In the absence of APA, β2GPI inhibits the uptake of oxLDL and 
cholesterol accumulation in macrophages resulting in anti-atherogenic effect [132]. On the other 
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hand, in the presence of APA, β2GPI increased oxLDL uptake, which indicates a pro-atherogenic 
effect [126, 127, 133].  
 
Figure 11. Proposed mechanisms of foam cell formation in immune-mediated atherosclerosis 
From Matsuura and Lopez, 2008 [134] 
 
1.2.6.3 β2GPI and Blood Coagulation 
 
The role of β2GPI in the coagulation system both in healthy people and patients with APS is being 
increasingly elucidated. The involvement of β2GPI in the coagulation cascade seems 
multifaceted because the protein can exert both procoagulant and anticoagulant activities (Figure 
12). β2GPI exerts anticoagulant activity by inhibiting the contact activation of the intrinsic 
coagulation pathway, both tenase and prothrombinase activity on platelets or phospholipids 
vesicles, it inhibits activation of factor X and XII [135] and modulates ADP-induced platelet 
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aggregation [136]. On the other hand, β2GPI exhibits procoagulant activities by reduction of 
activated protein C [137, 138]. Several in vivo experimental models have demonstrated a role of 
β2GPI in thrombotic complications. Mice lacking β2GPI have been produced by gene targeting; 
plasma from these knockout mice exhibited impaired thrombin generation in vitro [139]. These 
experiments provide direct evidence of the role of β2GPI in the direct coagulation cascade, at a 
stage upstream of thrombin generation. Despite the regulatory functions of β2GPI in the 
coagulation cascade, genetic deficiency of β2GPI does not represent a major risk factor of either 
thrombosis or bleeding in humans [140]. β2GPI appears to not only interact with factors of the 
coagulation cascade, but also participate in the regulation of intrinsic fibrinolysis [141, 142]. 
Fibrinolytic reactions involve the formation of plasmin generated from plasminogen and the 
hydrolytic cleavage of fibrin to fibrin degradation products by plasmin (Figure 13). Plasmin 
conversion from plasminogen by tissue plasminogen activator (tPA) occurs upon activation of 
extrinsic fibrinolysis for the thrombolysis against intravascular blood clots. Impaired fibrinolysis 
is a contributing factor for the development of thrombosis. β2GPI is proteolytically cleaved 
between Lys317 and Thr318 (nicked- β2GPI) by activated factor X and plasmin in domain V 
being unable to bind phospholipids. This cleavage may occur in vivo on the surface of activated 
endothelial cells or platelets. Once the nicked form of β2GPI is generated, it loses its antigenicity 
for pathogenic APA. Recently, increasing attention is focused on the role of nicked- β2GPI as a 
regulator of extrinsic fibrinolysis pathway. Nicked- β2GPI has been found in large quantities in 
plasma of patients with disseminated intravascular coagulation (DIC), a pathological state 
characterized by massive thrombin generation and fibrinolytic turnover [143]. The detection of 
nicked- β2GPI in plasma represents a sensitive marker of cerebral ischemic events and might be a 
useful screening tool in the assessment of patients at risk of ischemic stroke [142]. Nicked β2GPI 
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has been shown to be a physiologic inhibitor of fibrinolysis and that plasmin cleavage of β2GPI is 
part of the negative feedback pathway of extrinsic fibrinolysis [144]. 
 
 
Figure 12. β2GPI and blood coagulation 
From Atsumi et al. 2005 [144] 
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 Figure 13. Role of β2GPI in the negative feedback pathway of extrinsic fibrinolysis 
From Atsumi et al. 2005 [144] 
 
 
1.2.6.4 β2GPI and Antiphospholipid Syndrome 
 
The antiphospholipid syndrome (APS, Hughes’ syndrome) is a thrombophilic disorder that 
manifests clinically with arterial and/or venous thrombosis and/or pregnancy morbidity, 
associated with the presence of APA.  APS could occur independently in most cases as a primary 
entity or occur as a secondary condition in association with other autoimmune diseases, 
particularly SLE [141]. Among these autoantibodies, LAC and aCL are included in the list of 
biological criteria defining the APS [145]. Accumulating evidence from human and animal 
studies (NZW×BXSB F1 mice, an APS mouse model) [146] indicates that β2GPI represents the 
major target antigen for APA and it plays a critical role in the pathogenesis of APS [147]. In 
classical aCL immune assays, anti- β2GPI antibodies are involved in the aCL reactivity, which is 
directed mainly against the β2GPI–cardiolipin complex. Despite a high level of correlation 
between aCL and anti- β2GPI assays, the presence of anti- β2GPI antibodies alone has been 
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described in some SLE patients with clinical manifestations of APS. Controversial results have 
been reported regarding the APA-specific epitopes of β2GPI that are crucial in the development 
of APS. The positively charged (multiple lysine) region between cys281–cys288 is highly 
conserved in domain V and a critical phospholipid binding site that is essential for β2GPI -
dependent autoantibody binding [148]. Although short peptides containing sequences from 
domain V of β2GPI inhibited binding of human monoclonal antibodies to β2GPI, polyclonal 
antibodies from human APS patients did not bind to these peptides [149]. In a recent study using 
anti- β2GPI antibodies from APS patients with deleted mutants [150] and single-point mutated 
domain I of β2GPI, it was shown that domain I of β2GPI contains significant epitopes for the 
anti- β2GPI antibodies found in the APS [151]. The charged surface patch defined by residues 
40–43 on domain I of β2GPI contributes to an immunodominant epitope for anti- β2GPI 
antibodies [152]. Anti- β2GPI autoantibodies from most patients are intrinsically of low affinity 
and bind to β2GPI only in the presence of negatively charged phospholipids or on pre-irradiated 
plates The binding of low affinity anti- β2GPI was dependent on antigen density and dimerisation 
of β2GPI induces a significant increase in anti- β2GPI binding affinity enabling binding of anti- 
β2GPI autoantibodies to β2GPI coated on a normal plate. Once cell activation exposes anionic 
PL, the dimerisation of β2GPI then facilitates binding to β2GPI cell surface receptor (ApoER2 for 
platelet cells) and cell signaling (Figure 14) [141]. 
 
 44 
 Figure 14. Role of β2GPI in APS 
From Miyakis et al. 2004 [141] 
 
 
β2GPI constitutes the principal antigenic target in APS-related fetal loss. APA reacting 
with β2GPI can inhibit the proliferation and secretory activity of human placental trophoblast 
cells, confirming the involvement of β2GPI in pregnancy loss associated with APS [141]. The 
role of β2GPI in pregnancy failure has been further elucidated following experiments on 
genetically modified mice lacking β2GPI [139].  β2GPI knockout mice are able to carry 
pregnancies to term, with reproductive outcomes indistinguish able from that of the control mice. 
Direct interaction between β2GPI, FXI and plasmin in the coagulation and fibrinolysis cascades, 
have given impetus to the ongoing research directed towards the role of β2GPI in the thrombotic 
events of APS [141].  
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1.2.6.5 β2GPI and Systemic Lupus Erythematosus 
 
Some β2GPI -dependent APA exert lupus anticoagulant (LA) activity, which seems to depend on 
APA epitope specificity. The term LA has been defined as APA that prolong the clotting time of 
phospholipid-dependent coagulation tests. A number of studies have provided evidence that the 
persistent finding of β2GPI -dependent APA, which express high LA activity, is a real risk factor 
for thrombosis [153]. The most common and best characterized APA that occur in a variety of 
autoimmune diseases, particularly SLE are anti-aCL/β2GPI antibodies, anti-phosphatidylserine 
/prothrombin antibodies (anti-PS/PT) and LA activity that are detected by conventional enzyme-
linked immunosorbent assay (ELISA) and in vitro phospholipid-dependent coagulation reactions, 
respectively. Several clinical studies have established that the presence of aCL/ β2GPI, anti-
PS/PT and/or LA activity is associated with clinical events such as arterial and/or venous 
thromboembolic and obstetric complications in SLE and APS patients. Elevated blood levels of 
APA in autoimmune diseases such as in SLE, in which levels of these autoantibodies are raised 
in 20–60% of patients, have been associated with recurrent venous and arterial thromboses, fetal 
loss, thrombocytopenia and neurological disorders. Serum anti- β2GPI antibodies are strongly 
associated with thrombosis in SLE patients [154]. Measurement of anti- β2GPI IgG is clinically 
useful in identifying patients with SLE at higher risk for venous and arterial thrombosis [155]. 
Persistent positivity increased the association of IgG anti- β2GPI with venous thrombosis and 
anti- β2GPI IgM with arterial thrombosis. IgA anti- β2GPI was not significantly associated with 
APS manifestations. Atherosclerosis obliterans (ASO), ischaemic heart disease (IHD) and CVD 
are major causes of mortality in patients with SLE. Recently, the presence of aCL/ β2GPI 
contributing to the risk of development of ASO, which may represent an important mechanism 
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for the pathogenesis of IHD in patients with SLE [156]. No association between anti-ß2GPI 
antibodies and lupus nephritis either in patients with SLE or in patients with primary APS with 
nephritis was reported [157]. Patients with SLE develop subclinical atherosclerosis significantly 
more frequent than the general population. Coexistence of APS and presence of APA are risk 
factors for subclinical atherosclerosis development in patients with SLE. Thickened intima-
media in patients with SLE is significantly associated with an increased risk of cardiovascular 
manifestations. Reports showing association between IgG anti- oxLDL/ β2GPI and intima media 
thickness (IMT) of carotid arteries in primary APS (PAPS) and hence contribute to the 
development of autoimmune-mediated atherosclerosis [129]. oxLDL binds to endogenous β2GPI 
and that these complexes (oxLDL/ β2GPI) can be found circulating in the blood stream of 
patients with various chronic diseases, such as SLE, APS, chronic renal disease, diabetes 
mellitus. IgG autoantibodies against oxLDL/ β2GPI were significantly elevated in about 40% of 
patients with APS as compared to SLE patients without APS. Further, these antibodies showed a 
stronger correlation with arterial thrombosis than venous thrombosis and pregnancy morbidity. 
The coexistence of oxLig-1/ β2GPI autoantibodies with oxLDL/ β2GPI complexes, suggest that 
these two elements interact perhaps forming circulating immune complexes (oxLDL/β2GPI 
/antibody) (Figure 15). Such immune complexes in serum samples of SLE and/or APS has been 
detected [133]. This observation along with the increased macrophage uptake of oxLDL/ β2GPI 
complexes in the presence of anti- oxLDL / β2GPI antibodies [126, 133], provide a possible 
explanation for the accelerated development of atherosclerosis in autoimmune patients. 
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Figure 15. Development of thrombosis in SLE and/or APS patients by circulating IgG 
oxLDL/β2GPI immune complexes 
From Matsuura and Lopez, 2004 [158] 
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2.0  RATIONALE AND SIGNIFICANCE 
Genome-wide comparisons indicate that studying the coding regions alone will not be sufficient 
for explaining the biological complexity of complex diseases. Genetic variants and the epigenetic 
differences of cis-regulatory elements are also crucial to elucidate many complicated biological 
phenomena [159]. Regulatory polymorphisms are DNA elements that modify the expression 
level of a transcript or its isoforms. Recently, there has been a considerable upsurge of interest in 
the influence of cis-acting polymorphisms and trans-acting elements on gene transcription in 
human diseases (Figure 16).  
 
 
Figure 16. Cis- and Trans- Transcriptional Regulation and Human Diseases 
From Villard, 2004 [160] 
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Cis-acting regulatory factors (such as DNA polymorphisms and methylation) in the 
flanking DNA sequence of the gene may explain up to 25 to 35% of interindividual differences 
in gene expression. In contrast to coding sequence polymorphisms, where the consequences of 
non-synonymous variation may be resolved at the level of the protein phenotype, defining 
specific functional regulatory polymorphisms has proved problematic. Current techniques can 
detect expression differences as low as 1.2-fold between samples or alleles; the phenotypic 
consequences (if any) of such small differences are likely to depend on the function of the gene 
in question. Most known regulatory polymorphisms are located in gene promoter regions and 
function by altering gene transcription. Promoters are the best characterized transcriptional 
regulatory sequences in complex genomes [161]. Identification and characterization of these 
regulatory elements are vital in understanding the complex network of human gene regulation. It 
has long been known that mutations in non-coding regions which affect gene expression can 
cause human genetic disease [162]. Promoter sequences are potential sources of polymorphisms 
affecting gene expression, phenotypic variation and possibly susceptibility to common diseases 
[163]. Variations in the promoter DNA sequence may potentially alter the affinities of existing 
protein-DNA interactions or recruit new proteins to bind to the DNA, altering the specificity and 
kinetics of the transcriptional process (Figure 17). 
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 A) Promoter structure and function B) Promoter operation in transcription 
 
Figure 17. Transcriptional regulation of eukaryotic promoter 
From Wray et al. 2003 [164] 
 
 
Evidence for the medical importance of cis-acting polymorphisms has been provided by 
recent positional cloning of susceptibility genes that are not associated with protein coding or 
splice-site polymorphisms for common diseases such as stroke [165] and type 2 diabetes [166]. 
Classic examples include variants located within the highly conserved proximal promoter 
element (the “TATA” box) associated with thalassemias [167] and a SNP in the proximal Sp1 
site of the human LDL receptor promoter as a cause of familial hypercholesterolemia [168]. A 
review of 107 genes with functional polymorphisms in the 5`-flanking region shows that 63% are 
associated with two-fold or greater allelic differences in their rates of transcription and 10% had 
10-fold or more differences, indicating that functional cis-regulatory variation is widespread in 
the human genome [169]. A large number of putative functional SNPs present in promoter 
regions of candidate genes have been analyzed using traditional experimental techniques that 
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assay protein-DNA interactions, such as gel-shift assays, and those measuring gene expression 
using reporter gene assays. The most widely used experimental tool to interrogate the 
significance of specific putative regulatory polymorphisms are reporter gene assays in which 
cells are transiently transfected with allele- or SNP-specific promoter constructs. Using both 
luciferase- gene reporter and electrophoretic mobility shift assays Belanger et al. (2005) [170] 
reported four promoter SNPs associated with the cell-cycle check point genes, E2F1, HDAC1, 
RB1 and CCND1 to influence transcriptional activity in an allele specific manner. Systematic 
surveys of promoter haplotypes by reporter gene analysis on chromosomes 21 [162] and 22q11 
[171] show functional variation among 18% and 20% of polymorphisms tested, respectively; a 
proportion similar to that reported on analysis of allele-specific expression for other genomic 
regions. Some examples in which promoter variation has been linked with disease and altered 
expression of gene include APOE and Alzheimer’s disease [172], functional polymorphisms in 
the promoter region of the β-fibrinogen gene influencing plasma fibrinogen levels, which is a 
major risk factor for CHD, stroke, and peripheral arterial disease [173]; VLDL response element 
in the promoter region of the human plasminogen activator inhibitor-1 gene was implicated in 
impaired fibrinolysis of hypertriglyceridemia which increases risk of CHD and other 
atherothrombotic disorders [174]. Several studies have suggested associations of interleukin-10 
(IL-10) and IL -18 promoter SNPs [175] and TNF-α in SLE disease susceptibility [176]. Two 
functional polymorphisms in the CRP gene (-409G>A and -390C>T>A) were identified by in 
vitro assays, wherein the CRP-promoter haplotype, -409G/-390T showed highest promoter 
activity in luciferase reporter assays [177]. The important functional role of CRP promoter 
polymorphisms having a significant influence on CRP levels in SLE patients has been recently 
reported [178]. Recent studies proposed a role to the MBL in the SLE physiopathogenesis with 
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distinct MBL-2 polymorphisms, both at the coding and the promoter regions, associated with low 
serum MBL levels and with SLE susceptibility, as well as with clinical and laboratory typical 
features of the disease, cardiovascular events, and infections [179]. Genome-wide association 
studies identified a new genetic locus (BLK–C8orf13 on chromosome 8) for SLE susceptibility 
which involved a promoter variant  associated with reduced expression of BLK and increased 
expression of C8orf13 [51]. Although novel high-throughput stratagies and in silico analysis 
make it relatively easier to identify different classes of cis-DNAs, they are limited with regard to 
the underlying mechanism of how these variations affect gene expression and contribute to 
phenotypic variances. Promoters are involved in initiating transcription and are therefore among 
the many important cis-acting elements that regulate gene expression that might harbor 
functionally relevant polymorphisms. The proposed study lends credibility to the hypothesis that 
polymorphism within promoters may be a common source of phenotypic variation and possibly 
susceptibility to common disease, particularly SLE.  
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3.0  OBJECTIVES 
Since variation in promoter region could affect gene expression and disease risk, the objective of 
this study, in part, was to characterize the putative APOH promoter. For this purpose, we have 
subcloned a ~1.4 kb genomic fragment of the human putative APOH promoter region and 
characterized the proximal promoter region using traditional techniques such as in vitro promoter 
– reporter gene assay, electrophoretic mobility shift assay and 5´ deletion analysis. The 
association of genetic variation in the coding region of APOH with SLE risk has been examined 
extensively; however, a comprehensive analysis of APOH promoter SNPs has not been reported 
yet. Therefore, this study also aims to test the association of APOH promoter SNPs with SLE 
risk and/or SLE-related clinical phenotypes in a cohort of SLE cases and controls. The APOH 
promoter polymorphisms were also investigated for association with difference in plasma ß2GPI 
levels among individuals. All eight APOH promoter SNPs previously reported to be present in 
Caucasians (-1284C>G, -1219G>A, -1190G>C, -759 A>G, - 700C>A, -643T>C, -38G>A, and -
32C>A) and five present in African Americans (-1076G>A, -1055T>G, -627A>C, -581A>C and 
-363C>T) were examined [106]. The insertion/deletion polymorphism (-742delT) could not be 
characterized due to repetitive sequences in the surrounding region. 
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4.0  SPECIFIC AIMS 
Following are the specific aims of the project: 
 
Specific Aim 1: To characterize the putative APOH functional promoter and its cis-acting 
regulatory elements by 5´-deletion analysis. 
 
Specific Aim 2: To functionally characterize the APOH promoter polymorphisms by dual-
luciferase reporter gene assay and electrophoretic mobility shift assay. 
 
Specific Aim 3: To perform genetic association of APOH promoter SNPs with SLE risk and/or 
SLE-related clinical phenotypes (autoimmune-mediated cardiovascular, lupus nephritis, 
occurrence of APA) in SLE cases and controls. 
 
Specific Aim 4: To determine the genetic association of APOH promoter SNPs with plasma 
β2GPI levels in a SLE cohort. 
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5.0  PATIENTS AND METHODS 
5.1 SUBJECTS 
Peripheral blood samples were obtained from 393 (345 white and 48 black) women with SLE 
and 496 (454 white and 42 black) healthy control women. SLE subjects were derived from the 
Pittsburgh Lupus Registry and were 18 years of age or older (mean age ± standard deviation 
(SD) = 43.45 ± 11.40 for whites and 41.69 ± 12.11 for blacks), and met the 1982 and the 1997 
revised American College of ACR classification criteria for definite or probable SLE [180, 181]. 
The spectrum of ACR criteria for our Caucasian patient population is shown in Table 3. Blood 
samples from Caucasian control subjects (mean age ± SD = 45.28 ± 13.14 for whites and 49.39 ± 
16.36 for blacks) with no history of SLE were obtained from Central Blood Bank of Pittsburgh. 
This study was approved by the University of Pittsburgh Institutional Review Board and all 
participants provided written informed consent.  A second cohort of Caucasian female SLE 
patients (n = 109) and controls (n = 81) from the Chicago SOLVABLE  (Study of Lupus 
Vascular and Bone Longterm Endpoints) study was used to replicate the most significant SLE 
disease association and the most significant carotid plaque association (cases only)  detected in 
the Pittsburgh cohort. Detailed description of the Chicago study population is reported elsewhere 
[182]. 
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Table 3. Clinical characteristics of Caucasian SLE patients 
 
Diagnosis criteria for lupus nephritis among SLE patients was based on the presence of 
either 1) renal biopsy showing lupus nephritis, 2) at least 2 readings of proteinuria > 0.5 gm/24 
hours or 3 + protein by dipstick, or 3) red blood cell casts. Two main clinical parameters that 
were used to define subclinical CVD in a subgroup of SLE patients (n = 245) were the 
measurements of carotid IMT and carotid plaque index. B-mode carotid ultrasound was 
performed using a Toshiba SSA-270 A scanner (Tustin, CA) equipped with a 5-mHz linear array 
imaging probe as described previously [23]. Sonographers scanned the right and left common 
carotid artery, carotid bulb, and the first 1.5 cm of the internal and external carotid arteries. 
Plaque was defined as a distinct area protruding into the vessel lumen that was at least 50% 
thicker than the surrounding areas. The average carotid IMT was measured across 1-cm 
segments of both the right and left sides of the near and far walls of the distal common carotid 
artery and the far wall of the carotid bulb and internal carotid artery. Values from each location 
were then averaged to produce an overall measure of carotid IMT. 
Clinical features Occurrence 
skin (malar rash and discoid rash) 55% 
photosensitivity 59% 
oral ulcers 54 % 
arthritis 91% 
serositis 45% 
renal involvement 30% 
neurologic involvement 9% 
hematologic involvement 52% 
immunologic involvement 72% 
antinuclear antibody 98% 
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5.2 MEASUREMENT OF ANTIPHOSPHOLIPID ANTIBODIES  
Serum samples were screened in duplicate for the presence of aCL (IgG aCL positivity defined 
as >15 IgG phospholipid units, IgM aCL positivity defined as >10 IgM phospholipid units; kits 
obtained from Incstar, Stillwater, MN), LAC (by partial thromboplastin time or Russell’s viper 
venom time with mix), and anti-β2GPI (Quantalite β2GPI screen, INOVA Diagnostics, San 
Diego, CA). Additional information regarding the methods that were used to measure these three 
APA is provided elsewhere [105, 113]. 
 
5.3 GENOTYPING 
QIAamp kit (Qiagen, Chatsworth, CA) was used to isolate genomic DNA from buffy coat. The 
APOH promoter was sub-divided into smaller PCR fragments containing specific SNPs as listed 
in Table 4. For two of the amplicons (Promoter 1 and Promoter 2), the PCR involved three 
primers: two amplification primers (forward and reverse) that are specific to the sequence of 
interest, one of which is tagged to the universal biotinylated primer. For the rest, PCR was 
performed with either the forward or the reverse primer biotinylated (Table 4). For each 
fragment, 1 nanogram of genomic DNA was amplified in a 50 µL reaction using the cycling 
conditions as shown in Table 5. Genotyping was performed using standard PCR procedures. A 5 
μL aliquot of the amplified PCR product was verified by gel electrophoresis (2% gel stained with 
ethidium bromide). The robustness of the genotyping results was tested by randomly selecting 
about 10% of the samples for repeated assays and check for concordance. 
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 Table 4. Primer pairs used for PCR amplification of genomic APOH 
 
APOH genomic promoter reference sequence is shown in Figure 21 
 
Table 5. PCR conditions 
 
PCR reaction Promoter 1  Promoter  2 Promoter 3 Promoter 4 & 5 
10X Buffer 
MgCl2 
dNTPs 
Forward Primer 
Reverse Primer 
Universal Tag Primer 
Taq Polymerase 
6.0 μL 
4.8 μL 
3.0 μL 
(Tag)  0.06 μL 
0.6 μL 
0.6 μL 
0.3 μL 
6.0 μL 
4.8 μL 
3.0 μL 
0.6 μL 
(Tag)  0.06 μL 
0.6 μL 
0.3 μL 
5.0 μL 
2.0 μL 
2.5 μL 
0.3 μL 
0.3 μL 
--- 
0.25 μL 
5.0 μL 
2.0 μL 
2.5 μL 
0.5 μL 
0.5 μL 
--- 
0.25 μL 
 
 
Cycling conditions 
 
 
95°C for 5 min. – 1 cycle 
95°C for 30 sec | 
60°C for 30 sec | x 45 cycles 
72°C for 30 sec | 
72°C for 5 min. – 1 cycle 
95°C for 5 min. – 1 cycle 
95°C for 30 sec | 
60°C for 30 sec | x 35 cycles 
72°C for 30 sec | 
72°C for 5 min. – 1 cycle 
 
10X PCR buffer (100mM Tris-HCl, pH=8.3, 500mM KCl), 50 mM MgCl₂, 1.25mM of each 
dNTP , 20 μmol/L PCR primers, 20μmol/L biotinylated universal tag sequence, and 1.25 units of 
Taq DNA polymerase (Invitrogen), sec = second, min = minute 
 
APOH 
Promoter 
PCR 
Fragments 
 
SNPs 
 
PCR Primers 
  
Promoter 1 
  
-1284C>G 
-1219G>A 
-1190G>C 
Universal Biotinylated Tag 5´ GCTGCTCCGGTTCATAGATT 
Forward + Tag - 5´ AGCGCTGCTCCGGTTCATAGATTTCTGCCTGACAGATGGA 
GATT 
Reverse - 5´ CACACCTGAAGCCTTTCC
  
Promoter 2 
  
-759A>G 
-700C>A 
-643T>C 
Universal Biotinylated Tag 5´ GCTGCTCCGGTTCATAGATT 
Forward - 5´ CGAACCCTCTCAAGCAACA 
Reverse + Tag - 5´ AGCGCTGCTCCGGTTCATAGATTTTGCAAGCTCCTATAGCT 
CCA 
 
Promoter 3 
-627A>C 
-581A>C 
Forward - 5´ GGCCCATTATCTTATCCTACTCAA 
Reverse - 5´ Biotin - TGCAAGCTCCTATAGCTCCAGTTA
 
Promoter 4 
-1076G>A 
-1055T>G 
Forward - 5´ AAAGGAAAGGCTTCAGGTGTG 
Reverse - 5´ Biotin - CCCAACTTAAGGCCAACCA
 
Promoter 5 
-38G>A 
-32C>A 
Forward - 5´ Biotin - GTGGGTCTCAGAGTTCCATTCAA 
Reverse - 5´ CCTGACATATACGAAGGGGTTGGA
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5.3.1 Pyrosequencing 
Pyrosequencing, a non-electrophoretic DNA sequencing platform for the analysis of SNPs, was 
used to genotype each genomic DNA sample for all APOH promoter SNPs. Table 6 shows the 
sequence of the primers for each pyrosequencing reaction. Primers were designed using 
Pyrosequencing Assay Design Software version 1.0.6 (Biotage, Charlottesville, VA). The 
principle of pyrosequencing analysis using a universal biotinylated primer for mutation detection 
and SNP genotyping has been described elsewhere [183]. For each pyrosequencing reaction, 10-
20 μL of each biotinylated PCR product (depending on product yield) was aliquoted into the 
wells of a 96-well plate. To bind the products to sepharose beads, 80 μL of binding reaction mix 
was added to each well. The binding reaction mix consists of 40 μL Binding Buffer (Biotage, 
Charlottesville, VA), 18 μL high purity water, and 2 μL Streptavidin-Sepharose beads 
(Amersham Biosciences, Piscataway, NJ). The binding reaction mix and PCR products were 
mixed at 1400 rpm at room temperature for at least ten minutes. Each pyrosequencing primer 
(Table 6) was diluted to 1:10 in annealing buffer, and 10 μL of the annealing mix (including 
pyrosequencing primer) was added to each well of a PSQ™ HS 96-well plate, resulting in 5 
pmol of pyrosequencing primer per well. Negative controls (i.e. pyrosequencing primer only and 
biotinylated primer and Pyrosequencing primer without template) were included on each plate to 
confirm that background signal was negligible. Sepharose-bound PCR products were captured on 
the probes of the Pyrosequencing Vacuum Prep Tool (Biotage, Charlottesville, VA). The beads 
were washed in 70% ethanol (5 secs), followed by denaturation solution (0.2 M NaOH) (5 secs), 
and then washing buffer (10 secs). The vacuum was released, and the probes were immersed in 
the PSQ HS 96-well plate containing the annealing solution, and the beads were released by 
gentle shaking. The plate was then incubated on a heat block at 90°C for 2 minutes and allowed 
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to cool to room temperature prior to reading. Plates were read on a PSQ HS Pyrosequencer using 
PyroGold reagents and analysis software version 1.2 in allele quantification (AQ) mode.  
 
Table 6. Pyrosequencing primers 
 
APOH Promoter PCR 
Fragments SNPs  Pyrosequencing Primers
Promoter 2 
-1284C>G 
-1219G>A 
-1190G>C 
5´ CTAAAATTCCCTGAGACAC 
5´ AGCTCTGAATAAATAACCTC 
5´ TTAATGGCTGCCTCC 
Promoter 3 
-759A>G 
-700C>A 
-643T>C 
 5´ TCAGCACTGGCCC 
 5´ CCCAAGTTGTTAATTTCA 
 5´ CTAGACAGATCCAAGACATA 
Promoter 4 -627A>C -581A>C 
 5´ ACATATTAAGAATGGATGAG 
 5´ AGAAGATAGAGAATTCAAGG 
Promoter 5 -1076G>A -1055T>G 
 5´ TCAGGTGTGCTCCAA 
 5´ TTGTTGGTATGGGGA 
Promoter 6 -38G>A -32C>A 5´ TCACACTGGCACTACC 
 
5.3.1.1 Principle of Pyrosequencing 
In the initial step, biotin-labeled PCR amplicons are immobilized by binding to streptavidin-
coated Sepharose beads, and DNA is denatured to produce single-stranded DNA template for the 
Pyrosequencing assay. Next, the reaction is incubated with four catalytic enzymes, DNA 
polymerase, ATP sulfurylase, luciferase, and apyrase, and the substrates, adenosine 5´ 
phosphosulfate (APS) and luciferin. In a cascade of enzymatic reactions (Figure 18), visible light 
is generated that is proportional to the number of incorporated nucleotides. The cascade begins 
with a nucleic acid polymerization reaction in which pyrophsophate (PPi) is released as a result 
of nucleotide incorporation by polymerase, in a quantity equimolar to the amount of nucleotide 
incorporated. ATP sulfurylase quantitatively converts PPi to ATP in the presence of adenosine 5' 
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phosphosulfate. ATP then drives the luciferase-mediated conversion of luciferin to oxyluciferin 
that generates visible light in amounts that are proportional to the amount of ATP. In the next 
step, unincorporated dNTPs and excess ATP are continuously degraded by, the nucleotide 
degrading enzyme, apyrase, leading to loss of light emission. After the degradation is completed, 
the next dNTP is added and a new Pyrosequencing cycle is started. Finally, the sequential 
incorporation of every nucleotide is converted to light, which is detected by the PSQ 96 
instrument and displayed as a peak in pyrosequencing readouts (pyrogram), enabling the 
sequence of the template strand to be determined and SNPs to be genotyped. Each peak height is 
proportional to the number of nucleotides incorporated. Genotypes are assigned by both system-
generated and manual calls using the pyrosequencing software (PSQ-96MA). An example of the 
theoretical histograms along with the actual pyrograms of the three possible genotypes for the 
complementary (c) strands of APOH promoter -38G>A and -32C>A SNPs are shown in Figure 
19. 
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Figure 18. Principle of pyrosequencing 
From Biotage, 2006 
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Figure 19. (Continued Below) 
  
 
 
 
 
 
 
Figure 19. APOH Promoter 6 -32C>A (antisense: G>T) & -38 G>A (antisense: C>T) 
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Actual Pyrogram: c(-32C>A): TT                                          c(-38G>A): TT 
 
Actual Pyrogram: c(-32C>A): GT  
                 c(-38G>A): CT 
Theoretical Histogram: c(-32C>A): TT  
                             c(-38G>A): TT 
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5.3.2 TaqMan 
The APOH promoter SNP -643T>C (rs3760292) was genotyped in the Chicago SLE sample 
using a custom TaqMan allelic discrimination genotyping assay (Assay ID: C___2658405_10) 
(Applied Biosystems, Foster City, CA). Standard ABI protocol for TaqMan SNP Genotyping 
Assay was followed that utilizes 3´ minor groove binder (MGB) probe-based technology 
consisting of two unlabeled PCR primers, one VIC dye-labeled probe, and one FAM dye- 
labeled probe for allelic discrimination (Figure 20). The MGB molecule binds to the minor 
groove of the DNA helix, improving hybridization-based assays by stabilizing the MGB-
probe/template complex. Allele detection is achieved with exonuclease cleavage of a 5´ allele-
specific dye label, which generates the permanent assay signal A non-fluorescent quencher 
(NFQ) is also implemented to eliminates background fluorescence and improve signal strength, 
and therefore call accuracy. PCR was performed on a using a PTC-200 Peltier Thermal Cycler 
(MJ Research)  and an ABI PRISM® 7900HT Sequence Detection System was used to run the 
samples and analyze the results. The cycling conditions involve an initial hold for 10 min at 
95 °C, followed by 40 amplification cycles (15 secs at 95 °C, 1 min at 60 °C). 
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Figure 20. Schematic representation of TaqMan probe-target matches and mismatches 
From Applied Biosystems, 2004 
 
5.4 IN VITRO ANALYSIS 
5.4.1 Construction of APOH Promoter Luciferase Reporter Gene Vector (Wild-type) 
A 1,418 bp fragment of the human APOH 5´-flanking region (-1375/+43 nucleotides from the 
translation initiation codon ATG) containing the promoter and the first untranslated exon (Figure 
21, http://pga.gs.washington.edu/data/apoh/apoh.ColorFasta.htm [106]) was PCR amplified 
using forward (5'-TGGCAGCACACTCTTCTTAT-3') and reverse (5´-
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GTTCTCGAGTTTTCTCTGCC-3´) primers. This APOH promoter fragment was amplified from 
an individual who had wild-type alleles for all 14 promoter SNPs included in this study. The 
PCR conditions were denaturing at 95°C for two minutes, followed by 35 cycles of denaturing at 
95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for one minute, 
before a final extension at 72°C for 10 minutes. The PCR-generated fragment was cloned into 
the pCR-2.1-TOPO vector (Invitrogen Corporation, Carlsbad, CA) using the supplier’s standard 
protocol. The size and orientation of the DNA insert was confirmed by restriction analysis 
(HindIII and SacI). The promoter fragment was then excised out of the TOPO vector using 
enzymes KpnI and EcoRV and ligated into the KpnI-SmaI restricted pGL3-Basic firefly 
luciferase (Luc) reporter plasmid (Figure 22) and transformed into top 10 chemically competent 
cells (Invitrogen Corporation, Carlsbad, CA), with positive clones then selected. Following 
transformation, the reporter construct pGL3-APOH promoter was confirmed by sequencing. This 
constituted the original wild-type APOH promoter construct which contained the major alleles 
for all 14 APOH promoter SNPs. 
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 Figure 21. APOH promoter fragment (1,418 bp) containing the 14 SNPs 
 
 
 
 
AGTGGCAGCA CACTCTTCTT ATCATGGAAC ACAATGTTCA TTAGGATCGT  
AATTTAAGAA TCATCTGCCT GACAGATGGA GATTTCTCAA G ATGTGT  
CTCAGGGAAT TTTAGACCTC TGGATATAAA CCAAGATCAC CCAAATGAGA  
GCAAGC GAG GTTATTTATT CAGAGCTTGC TATAG AAGG GAGGCAGCCA 
CTG -1284C>G
G G -1219G>A;-1190G>
TTAACAGTTG TGTTTGGCAG AGACTCAAAG TCAAAGTCAG ACAGAGGAGT   
GGGAAAGCTT TATAATAGAA AAAAGGAAAG GCTTCAGGTG TGCTCCAAC
GATTGTTGGT ATGGGGAGGA GGAAGGAAA CTAACTAGAA GTGAGGTGTC  
CATGTGATTG GTTAGAGAAA TATGTTTGGA TTTCTCTGGT TGGCCTTAAG   
TTGGGCCAAC TGCTATAGAG GTTGTAGGTT TGGCTTTCTA GACCTGTTGC   
TACAGATGTG TGGGTCAGAG TTCTGTTTTC ACATATGGCC TGGCTATTGT   
CCATTTATAT ATCCTTTTTT TTTTTTTTAG AGCAAATGAT GTAGAAGAGA   
ACTAGGGAAT CAAAGACAAC CCCCCTTCCG AACCCTCTCA AGCAACAACA   
TCAGCACTGG CCCATT T TATCCTACTC AAG TTT TTTCTTCTTC 
G -1076G>A 
 T -1055T>G
ATC TTTT -759A>G; -742del
CAAT -700C>A
TTAAG AG -643T>C; -
GAGTCCCAAG TTGTTAATTT CAAAT T TTCAAATTCC TGAAACAGAT  
CTAGAAACCT GTCTAGACAG ATCCAAGACA TA AAT GGATGAGG  627A>C
GACTTTGTAT TGATCTGACG TAAGAGAAGA TAGAGAATTC AAGG CT  
CTAAGGTCCT AACTGGAGCT ATAGGAGCTT GCAAGAGAGG ATGTTGAGCT   
CAGTTTGTAG GGAATTAAAG TTGTAAGTGC CTCCTGGAAG ACATTCTTTG   
TAATTATACA TCTGAAAACT GGAACATCAT TTTAGAGAGG TGGAGACTGA   
GAACAGAGAG TAGGTGTTTG TCCAAAGTTT ATATGCCAAG GCTGTGAGTG   
AAACAGGAGC TT ATCTTT TGGTGTTCCA TCTACAACAT ACACAAAACA  
AAAGATGGAG AATGAGAAGT CCAGGCAACC CCGGAAACAA CAAGTTTCTG   
TCAAAAGCAA TAATGAACTG TTTTGTGCCA TTAACAAAAA CGTTATGAAG   
ACAGAAACCA TCTCCCAAAG ATTTCATAAC AGAGCCACAT AAGTGGAAAG   
TAAATGATTA AAGAATGTGG GTCTCAGAGT TCCATTCAAA TCATGATACT   
TTATCTTCTA TTTACAAAGA TAAAAGTACA CCAGAAAATG GTTAATGTTT   
AAGCGCTTTC ATATTTGGCT CTGTCTTTTT AGCAGAC  AAC ACTTTG  
GTAGTGCCAG TGTGACTCAT CCACAATGAT TTCTCCAGTG CTCATCTTGT  
                            M  I   S  P  V   L  I  L    
TCTCGAGTTT TCTCTGCC  
F  S  S  F   L  C               
     Repeat      UTR      SNPs 
ATAG -581A>C
CG -363C>T
GAA C -38G>A, -32C>A
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 Figure 22. Construction of APOH promoter luciferase reporter gene vector (wild-type) 
5.4.2 Construction of APOH Promoter Deletion Mutants 
Experimental Design: Examination of the 5´-flanking region helps localize previously 
unrecognized and functionally important positive/negative regulatory sequences. Deletion 
analysis with promoter-reporter fusion constructs is based on the assumption that elimination of 
important cis-elements will result in reduced or abolished reporter gene expression. For this 
purpose, we subcloned series of 5´- deletion mutants of the ~ 1.4 bp APOH promoter fragment 
into a new Luc reporter vector pGL3-Basic. The construction process involved excising the 
desired length deletion fragments from the initial wild-type construct and inserting them into an 
empty pGL3-Basic vector with no insert. For this purpose, the original wild-type construct 
carrying the 1,418 bp APOH promoter fragment served as a parental template for designing PCR 
primers to amplify several truncated APOH promoter fragments. Due to the presence of a large 
amount of repeat sequence within the ~1.4 kb fragment we designed five APOH deletion mutant 
constructs differing in approximately 200 bp between each fragment as shown in Figure 23. 
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APOH Deletion fragment 1 (APOH del FR #1): It is the largest of all 5 fragments (858 bp). The 
position of this region with respect to the translational start site is +43 to -815. 
APOH Deletion fragment 2 (APOH del FR #2): This fragment contains 618 bp. The location of 
this deletion mutant from the translational start site is +43 to -575. 
APOH Deletion fragment 3 (APOH del FR #3): The third fragment (368 bp) position with 
respect to the translational start site is +43 to -325. 
APOH Deletion fragment 4 (APOH del FR #4): The fourth fragment is further truncated to 
position -166 and is sized 209 bp. 
APOH Deletion fragment 5 (APOH del FR #5): It is the smallest of all 5 fragments (109 bp). The 
position of this region with respect to the translational start site is +43 to -65. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 APOH wild-type            -1375                                             +43 
 
 
APOH Del Fragment 1                -815                                  +43 
                                                                                     
 
APOH Del Fragment 2                            -575                      +43 
 
                                                                                    
APOH Del Fragment 3                                   -325               +43 
 
 
APOH Del Fragment 4                                           -166         +43 
 
 
APOH Del Fragment 5                                              -65        +43 
 
Figure 23. Schematic diagram to illustrate the APOH deletion mutant constructs 
f-Luc = Firefly luciferase reporter gene of pGL3-Basic vector 
 
 
 
Construction of Deletion Mutants: The initial construct comprised of the plasmid pGL3-Basic 
containing the 1418 bp fragment of the 5´-flanking region of APOH served as a template for 
PCR in order to amplify the five truncated fragments. Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) was used to design PCR primers containing 
linker sites for the restriction enzymes - KpnI and BamHI at the 5´ and 3´ ends of each deleted 
fragment respectively. Table 7 gives the list of PCR primers containing the KpnI and BamHI 
f-Luc 
f-Luc  
f-Luc 
f-Luc 
f-Luc 
f-Luc 
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sites. The PCR conditions used were, denaturing at 95°C for 5 minutes, followed by 35 cycles of 
denaturing at 95°C for 45 seconds, annealing at 55°C for 1 minute, and extension at 72°C for 1 
minute, before a final extension at 72°C for 10 minutes. 
 
Table 7. PCR primers containing the KpnI and BamHI sites for APOH promoter deletion 
analysis 
 
Bases highlighted in red indicate: Kpn1 site and blue: BamH1 site 
 
The PCR products were gel purified (Qiagen, Valencia, CA) and then excised from the 
original pGL3-Basic vector by double digestion with KpnI and BamHI restriction enzymes. The 
digested fragments were again gel purified. The promoter-less pGl3-Basic vector (Promega 
Corporation, Madison, WI) was digested with KpnI and BglII, gel purified and Calf Intestinal 
Alkaline Phosphatase (CIP) treated in order to prevent self ligation of the empty vector. The 
APOH-PCR DNA was then ligated to the gel purified and CIP-treated pGL3-Basic vector by T4 
DNA ligase to generate the fusion vector construct carrying APOH-upstream truncated sequence 
fused to the in-frame luciferase reporter gene (Figure 24). The ligated product was then 
transformed into competent E. coli followed by screening of recombinant plasmids by colony 
PCR technique. The positive clones carrying the PCR fragment inserted into the pGL3-Basic 
vector were further confirmed by DNA sequencing and restriction digestion.  
 
Deletion Mutants Forward Primer (5´ to 3´) Reverse Primer (5´ to 3´) 
  
APOH del  FR# 1  GCTCGGTACCCAAAGACAAC CATGGATCCGGCAGAGAAA 
APOH del  FR# 2 CTC TAAGGTCCTAACT TCATGGATCCGGCAGAGAA GGTACCC
APOH del  FR# 3 GCTC AAGATGGAG CATGGATCCGGCAGAGAA GGTACCA
APOH del  FR# 4 GCTC AGAATGTG CATGGATCCGGCAGAGAA GGTACCAA
APOH del  FR# 5 CTC TATTTGGCTCT TCATGGATCCGGCAGAGA GGTACCCA
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Figure 24. Construction of APOH promoter deletion mutants  
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 5.4.3 Site-Directed Mutagenesis 
Constructs bearing mutant/minor alleles for each APOH promoter variant were generated by 
PCR using the wild-type APOH promoter/luciferase report construct (~1.4 kb 5' region of APOH 
promoter inserted into the pGL3-Basic luciferase reporter vector) as template according to the 
manufacturer’s protocol in the QuickChange II Site-directed Mutagenesis kit (Stratagene, La 
Jolla, CA). Primers were designed according to manufacturer’s instruction using the PrimerX 
software (http://www.bioinformatics.org/primerx/index.htm) as listed in Table 8. The basic 
procedure (Figure 25) utilizes a supercoiled double-stranded plasmid DNA (dsDNA) vector with 
an insert of interest and two synthetic oligonucleotide primers containing the desired mutation. 
PfuTurbo DNA polymerase extends the oligonucleotide primers, each complementary to 
opposite strands of the vector, during PCR. The PCR conditions used were denaturing at 95°C 
for 30 seconds, followed by 16 cycles of denaturing at 95°C for 30 seconds, annealing at 55°C 
for one minute, and extension at 68°C for six minutes, before a final extension at 68°C for 10 
minutes. Incorporation of the oligonucleotide primers generates a mutated plasmid containing 
staggered nicks. Following the thermal cycling, the PCR product was incubated with 1 μL Dpn I 
enzyme for an hour at 37°C. Dpn I, a restriction endonuclease specific for methylated and 
hemimethylated DNA, is used to digest the parental DNA template and to select for mutation-
containing synthesized DNA. Then 4 μL of the digestion was transformed into XL1-Blue 
supercompetent cells and positive clones were cultured to prepare minipreps of DNA using 
Qiaprep Spin Miniprep Kit. The success/presence of mutant clones and the fidelity of the Pfu 
DNA polymerase were verified by sequencing the plasmid DNA. A pWhitescript 4.5-kb control 
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plasmid was used to test the efficiency of mutant plasmid generation using this kit. Following 
transformation, positive control colonies were screened for the β-galactosidase (β-gal+) 
phenotype of blue color on media containing IPTG (Isopropyl-Beta-d-Thiogalactopyranoside) 
and X-gal. 
 
 
 
Figure 25. Overview of Quikchange II site-directed mutagenesis method 
From Stratagene, 2007 
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Table 8. PCR primers for site-directed mutagenesis of APOH promoter SNPs 
APOH 
Promoter 
SNPs 
PCR Primers for Mutagenesis 
( sense primer sequence (5’-3’) / antisense primer sequence (5´-3´) ) 
-1284C>G GGAGATTTCTCAAGGTC
GATGTGTCTCAGGG / 
CCCTGAGACACATCA CTTGAGAAATCTCC 
-1219G>A CCCAAATGAGAGCAAGCAGTGC
AGGTTATTTATTCAG / 
CTGAATAAATAACCTC TTGCTCTCATTTGGG 
-1190G>C GAGCTTGCTATAG GGGAGGCAGC / CTGCCTCCCTT TATAGCAAGCTC CAA GC
-1076G>A CAGGTGTGCTCCAACAGTG
ATTGTTGGTATGG / 
TACCAACAATC TTGGAGCACACCTG  
-1055T>G GGTATGGGGAGGA AAGGAAACTAAC / GTTAGTTTCCTTCC CCTCCCCATACC GGG CT
-759A>G CAGCACTGGCCCATT TTATCCTACTCAAG / CTTGAGTAGGATAAGA TGGGCCAGTGCTG  
GTC
CAA
-700C>A CCCAAGTTGTTAATTTCAAATAAATAT
TTTTCAAATTCCTGAAAC / 
GTTTCAGGAATTTGAAAATT TTGAAATTAACAACTTGGG 
-643T>C GACAGATCCAAGACATA ATGAGGAG / CTCCTCATCCATTCTTA TGTCTTGGATCTGTC 
CTAAGAATGG
GTA
-627A>C CATATTAAGAATGGATGAGG GACTTTGTATTGATCTGACG / CGTCAGATCAATACAAAGTCC TCATCCATTCTTAATATG 
CG
GCC
-581A>C GAAGATAGAGAATTCAAGG GCTCTAAGGTCCTAAC / GTTAGGACCTTAGAGCTA CTTGAATTCTCTATCTTC 
CTA
GC
-363C>T GTGAAACAGGAGCTT ATCTTTTGGTGTTCC / GGAACACCAAAAGATC GCTCCTGTTTCAC 
TG
AAA
AAAA
TG-38G>A 
CTCTGTCTTTTTAGCAGAC ACCACTTTGGTAGTGC / 
GCACTACCAAAGTGGTTTT TCTGCTAAAAAGACAGAG 
-32C>A CTTTTTAGCAGACGAAAACAACTGTTTT
TTTGGTAGTGCCAGTG / 
CACTGGCACTACCAAAGT CGTCTGCTAAAAAG    
 
Bases highlighted in red indicate introduced point mutations 
 
5.4.4 Cell Culture, Transient Transfection and Dual-Luciferase Reporter Gene Assay 
Dual-Luciferase reporter gene assays were performed between wild-type and mutant constructs 
carrying minor allele at individual SNP sites for each of the APOH promoter polymorphisms. 
Reporter assays were also performed between the wild-type and mutant H3 (minor allele only at 
SNP -643T>C) and H7 (minor alleles at SNPs -643T>C, -1190G>C and -759A>G) haplotype 
pGL3-basic firefly luciferase reporter vectors. The wild-type and mutant constructs were used to 
transiently co-transfect COS-1 cells along with the Renilla luciferase control vector (pRL-TK) 
(Promega). COS-1 (African green monkey kidney) cells were obtained from the American Type 
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Culture Collection (ATCC CRL-1650, Rockville, MD) and cultured at 37°C under 5% CO2 in 
Dulbecco's modified Eagle's medium (DMEM, Gibco, Invitrogen) supplemented with 10% fetal 
bovine serum, 2mM glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin and were 
harvested at 50 to approximately 70% confluence. HepG2 cells (Human hepatocellular liver 
carcinoma; ATCC HB-8065) were grown in Eagle's minimal essential medium (EMEM, ATCC) 
supplemented with 10% fetal bovine serum, and penicillin/streptomycin.  A day prior to 
transfection, 1.6 x 105 cells were seeded in each well of a 12-well plate with 1mL of antibiotic-
free DMEM/EMEM media. Transfection of cells was performed utilizing Lipofectamine 2000 
reagent as per manufacturer's instructions (Invitrogen Corporation, Carlsbad, CA). Briefly, Opti-
MEM I reduced serum media (Invitrogen Corporation, Carlsbad, CA) was used to plate 60-80% 
confluent cells in 12-well culture plates and  each well was then  transiently co-transfected with 
1.5 µg of the pGL3 vector (with /without APOH promoter) and 50 ng of the pRL-TK vector 
(Promega Corporation, Madison, WI) using the cationic lipid-based transfection lipofectamine 
2000 (4 µl/ml ) reagent (Invitrogen Corporation, Carlsbad, CA, USA). The pRL-TK vector 
encoded for the Renilla luciferase transcribed by a HSV-TK promoter which was used as internal 
control to normalize firefly luciferase expression. After 5–7 hours (hrs) of exposure to the 
transfection medium, cells were incubated with serum-containing DMEM/ EMEM media and 
incubated for 48 hrs before dual-luciferase reporter assays (Promega Corporation, Madison, WI)  
were performed. Upon completion of 48 hrs, the cells were lysed in 100 μL passive lysis buffer 
(Promega Corporation, Madison, WI). Cell lysate was added to the luciferase substrate (dual 
luciferase reporter system, Promega) and firefly and Renilla luciferase light outputs were 
measured with either TD-20/20 Luminometer (Turner Design, Sunnyvale, CA) or the Tecan 
Infinite 200 plate reader (Tecan Trading, Switzerland) according to the manufacturer's 
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instructions. The luciferase data (firefly/renilla) was used in the statistical analysis and 
normalized to the average activity of the promoter-less empty vector to yield data reflecting fold-
activity increase over baseline levels for each APOH promoter construct. Triplicate wells for 
each transfection condition were assayed (intra-experiment variation), and three independent 
transfections were carried out (inter-experiment variation). 
 
5.4.4.1 Principle of Dual-Luciferase Reporter Assay  
 
In the Dual-Luciferase reporter assay, the activities of firefly (Photinus pyralis) and Renilla 
(Renilla reniformis, also known as sea pansy) luciferases are measured sequentially from a single 
sample. The firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II 
(LAR II) to generate a stabilized luminescent signal. After quantifying the firefly luminescence, 
this reaction is quenched, and the Renilla luciferase reaction is simultaneously initiated by 
adding Stop & Glo® Reagent to the same tube. The Stop & Glo® Reagent also produces a 
stabilized signal from the Renilla luciferase, which decays slowly over the course of the 
measurement. In the DLR. Assay System, both reporters yield linear assays with no endogenous 
activity of either reporter in the experimental host cells. Both firefly and Renilla luciferases have 
dissimilar enzyme structures and substrate requirements. Firefly luciferase is a 61kDa 
monomeric protein that functions as a genetic reporter immediately upon translation. Photon 
emission is achieved through oxidation of beetle luciferin in a reaction that requires ATP, Mg2+ 
and O2 (Figure 26).The luminescent reaction catalyzed by Renilla luciferase (36kDa monomeric 
protein) utilizes O2 and coelenterate-luciferin (coelenterazine; Figure 9). 
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Figure 26. Bioluminescent reactions catalyzed by firefly and Renilla luciferases 
 
5.4.5 Electrophoretic Mobility Shift Assay  
Electrophoretic mobility shift assays (EMSA) were performed to analyze the binding of nuclear 
proteins from HepG2 cell nuclear extracts to oligonucleotides comprising of APOH promoter 
SNPs. Four single-stranded ~30-mer oligonucleotides corresponding to the wild-type or mutant 
allele were custom ordered (Sigma Genosys, TX and Operon Biotechnologies, AL) for each 
APOH SNP (Table 9). To make double-stranded probes and competitors, complementary oligos 
of equal amount were heated at 95°C for 5 min and then annealed for an hour at room 
temperature. The wild-type oligonucleotide was 5'-end-labeled with [γ-32P] ATP using T4 
polynucleotide kinase (New England Biolabs, MA) and purified by the QIAquick Purification kit 
(Qiagen, Valencia, CA). To allow DNA-protein binding, the mixture of unlabeled and labeled 
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oligos were incubated with 1 μL (5.68μg) of human HepG2 cell nuclear extracts for 20 minutes 
at room temperature in gel shift binding buffer (1 mM MgCl2, 0.5 mM EDTA, 0.5 mM 
dithiothreitol, 50 mM NaCl, 10 mM TRIS-HCl pH 7.5, 20% glycerol). For the competition 
experiments, unlabeled competitor DNA was added in 1x, 5x, 20x, 50x, and 100x excess 
volumes of the labeled probe and was incubated with the HepG2 nuclear extract (Active Motif, 
CA) for 10 min before the addition of the labeled probe The DNA-protein complexes were then 
separated on 5% polyacrylamide gel at 120 volts for two hours, the gels were dried and exposed 
overnight for autoradiography on X-ray films (Kodak). For setting up of EMSA experimental 
procedures, an earlier published positive shift assay for the APOH promoter SNP -32C>A [116] 
was reproduced and used as a positive control. 
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Table 9. EMSA oligonucleotide sequences of APOH promoter SNPs 
APOH 
Promoter 
SNPs 
EMSA Oligonucleotides  
( sense primer sequence (5’-3’) / antisense primer sequence (5´-3´) ) 
-1284C GATTTCTCAAGCTG GCATGTGTCTCAGGGA / TCCCTGAGACACATCA TTGAGAAATC 
-1284G GATTTCTCAAG GATGTGTCTCAGGGA / TCCCTGAGACACATCAGT CCTTGAGAAATC 
-1219G AAATGAGAGCAAGCG CGCGAGGTTATTTATT / AATAAATAACCTC TTGCTCTCATTT 
-1219A AAATGAGAGCAAGC AGGTTATTTATT / AATAAATAACCTC TTGCTCTCATTT AG TGC
-1190G AGCTTGCTATAG GAGGCAGC / GCTGCCTCCCTTGAAGG CCTATAGCAAGCT 
-1190C AGCTTGCTATAG AGGCAGC / GCTGCCTCCCTT TATAGCAAGCT CAAGGG GC
G CGTT-1076G GGTGTGCTCCAAC GATTGTTGGTATGGGG / CCCCATACCAACAATC GGAGCACACC 
-1076A GGTGTGCTCCAAC ATTGTTGGTATGGGG / CCCCATACCAACAATC TGGAGCACACC AG TGT
-643T GACAGATCCAAGACATA GAATGG / CCATTCTTA TGTCTTGGATCTGTC TTAA ATA
-643C GACAGATCCAAGACATA AATGG / CCATTCTTA TGTCTTGGATCTGTC CTAAG GTA
-32C CAGACGAAAAC TTTGGTAGT / ACTACCAAAGT TTTTCGTCTG CAC GG
 
 Bases highlighted in red indicate SNP location 
5.5 STATISTICAL ANALYSIS 
Allele frequencies were determined by direct allele counting. Concordance of the genotype 
distribution to Hardy-Weinberg equilibrium was tested using χ2 goodness-of-fit test for each 
polymorphism. LD pattern was determined using the Haploview version 3.32 
(http://www.broad.mit.edu/mpg/haploview/). To control for multiple testing concerns, we 
performed two types of “gate-keeper” analyses to determine whether there was evidence that any 
of these SNPs influenced risk of SLE: (1) multiple regression incorporating all SNPs and (2) 
haplotype analyses. The multiple regression analysis was performed under additive model for 
genotypic effects, that is, major allele homozygote = 0, heterozygote = 1, minor allele 
homozygote = 2.  Subsequent to observing associations with SLE risk, we performed additional 
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analyses to determine if any of the promoter SNPs also influenced specific clinical 
manifestations of SLE to gain insights into possible mechanisms of action.  Again, to control for 
multiple testing concerns, we initially assessed possible associations of all SNPs with clinical 
variables assessed in patients only (the cases who were negative for these variables were treated 
as controls) using a multiple regression analysis.  In these analyses, the genotypic effects were 
modeled as dominant (i.e., major homozygote vs. heterozygote + minor homozygote) because of 
the small sample size. Only for those SNPs that showed significant association in multiple 
regression analysis, we performed follow-up single-site analysis of the genotype (using Fisher’s 
exact test or analysis of deviance when adjusting for covariates) and allele frequencies (standard 
Z-test of 2 binomial proportions). Carotid plaque was categorized as plaque positive (degree of 
plaque equal to or greater than 1) and plaque negative (degree of plaque equal to zero). The 
carotid IMT data was transformed to reduce the effects of non-normality. The covariates 
considered for analysis of variance (ANOVA), multiple regression analysis, and odds ratio (OR) 
calculation were age, body mass index (BMI), ever smoking, lipid profile (high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol 
and triglycerides) and C-reactive protein (CRP) levels whenever they were significant for a given 
phenotype. All computations were performed using the R statistical software package (version 
2.3.1, http://www.r-project.org). The haplotype analysis was performed using both EH (Estimate 
Haplotype-frequencies) (version 1.2, http://linkage.rockefeller.edu/ott/eh.htm) and Haploview 
programs to check for overall haplotype distribution differences and individual haplotype 
associations, respectively. A P value of less than 0.05 was considered as suggestive evidence of 
association. Student’s t-test was used to determine statistical significance of the expression 
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difference between the wild-type and mutant constructs. Power analysis was performed using the 
QUANTO software (http://hydra.usc.edu/GxE).  
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6.0  RESULTS 
6.1  5´ SERIAL DELETION ANALYSIS OF APOH PROMOTER 
In order to localize the active promoter regions and to identify regions that are important for 
regulation of the human APOH activity, the wild-type 1,418 bp 5'–flanking region of APOH was 
amplified from genomic DNA and used as template to create a series of five different deletion 
constructs containing 5' truncated fragments of APOH promoter fused upstream to a 
promoterless firefly luciferase (Luc) gene of the pGL3-Basic reporter vector (Figure 23). The 
sequence of each construct was verified by sequencing (data not shown) and confirmed by 
alignment with the human genomic DNA database. For COS-1 cells, as shown in Figures 27-29, 
the wild-type region extending from −1375 to +43 had promoter activity since luciferase activity 
of the reporter gene was ~4.5 fold that of the empty vector. A 5′ deletion of the promoter 
sequence to −815 (mutant 1, -815/+43), and further deletion to -575 (mutant 2, -575/+43) 
increased promoter activity; however there was no significant difference in luciferase activity 
between the wild-type, mutant 1, and mutant 2 constructs (Experiment III: wild-type vs. mutant 
1; P = 0.260, wild-type vs. mutant 2; P = 0.135). Successive removal of nucleotides from −575 
(mutant 2, -575/+43), to −325 (mutant 3, -325/+43), enhanced promoter activity appreciably 
(Experiment III: wild-type vs. mutant 3; P = 0.019), suggesting the possibility of negative 
regulatory elements within the −575/−325 regions. The mutant 3 construct (-325/+43) conferred 
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maximum luciferase activity in COS-1 cells. Decrease in promoter activity was observed for 
further deletion of sequence from -325 to -166 (mutant 4, -166/+43), however not to a significant 
extent (Experiment III: P = 0.04). But when the sequence from −166 to −65 was removed 
(mutant 5, -65/+43), promoter activity dropped significantly (P < 0.001) compared to the wild-
type. This suggests the presence of a critical element in the region extending from −166 to −65.   
Although COS-1 transiently transfected cells have been widely used in studying APOH 
expression, we replicated the deletion analysis using human hepatoma cell line (HepG2) since 
the liver is a major site of synthesis of β2GPI. The magnitude of expression efficiency was much 
higher for HepG2 cells as compared to COS-1 cells because hepatocytes are the predominant cell 
type in the liver (Figures 30-31). Transfection of HepG2 cells revealed an overall similar trend as 
seen in COS-1 cells with mutant 3 (-325/+43) showing the highest promoter activity. A slight 
difference in trend was observed for the wild-type, mutant 1 (-815/+43), and mutant 2 (-575/+43) 
constructs, wherein mutant 1 was lower than the wild-type for HepG2 but not in COS-1 cells. 
Although, there was no significant difference between the three fragments (wild-type, mutant 1 
and mutant 2) for both cell lines, the inconsistency in trend can be attributed due to the cell-type 
related factors influencing the basal and inducible APOH expression. Consistent with COS-1 
cells, deletion from -166 (mutant 4, -166/+43) to -65 (mutant 5, -65/+43) almost abolished 
promoter activity by ~ 98% decrease in the promoter-luciferase activity when compared to the 
wild-type (P < 0.001, Table 11), indicating that the region between – 166 and − 65 contains cis-
elements that are critical for transcription of APOH.  
The average and standard deviation (SD) values along with the % increase/decrease with 
wild-type and significance of difference for each experiment is listed in Table 10 and Table 11 
for COS-1 cells and HepG2 cells, respectively. Thus, using both COS-1 and HepG2 cell lines, 
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we have identified the region ~166 bp upstream of the translation start site as the basal promoter 
of the human APOH and also the presence of key cis-acting elements located in the regions 
between -166 and -65 from ATG codon to regulate APOH expression. 
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Figure 27. Dual-luciferase of APOH promoter deletion experiment I In Cos-1 cells 
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Figure 28. Dual-luciferase of APOH promoter deletion experiment II in COS-1 cells 
 
 
 
Figure 29. Dual-luciferase of APOH promoter deletion experiment III in COS-1 cells 
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Figure 30. Dual-luciferase of APOH promoter deletion experiment I in HepG2 cells 
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Figure 31. Dual-luciferase of APOH promoter deletion experiment II in HepG2 cells 
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Table 10. Data values (average and SD) of APOH promoter deletion in COS-1 cells 
Experiment I 
Constructs Average SD 
% Increase (+) / 
Decrease (-) 
pGL3-Basic 1.00 0.04 -- 
Wild-type 4.35 0.35 -- 
Mutant 1 4.95 0.46 +13.84
Mutant 2 5.03 0.15 +15.67 
Mutant 3 6.29 0.43 +44.73 
Mutant 4 5.35 0.29 +23.01 
Mutant 5 1.74 0.07 -60.00 
Experiment II 
Constructs Average SD 
% Increase (+) / 
Decrease (-) 
pGL3-Basic 1.00 0.13 -- 
Wild-type 4.34 0.05 -- 
Mutant 1 4.78 0.07 +10.17 
Mutant 2 5.15 0.17 +18.77 
Mutant 3 6.16 0.25 +42.03
Mutant 4 5.54 0.16 +27.62 
Mutant 5 1.79 0.05 -58.63 
Experiment III 
Constructs Average SD 
% Increase (+) / 
Decrease (-) 
pGL3-Basic 1.00 0.12 -- 
Wild-type 4.47 0.47 --
Mutant 1 4.92 0.36 +10.05 
Mutant 2 5.13 0.39 +14.73 
Mutant 3 6.36 0.03 +42.33 
Mutant 4 5.36 0.20 +19.92 
Mutant 5 1.70 0.04 -61.90
  
% Increase/Decrease of each mutant is as compared to the wild-type  
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Table 11. Data values (average and SD) of APOH promoter deletion in HepG2 cells 
Experiment I 
Constructs Average SD 
% Increase (+) / 
Decrease (-) P - values 
pGL3-Basic 1.00 0.19 -- -- 
Wild-type 66.70 10.64 -- -- 
Mutant 1 60.00 5.75 -10.04 0.392
Mutant 2 73.51 9.62 +10.20 0.457 
Mutant 3 75.57 1.68 +13.30 0.284 
Mutant 4 57.26 5.87 -14.15 0.250 
Mutant 5 1.84 0.35 -97.24 0.009 
Experiment II 
Constructs Average SD 
% Increase (+) / 
Decrease (-) P - values 
pGL3-Basic 1.00 0.09 -- -- 
Wild-type 68.23 0.59 -- -- 
Mutant 1 59.84 3.32 -12.30 0.013 
Mutant 2 73.31 2.08 +7.45 0.015 
Mutant 3 88.74 0.99 +30.06 0.000
Mutant 4 67.64 0.43 -0.86 0.233 
Mutant 5 1.31 0.07 -98.08 0.000 
  
% Increase/Decrease of each mutant is as compared to the wild-type  
 
6.2 FUNCTIONAL CHARACTERIZATION OF APOH PROMOTER SNPS 
6.2.1 Dual-luciferase activity of individual APOH promoter SNPs in COS-1 cells 
In order to investigate the differential allele-specific effect on promoter activity, pGl3-Basic –
APOH promoter constructs harboring individual point mutations for each of the 12 APOH 
promoter SNPs (-1284C>G, -1219G>A, -1190G>C, -1076G>A, -1055T>G, -759 A>G, - 
700C>A, -627A>C, -643T>C, -363C>T -38G>A, and -32C>A) were generated. The summary of 
the results for each luciferase activity along with the average ± SD, % decrease as compared with 
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the wild-type construct and significance of difference between the wild-type and mutant APOH 
promoter constructs is listed in Table 12. The relative luciferase activity assessed in three 
independent experiments performed in triplicate for all of the APOH promoter SNP constructs is 
illustrated in Figures 32-43.  
Our results indicate that three APOH promoter SNPs (-1219G>A, -643T>C, and -
32C>A) possess a functional activity, because they significantly affected the production of the 
luciferase gene (P < 0.0001). All the three mutant alleles, -1219A, -643C, and -32A showed ~ 
51%, ~40% and ~ 36%  mean reduction of gene expression respectively when compared with the 
wild-type alleles (Table 12). None of the SNPs present in African Americans (-1076G>A, -
1055T>G, -627A>C, -581A>C and -363C>T) showed statistically significant reduction in gene 
expression (Table 12). The -32C>A SNP showed similar significant reduction effect as reported 
earlier by [116]; however the extent of reduction was slightly less in this study (~36% vs. ~50%) 
which can be attributed due to difference in constructs and experimental setup.  
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Table 12. Dual-luciferase of individual APOH promoter SNPs in COS-1 cells 
Wild-type Allele Mutant Allele 
(Mean ± SD) (Mean ± SD)
C G
5.06 ± 0.10 4.16 ± 0.36 17.79 0.014
5.27 ± 0.06 4.56 ± 0.34 13.47 0.023
5.55 ± 0.46 4.64 ± 0.46 16.40 0.075
G A
2.86 ± 0.05 1.40 ± 0.01 51.05 < 0.001
4.10 ± 0.21 2.06 ± 0.16 49.76 < 0.001
3.70 ± 0.12 1.81 ± 0.08 51.08 < 0.001
G C
3.01 ± 0.19 2.16 ± 0.03 28.24 < 0.01
2.79 ± 0.19 1.98 ± 0.23 29.03 < 0.01
3.93 ± 0.50 2.84 ± 0.08 27.74 < 0.01
G A
10.01 ± 0.38 9.13 ± 0.86 8.79 0.178
10.86 ± 0.53 9.98 ± 0.60 8.10 0.129
8.40 ± 0.47 7.74 ± 0.07 7.86 0.075
T G
4.66 ± 0.18 3.44 ± 0.17 26.18 < 0.01
7.66 ± 0.53 6.13 ± 0.04 19.97 < 0.01
3.49 ± 0.09 2.53 ± 0.14 27.51 < 0.01
A G
5.28 ± 0.29 4.57 ± 0.11 13.45 0.017
4.82 ± 0.27 4.27± 0.18 11.41 0.042
4.90 ± 0.12 4.38 ± 0.50 10.61 0.155
C A
4.65 ± 0.05 4.31 ± 0.10 7.31 < 0.01
4.90 ± 0.17 4.58 ± 0.33 6.53 0.214
4.27 ± 1.32 3.99 ± 0.51 6.56 0.745
T C
19.91 ± 1.68 11.94 ± 0.15 40.03 0.001
5.73 ± 0.07 3.20 ± 0.24 44.15 < 0.001
10.79 ± 0.88 6.26 ± 0.39 41.98 0.002
A C
3.09 ± 0.15 2.85 ± 0.11 7.77 0.086
6.72 ± 0.31 6.18 ± 0.12 8.04 0.049
5.75 ± 0.23 5.12 ± 0.01 10.96 0.009
C T
3.82 ± 0.34 3.34 ± 0.25 12.57 0.117
2.96 ± 0.49 2.42 ± 0.40 18.24 0.212
2.88 ± 0.16 2.44 ± 0.26 15.28 0.065
G A
4.56 ± 0.15 3.62 ± 0.15 20.61 0.002
3.95 ± 0.20 3.21 ± 0.17 18.73 0.009
3.81 ± 0.09 3.16 ± 0.03 17.06 < 0.001
C A
18.91 ± 0.38 11.92 ± 0.39 36.96 < 0.001
15.79 ± 1.03 10.32 ± 0.17 34.64 < 0.001
16.71 ± 0.92 10.56 ± 0.06 36.80 < 0.001
-1076G>A
-38G>A
-32C>A
-627A>C
-363 C>T
P -value% Decrease
-1055T>G
-759A>G
-700C>A
-643T>C
SNPs
-1284C>G
-1219G>A
-1190G>C
 
% Decrease and significance (P - values) of each mutant is as compared with wild-type 
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Figure 32. Dual-luciferase of APOH promoter -1284C>G SNP 
 
 
  
Figure 33. Dual-luciferase of APOH promoter -1219G>A SNP 
(* P < 0.0001)  
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 Figure 34. Dual-luciferase of APOH promoter -1190G>C SNP 
 
 
Figure 35. Dual-luciferase of APOH promoter -1076G>A SNP 
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 Figure 36. Dual-luciferase of APOH promoter -1055T>G SNP 
 
 
Figure 37. Dual-luciferase of APOH promoter  -759A>G SNP 
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 Figure 38. Dual-luciferase of APOH promoter -700C>A SNP 
 
 
   Figure 39. Dual-luciferase of APOH promoter -643T>C SNP                                                                               
   (* P < 0.0001) 
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 Figure 40. Dual-luciferase of APOH promoter -627A>C SNP 
 
 
Figure 41. Dual-luciferase of APOH promoter -363C>T SNP 
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 Figure 42. Dual-luciferase of APOH promoter -38G>A SNP 
 
 
Figure 43. Dual-luciferase assay of APOH promoter -32C>A SNP 
(* P < 0.0001) 
 
 99 
6.2.2 Electrophoretic mobility shift assays of APOH promoter SNPs 
To determine whether the APOH promoter polymorphisms affect the binding activity of nuclear 
factors, synthetic wild-type and mutant oligonucleotides were incubated with HepG2 cell nuclear 
extracts and subjected to EMSA. We assessed by EMSA whether a promoter SNP in a predicted 
transcription factor binding site (TFBS) would modify the binding of protein to the polymorphic 
DNA sequences. Upon incubation of radiolabeled oligonucleotides specific for wild-type and 
mutant alleles with HepG2 nuclear extracts, for each of the five promoter SNPs tested (-
1284C>G, -1219G>A, -1190G>C, -643T>C and -1076G>A), DNA-protein complexes were 
observed (Figures 44-48), indicating that a nuclear factor(s) binds these sequences. Competition 
assays using increasing amounts of unlabeled wild-type oligonucleotides lead to decrease in level 
of the labeled product as a consequence of increasing non-labeled oligomer concentration. This 
is an indication of the efficiency of displacement, thereby reflecting the relative stability and 
specificity of the formed DNA-protein complex. For all of the five of the APOH promoter SNPs 
processed similarly, none of them showed differential allelic shifts in HepG2 cell lines.  
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                                          -1284 C (Wild-type)                            -1284 G (Mutant) 
           _________________________________    ________________________ 
Lane               1        2        3         4         5          6         7         8          9        10       11       12      
Extract            -        +       +         +         +         +         +        +         +         +        +         +       
Competitor      -        -        1x        5x       20x      50x     100x     1x        5x      20x      50x     100x  
 
 
 
Figure 44. EMSA of -1284C>G SNP 
Each sample contains a mixture of 5 µg of nuclear extract derived from human HepG2 cell 
nuclear extract and 30xmer 32P-labeled wild-type oligonucleotide containing C allele. 
Arrowhead indicates specific DNA-protein complex associated with the -1284C>G polymorphic 
site. Lane 1, labeled oligonucleotide without nuclear extract from HepG2 cells; 2, labeled 
oligonucleotide with nuclear extracts. Lanes 3 to 7 have increasing amounts of C oligo 
competitor (1x, 5x, 20x, 50x, 100x, respectively); lanes 8 to 12 have increasing amounts of G 
oligo competitor (1x, 5x, 20x, 50x, 100x, respectively). 
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                                            -1219 G (Wild-type)                                  -1219 A (Mutant) 
             _______________________________________    ______________________________ 
Lane        1      2          3         4         5          6        7         8          9         10      11        12     
Extract     -      +         +          +        +         +        +         +         +         +        +         +       
        Competit       -      -         1x        5x       20x      50x     100x     1x        5x       20x     50x      100x   
 
 
 
Figure 45. EMSA of -1219G>A SNP 
Each sample contains a mixture of 5 µg of nuclear extract derived from human HepG2 cell 
nuclear extract and 30xmer 32P-labeled wild-type oligonucleotide containing G allele. 
Arrowhead indicates specific DNA-protein complex associated with the -1219G>A polymorphic 
site. Lane 1, labeled oligonucleotide without nuclear extract from HepG2 cells; 2, labeled 
oligonucleotide with nuclear extracts. Lanes 3 to 7 have increasing amounts of G oligo 
competitor (1x, 5x, 20x, 50x, 100x, respectively); lanes 8 to 12 have increasing amounts of A 
oligo competitor (1x, 5x, 20x, 50x, 100x, respectively). 
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                                         -1190 G (Wild-type)                                -1190 C (Mutant) 
                ___________________________________        __________________________ 
Lane         1       2          3        4         5       6         7           8        9        10      11        12      
Extract      -       +         +       +         +       +        +            +       +        +        +        +       
         Competitor   -        -         1x       5x      20x    50x    100x       1x       5x      20x    50x    100x  
 
 
Figure 46. EMSA of -1190G>C SNP 
Each sample contains a mixture of 5 µg of nuclear extract derived from human HepG2 cell 
nuclear extract and 30xmer 32P-labeled wild-type oligonucleotide containing G allele. 
Arrowhead indicates specific DNA-protein complex associated with the -1190G>C polymorphic 
site. Lane 1, labeled oligonucleotide without nuclear extract from HepG2 cells; 2, labeled 
oligonucleotide with nuclear extracts. Lanes 3 to 7 have increasing amounts of G oligo 
competitor (1x, 5x, 20x, 50x, 100x, respectively); lanes 8 to 12 have increasing amounts of C 
oligo competitor (1x, 5x, 20x, 50x, 100x, respectively). 
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                                      -1076 G (Wild-type)                                     -1076 A (Mutant) 
              ___________________________________           __________________________ 
            Lane         1          2        3        4         5        6        7             8        9        10      11        12      
             Extract      -         +       +        +         +        +        +            +        +        +        +        +       
          Competitor    -         -       1x        5x       20x     50x     100x      1x      5x       20x      50x    100x  
 
 
 
 
Figure 47. EMSA of -1076G>A SNP 
Each sample contains a mixture of 5 µg of nuclear extract derived from human HepG2 cell 
nuclear extract and 30xmer 32P-labeled wild-type oligonucleotide containing G allele. 
Arrowhead indicates specific DNA-protein complex associated with the -1076 G>A polymorphic 
site. Lane 1, labeled oligonucleotide without nuclear extract from HepG2 cells; 2, labeled 
oligonucleotide with nuclear extracts. Lanes 3 to 7 have increasing amounts of G oligo 
competitor (1x, 5x, 20x, 50x, 100x, respectively); lanes 8 to 12 have increasing amounts of A 
oligo competitor (1x, 5x, 20x, 50x, 100x, respectively). 
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               -643 T (Wild-type)                                           -643 C (Mutant) 
             _______________________________________    ______________________________ 
          Lane        1      2       3       4        5        6       7      8       9      10      11    12     13     14    15    16  
          Extract     -      +      +      +        +        +      +      +      +      +        +      +      +      +     +     + 
      Competitor   -      -      1x      5x     20x    50x  100x  200x  400x   1x    5x     20x    50x 100x  200x 400x 
 
 
Figure 48. EMSA of -643T>C SNP 
Each sample contains a mixture of 5 µg of nuclear extract derived from human HepG2 cell 
nuclear extract and 30xmer 32P-labeled wild-type oligonucleotide containing T allele. 
Arrowhead indicates specific DNA-protein complex associated with the -643T>C polymorphic 
site. Lane 1, labeled oligonucleotide without nuclear extract from HepG2 cells; 2, labeled 
oligonucleotide with nuclear extracts. Competition assay was performed by adding excess cold 
oligonucleotides containing either the -643 T allele (lanes 3 to 9) or the C allele (lanes 10 to 16). 
Lanes 3 to 9 have increasing amounts of T oligo competitor (1x, 5x, 20x, 50x, 100x, 200x, and 
400x, respectively); lanes 10 to 16 have increasing amounts of C oligo competitor (1x, 5x, 20x, 
50x, 100x, 200x, and 400x, respectively). 
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6.3 GENETIC ASSOCIATION OF APOH PROMOTER SNPS WITH SLE RISK 
AND/OR SLE-RELATED CLINICAL PHENOTYPES  
6.3.1 Linkage disequilibrium of APOH promoter SNPs in whites 
Pairwise LD analysis (quantified by D' and r 2) using seven SNPs showed similar patterns in 
cases and controls (data not shown), therefore only the results from combined case + control 
cohort are presented in Figures 49-50. There was a strong LD with high correlation (D' = 0.92, r2 
= 0.79) between -759A>G and -700C>A SNPs, hence one of these SNPs (-700C>A) was 
excluded from subsequent multiple regression and haplotype analyses.  
 
 
 
 
 
 
 
 
 
Figure 49. Pairwise LD analysis (D') of white cases + controls of APOH promoter SNPs 
 
Each square indicates the level of LD between two variants. The colors are defined as: red (high 
LD), LOD ≥ 2 and D' = 1; blue, LOD < 2 and D' = 1; white, LOD < 2 and D'<1. The top of the 
figure shows the genomic position of the SNPs. 
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Figure 50. Pairwise LD analysis (r2 x 100) of white cases + controls of APOH promoter SNPs 
The intensity of gray is proportional to r2, with the darkest gray being the highest r2 value. 
 
6.3.2 APOH promoter polymorphisms and race 
The genotype and allele frequencies of the APOH promoter polymorphisms between the white 
cases + controls (n =799) and black cases + controls (n = 90) are given in Table 13. The 
genotype distributions of all SNPs were in accordance with Hardy-Weinberg equilibrium 
expectations in both races. Both genotype distribution and allele frequency were significantly 
different between races (P < 0.001), for the -759A>G and -700C>A SNPs, that are in strong LD, 
with whites showing a higher frequency of the variant -759G (25.5% vs. 10.8%) and -700A 
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(24.1% vs. 10.3%) alleles than blacks, respectively. Significant difference in allele frequencies 
were also seen for the -1219G>A (P = 0.012) and -643T>C (P = 0.005) SNPs. 
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Table 13. Distribution of APOH promoter SNPs between whites and blacks 
 
SNP* Genotypes/ Whites Blacks SNP* Genotypes/ Whites Blacks 
 Alleles n (%) n (%)  Alleles n (%) n (%) 
-1284C>G Genotype  -700C>A Genotype   
(rs8178818) CC 795 (99.8) 88 (100.0) (rs3760291) CC 458 (57.8) 70 (80.5)
 CG 2 (0.25) 0 (0.0)  CA 288 (36.3) 16 (18.4) 
 GG 0 (0.0) 0 (0.0)  AA 47 (5.9) 1 (1.2) 
 total 797 88  total 793 87 
  **P = 1.000   **P < 0.001 
 Allele    Allele    
 C/G 0.999/0.001 1.000/0.000  C/A 0.759/0.241 0.897/0.103
  ***P = 0.157   ***P < 0.001 
-1219G>A Genotype  -643T>C Genotype   
(rs8178819) GG 662 (83.6) 80 (90.9) (rs3760292) TT 573 (72.1) 72 (81.8)
 GA 119 (15.0) 8 (9.1) TC 195 (24.5) 16 (18.2)
 AA 11 (1.4) 0  (0.0)  CC 27 (3.4) 0 (0.0) 
 total 792 88  total 795 88 
  **P = 0.219   **P = 0.065 
 Allele     Allele    
 G/A 0.911/0.089 0.955/0.045  T/C 0.843/0.157 0.909/0.091
  ***P = 0.012   ***P = 0.005 
-1190G>C Genotype   -38G>A Genotype   
(rs3760290) GG 294 (37.0) 40 (45.5)  GG 763 (96.0) 86 (97.7) 
 GC 393 (49.5) 37 (42.1) GA 30 (3.8) 2 (2.3)
 CC 107 (13.5) 11 (12.5) AA 2 (0.3) 0 (0.0)
 total 794 88  total 795 88 
  **P = 0.302   **P = 0.807 
 Allele    Allele   
 G/C 0.618/0.382 0.665/0.335  G/A 0.979/0.021 0.989/0.011
  ***P = 0.211   ***P = 0.254 
-759A>G Genotype    -32C>A Genotype   
(rs8178820) AA 444 (55.9) 70 (79.6) (rs8178822) CC 697 (87.7) 76 (86.4) 
 AG 295 (37.2) 17 (19.3)  CA 95 (12.0 11 (12.5) 
 GG 55 (6.9) 1 (1.1) AA 3 (0.4) 1 (1.1)
 total 794 88 total 795 88
  **P < 0.001   **P = 0.412 
 Allele     Allele   
 A/G 0.745/0.255 0.892/0.108  C/A 0.936/0.064 0.926/0.074
  ***P < 0.001   ***P = 0.616 
 
SNPs are numbered according to their positions relative to the first base of the start codon (ATG) 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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6.3.3 APOH promoter polymorphisms and SLE 
The genotype distributions in SLE cases and controls did not deviate significantly from Hardy–
Weinberg equilibrium for all the polymorphisms examined (data not shown). Minor allele 
frequencies (MAFs) of the APOH promoter SNPs that we observed in our control population (-
1284G: 0.1%, -1219A: 9.9%, -1190C: 37.6%, -759G: 24.1%, -700A: 24.4%, -643C: 13.8%, -
38A: 2.5%, -32A:6.2%) were similar to those previously reported in the literature (Chen and 
Kamboh, 2006) and/or in public databases. Due to its rare presence (MAF < 0.01), -1284C>G 
SNP was excluded from multiple regression and haplotype analyses.  
Multiple regression analysis (Table 14) of the remaining 6 SNPs showed significant 
association of the -1219G>A and -643T>C SNPs with SLE risk after adjusting for age (P = 
0.016 for each). However, the follow-up single-site analysis for the difference in genotype 
distribution and allele frequencies (Table 15) showed a significant association for only -643T>C; 
the genotype distribution of -643T>C in cases/controls was: 68.8%/74.6% for TT, 26.2%/23.2% 
for TC and 5.0%/2.2% for CC (age-adjusted P = 0.020); the -643C allele frequency was 18.1% 
in SLE cases vs. 13.8% in controls. The age-adjusted OR for the -643C allele under the additive 
model was 1.41 (95% CI: 1.07-1.86, P = 0.014). In order to replicate the -643 finding, we 
genotyped an independent sample from Chicago (109 SLE cases, 81 controls). No 
association/trend for association was observed in the Chicago (P = 0.919); the genotype 
distribution of -643T>C in cases/controls was: 73.3%/73.8% for TT and 26.7%/26.3% for TC). 
When the data from both cohorts was combined and analyzed by adjusting for the recruitment 
site, the association became less significant despite the increase in sample size and power 
(combined adjusted OR was 1.33 (95% CI: 1.04-1.70, P = 0.025). This suggests that the 
association of -643 with SLE risk may not be real. Analysis of genotype frequencies revealed no 
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significant difference between SLE patients and control subjects for the APOH promoter 
polymorphisms in the black population (Table 16). A caveat of this study is that the sample size 
of the black population is small and we did not have sufficient power in our study for the black 
population. Therefore, all further analyses were performed only in the white population. 
 
Table 14. Multiple regression * analysis of APOH promoter SNPs for SLE disease status, 
nephritis and subclinical CVD (carotid plaque and IMT) 
 
                                                                 P Value for **         
  SLE Nephritis Carotid Plaque Carotid IMT                        APA 
          Cases Controls 
rs8178819 (-1219G>A) 0.016 0.014 0.344 0.887 0.308 0.830
rs3760290 (-1190G>C) 0.982 0.790 0.070 0.322 0.105 0.374
rs8178820 (-759A>G) 0.182 0.185 0.884 0.903 0.469 0.686
rs3760292 (-643T>C) 0.016 0.944 0.003 0.036 0.703 0.302
(-38G>A) 0.295 0.200 0.022 0.836 4.57 x 10-4 0.644
rs8178822 (-32C>A)  0.646 0.344 0.033 0.753 0.356 0.617
 
* SLE risk was analyzed under additive model while lupus nephritis and carotid plaque, carotid 
IMT and APA under dominant model. 
** Adjusted for age for SLE and nephritis risk; adjusted for age, HDL-C, LDL-C, cholesterol 
and triglycerides for carotid plaque and IMT. 
 
 
 
 
 
 
 
 
 
 111 
Table 15. Distribution of APOH promoter SNPs between SLE white cases and controls 
 
Whites 
SNP* Genotypes/ Cases Controls SNP* Genotypes/ Cases Controls 
  Alleles n (%) n (%)   Alleles n (%) n (%) 
-1284C>G Genotype   -700C>A Genotype    
(rs8178818) CC 343 (99.7) 452 (99.8) (rs3760291) CC 201 (58.8) 257 (57.0) 
 CG 1 (0.3) 1 (0.2)  CA 120 (35.1) 168 (37.3) 
 GG 0 (0.0) 0 (0.0)  AA 21 (6.1) 26 (5.8) 
 total 344 453  total 342 451 
  **P = 1.000    **P = 0.827 
 Allele    Allele    
 C/G 0.999/0.001 0.999/0.001  C/A 0.763/0.237 0.756/0.244
   ***P = 0.848    ***P = 0.744 
-1219G>A Genotype     -643T>C Genotype      
(rs8178819) GG 295 (86.3) 367 (81.6) (rs3760292) TT 236 (68.8) 337 (74.6) 
 GA 42 (12.3) 77 (17.1)  TC 90 (26.2) 105 (23.2) 
 AA 5 (1.5) 6 (1.3)  CC 17 (5.0) 10 (2.2) 
 total 342 450  total 343 452 
  **P = 0.169    **P = 0.053 
 Allele    Allele     
 G/A 0.924/0.076 0.901/0.099  T/C 0.819/0.181 0.862/0.138
  ***P = 0.107    ***P = 0.023 
-1190G>C Genotype     -38G>A Genotype     
(rs3760290) GG 126 (36.7) 168 (37.3)  GG 332 (96.8) 431 (95.4) 
 GC 166 (48.4) 227 (50.3)  GA 11 (3.2) 19 (4.2) 
 CC 51 (14.9) 56 (12.4)  AA 0 (0.0) 2 (0.4) 
 total 343 451  total 343 452 
  **P = 0.599    **P = 0.463 
 Allele    Allele    
 G/C 0.609/0.391 0.624/0.376  G/A 0.984/0.016 0.975/0.025
   ***P = 0.547    ***P = 0.185 
-759A>G Genotype   -32C>A Genotype    
(rs8178820) AA 184 (53.8) 260 (57.5) (rs8178822) CC 300 (87.5) 397 (87.8) 
 AG 129 (37.7) 166 (36.7)  CA 41 (12.0) 54 (11.9) 
 GG 29 (8.5) 26 (5.8)  AA 2 (0.6) 1 (0.2) 
 total 342 452  total 343 452 
  **P = 0.273    **P = 0.765 
 Allele    Allele    
 A/G 0.727/0.273 0.759/0.241  C/A 0.934/0.066 0.938/0.062
   ***P = 0.146    ***P = 0.768 
 
 
 SNPs are numbered according to their positions relative to the first base of the start codon (ATG) 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 16. Distribution of APOH promoter SNPs between SLE black cases and controls 
 
Blacks 
SNP* Genotypes/ Cases Controls SNP* Genotypes/ Cases Controls 
  Alleles n (%) n (%)   Alleles n (%) n (%) 
-1284C>G Genotype   -700C>A Genotype    
(rs8178818) CC 46 (100.0) 42 (100.0) (rs3760291) CC 35 (77.8) 35 (83.3) 
 CG 0 (0.0) 0 (0.0)  CA 10 (22.2) 6 (14.3) 
 GG 0 (0.0) 0 (0.0)  AA 0 (0.0) 1 (2.4) 
 total 46 42  total 45 42 
  **P = 1.000    **P = 0.413 
 Allele    Allele    
 C/G 1.000/0.000 1.000/0.000  C/A 0.889/0.111 0.905/0.095
    ***P = 0.730 
-1219G>A Genotype     -643T>C Genotype      
(rs8178819) GG 43 (93.5) 37 (88.1) (rs3760292) TT 38 (82.6) 34 (81.0) 
 GA 3 (6.5) 5 (11.9)  TC 8 (17.4 8 (19.1) 
 AA 0 (0.0) 0 (0.0)  CC 0 (0.0) 0 (0.0) 
 total 46 42  total 46 42 
  **P = 0.471    **P = 1.000 
 Allele    Allele     
 G/A 0.967/0.033 0.940/0.060  T/C 0.913/0.087 0.905/0.095
  ***P = 0.397    ***P = 0.849 
-1190G>C Genotype     -38G>A Genotype     
(rs3760290) GG 22 (47.8) 18 (42.9)  GG 46 (100.0) 40 (95.2) 
 GC 17 (37.0) 20 (47.6)  GA 0 (0.0) 2 (4.8) 
 CC 7 (15.2) 4 (9.5)  AA 0 (0.0) 0 (0.0) 
 total 46 42  total 46 42 
  **P = 0.578    **P = 0.225 
 Allele    Allele    
 G/C 0.663/0.337 0.667/0.333  G/A 1.000/0.000 0.976/0.024
   ***P = 0.959    ***P = 0.152 
-759A>G Genotype   -32C>A Genotype    
(rs8178820) AA 35 (76.1) 35 (83.3) (rs8178822) CC 38 (82.6) 38 (90.5) 
 AG 11 (23.9) 6 (14.3)  CA 7 (15.2) 4 (9.5) 
 GG 0 (0.0) 1 (2.4)  AA 1 (2.2) 0 (0.0) 
 total 46 42  total 46 42 
  **P = 0.290    **P = 0.526 
 Allele    Allele    
 A/G 0.880/0.120 0.905/0.095  C/A 0.902/0.098 0.952/0.048
   ***P = 0.602    ***P = 0.195 
 
SNPs are numbered according to their positions relative to the first base of the start codon (ATG) 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Six-site haplotype analysis identified a total of nine haplotypes with a frequency of > 1% 
(Table 17). Using EH program, the overall haplotype distribution was found to differ 
significantly between cases and controls (P = 0.009). Using Haploview program, one particular 
haplotype (H7) was found to be present predominantly in cases (χ2 = 19.151, P = 1.21 x 10-5). 
This haplotype harbored the minor alleles for the -1190G>C, -759A>G and -643T>C SNPs. 
When we carried out a permutation test for haplotypes in Haploview (permutation number = 
1000), none of the permutations exceeded the highest observed χ2, confirming that the observed 
association of H7 was not just by chance.  
 
Table 17. Six-site haplotype analysis* of APOH promoter SNPs in SLE cases and controls 
 
              Haplotype frequencies 
  rs8178819 rs3760290 rs8178820 rs3760292  rs8178822 Total Cases Controls
Haplotype (-1219G>A) (-1190G>C) (-759A>G) (-643T>C) (-38G>A) (-32C>A) (n=783) (n=339) (n=444) 
H1 G G A T G C 0.441 0.424 0.455 
H2 G C G T G C 0.156 0.138 0.168 
H3 G G A C G C 0.119 0.104 0.129 
H4 G C A T G C 0.083 0.099 0.071 
H5 A C G T G C 0.057 0.043 0.069 
H6 G C A T G A 0.053 0.054 0.052 
H7 G C G C G C 0.018 0.045 0.000 
H8 G G A T A C 0.017 0.014 0.019 
H9 A G A T G C 0.012 0.018 0.007 
                                                                                                                                            P** = 0.009 
* Using program EH version 1.2 (excluding individuals with missing genotypes). 
** P value for overall haplotype distribution difference between cases and controls. 
 
Although the -643C allele appears to be functional, the two haplotypes (H3 and H7 in 
Table 2) that carry -643C, only H7 showed significant association with SLE risk. This suggests 
that other variants in the H7 haplotype might also be important in affecting APOH expression. 
To test this hypothesis, we mutated the defining alleles in H7 haplotype (-1190G>C, -759A>G, -
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643T>C) and compared its gene expression with the wild-type and H3 haplotypes. As shown in 
Figure 51, the H7 haplotype had the lowest luciferase activity as compared to the H3 haplotype 
in duplicate experiments. The data values (mean ± SD) along with the significance of difference 
(P - values) between constructs are summarized in Table 18.  
 
Table 18. Dual-luciferase of H3 and H7 haplotypes in COS 1 cells 
Experiment I 
Constructs Average SD % Decrease  P - values 
pGL3-Basic 1.00 0.13 -- -- 
Wild-type 6.99 0.68 -- -- 
H3 haplotype 3.94 0.05 43.63 0.016 
H7 haplotype 3.33 0.14 52.36 0.001 
Experiment II 
Constructs Average SD % Decrease P - values 
pGL3-Basic 1.00 0.09 -- -- 
Wild-type 6.84 0.95 -- -- 
H3 haplotype 3.94 0.07 42.40 0.033 
H7 haplotype 3.17 0.13 53.65 0.003 
 
% Decrease of each mutant is as compared with wild-type 
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Figure 51. Dual-luciferase of APOH haplotypes 
Bars indicate the means of luciferase activity from two independent experiments (*P < 0.05). 
The effect of wild-type and mutants were measured as the mean of the firefly luciferase levels, 
which were normalized by the Renilla luciferase activity, which served as the reference for the 
transfection efficiency. The results presented are from one out of two independent experiments. 
The wild-type haplotype contains the major alleles at all sites. While the H3 haplotype is defined 
by minor allele at SNP -643T>C, the H7 haplotype is defined by minor alleles at SNPs -643T>C, 
-1190G>C and -759A>G. 
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6.3.4 APOH promoter polymorphisms and lupus nephritis 
Because we obtained significant evidence that APOH promoter SNPs influenced SLE risk, we 
next investigated whether these SNPs influenced specific clinical manifestations of SLE.  
Multiple regression analysis in lupus patients stratified by the presence (n = 103) or absence (n = 
241) of renal disease showed significant association with -1219G>A (P = 0.014) after adjusting 
for age (Table 14). The -1219A allele frequency was 4.4% in SLE cases with nephritis vs. 9.0% 
in SLE cases without nephritis. The age-adjusted OR for the -1219A allele under dominant 
model was 0.36 (95% CI: 0.16-0.83, P = 0.016). Single-site genotype and allele carrier 
frequencies of the APOH promoter SNPs in SLE cases with/without nephritis is illustrated in 
Table 19. Although no significant associations were seen in the multiple regression analysis, two 
of the highly correlated promoter SNPs -759A>G and -700C>A SNPs were significantly 
associated with renal disease in SLE patients. The frequencies of the -759G (22.5% vs. 29.4%) 
and -700A (16.2% vs. 26.9%) alleles was lower in SLE nephritis subjects as compared to those 
without, respectively.   
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Table 19. Distribution of APOH promoter SNPs between SLE white cases with and  
without lupus nephritis 
 
Whites 
SNP* Genotypes/ Nephritis No Nephritis SNP* Genotypes/    Nephritis No Nephritis
  Alleles n (%) n (%)   Alleles n (%) n (%) 
-1284C>G Genotype   -700C>A Genotype     
(rs8178818) CC 102 (99.0) 241 (100.0) (rs3760291) CC 73 (71.6) 128 (53.3) 
 CG 1 (1.0) 0 (0.0)  CA 25 (24.5) 95 (39.6) 
 GG 0 (0.0) 0 (0.0)  AA 4 (3.9) 17 (7.1) 
 total 103 241  total 102 240 
  **P = 0.299    **P = 0.007 
 Allele    Allele     
 C/G 0.995/1.000 0.005/0.000  C/A 0.838/0.162 0.731/0.269
   ***P = 0.316    ***P = 0.001 
-1219G>A Genotype     -643T>C Genotype      
(rs8178819) GG 94 (92.2) 201 (83.8) (rs3760292) TT 69 (67.7) 167 (69.3) 
 GA 7 (6.9)  35 (14.6)  TC 27 (26.5) 63 (26.1) 
 AA       1 (1.0)  4  (1.7)  CC 6 (5.9)     11 (4.6) 
 total 102 240  total 102 241 
  **P = 0.105    **P = 0.832 
 Allele    Allele     
 G/A 0.956/0.044 0.910/0.090  T/C 0.809/0.191 0.824/0.176
  ***P = 0.019    ***P = 0.649 
-1190G>C Genotype     -38G>A Genotype     
(rs3760290) GG    45 (44.1) 81 (33.6)  GG 97 (95.1) 235 (97.5) 
 GC    43 (42.2)  123 (51.0)  GA 5 (4.9) 6 (2.5) 
 CC    14 (13.7)    37 (15.4)  AA 0 (0.0) 0 (0.0) 
 total 102 241  total 102 241 
  **P = 0.183    **P = 0.314 
 Allele    Allele    
 G/C 0.652/0.348 0.591/0.409  G/A 0.975/0.025 0.988/0.012
   ***P = 0.131    ***P = 0.313 
-759A>G Genotype    -32C>A Genotype    
(rs8178820) AA 66 (64.7) 118 (49.2) (rs8178822) CC 90 (88.2) 210 (87.1) 
 AG 26 (25.5) 103 (42.9)  CA 10 (9.8) 31 (12.9) 
 GG 10 (9.8) 19 (7.9)  AA 1 (2.0) 0 (0.0) 
 total 102 240  total 102 241 
  **P = 0.008    **P = 0.765 
 Allele     Allele    
 A/G 0.775/0.225 0.706/0.294  C/A 0.931/0.069 0.936/0.064
   ***P = 0.057    ***P = 0.837 
 
 
SNPs are numbered according to their positions relative to the first base of the start codon (ATG) 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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6.3.5 APOH promoter polymorphisms and subclinical cardiovascular disease (carotid 
plaque and carotid IMT) 
Multiple regression analysis of 6 SNPs in lupus patients stratified by the presence (n = 81) or 
absence (n = 164) of carotid plaque revealed significant associations with -643T>C (P = 0.003), -
38G>A (P = 0.022) and -32C>A (P = 0.033) SNPs after adjusting for age and lipid profile (Table 
14). Subsequent single-site analyses (adjusted for age and lipid profile) revealed significant 
genotype differences between the two groups for -643T>C and -32C>A SNPs but not for -
38G>A. Unadjusted single-site analysis revealed significance only for the -643T>C SNP (Table 
20: P = 0.017 for the genotype distribution; P = 0.002 for the allele distribution). The -643C 
allele frequency was 8.6% in SLE cases with carotid plaque vs. 18.4% in patients without plaque; 
the age- and lipid profile-adjusted OR for the -643C allele carriers (TT vs. TC + CC genotypes) 
was 0.37 (95% CI: 0.17-0.81, P = 0.013). The -32A allele frequency was 8.6% in SLE cases with 
carotid plaque vs. 5.8% in patients without plaque; the adjusted OR for the -32A allele carriers 
(CC vs. AA+CA genotypes) was 2.63 (95% CI: 1.09-6.35, P = 0.031). Multiple linear regression 
analysis of carotid IMT using the same model as for plaque demonstrated a significant 
association for only -643T>C after adjusting for age and lipid profile (P = 0.036) (Table 14) 
which was not observed in the single-site analysis (Table 21). 
Because -643T>C SNP was found to be associated with both carotid plaque and IMT in 
multiple regression analysis, we also genotyped this SNP in our Chicago SLE sample. The 
association of the -643T>C SNP with carotid plaque was confirmed in this independent sample 
of SLE patients from Chicago (37 with carotid plaque vs. 72 without carotid plaque). The age 
and lipid profile adjusted OR for the -643C allele carriers (TC + CC vs. TT genotypes) was 0.22 
(95% CI: 0.06-0.78, P = 0.019). When the data from both Pittsburgh and Chicago cohorts were 
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combined and analyzed by adjusting for the recruitment site, the adjusted OR was 0.35 (95% CI: 
0.18-0.67, P = 0.002) suggesting a protective effect of -643C allele against developing carotid 
plaque. 
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Table 20. Distribution of APOH promoter SNPs between SLE white cases with and without
   carotid plaque 
 
Whites 
SNP* Genotypes/ Plaque No Plaque SNP* Genotypes/ Plaque No Plaque
 Alleles n (%) n (%)  Alleles n (%) n (%) 
-1284C>G Genotype   -700C>A Genotype   
(rs8178818) CC 81 (100.0) 164 (100.0) (rs3760291) CC 47 (58.0) 90 (55.6) 
 CG 0 (0.0) 0 (0.0)  CA 26 (32.1) 63 (38.9) 
 GG 0 (0.0) 0 (0.0)  AA 8 (9.9) 9 (5.6) 
 total 81 164  total 81 162 
  **P = 1.000   **P = 0.320 
 Allele    Allele   
 C/G 1.000/0.000 1.000/0.000  C/A 0.741/0.259 0.750/0.250
     ***P = 0.826 
-1219G>A Genotype   -643T>C Genotype    
(rs8178819) GG 74 (91.4) 139 (85.8) (rs3760292) TT 68 (84.0) 109 (66.9) 
 GA 6 (7.4) 23 (14.2)  TC 12 (14.8) 48 (29.5) 
 AA 1 (1.2) 0  (0.0)  CC 1 (1.2) 6 (3.7) 
 total 81 162  total 81 163 
  **P = 0.088   **P = 0.017 
 Allele    Allele    
 G/A 0.951/0.049 0.929/0.071  T/C 0.914/0.086 0.816/0.184
  ***P = 0.331   ***P = 0.002 
-1190G>C Genotype   -38G>A Genotype   
(rs3760290) GG 29 (35.8) 56 (34.2)  GG 80 (98.8) 156 (95.1) 
 GC 38 (46.9) 87 (53.1)  GA 1 (1.2) 8 (4.9) 
 CC 14 (17.3) 21 (12.8)  AA 0 (0.0) 0 (0.0) 
 total 81 164  total 81 164 
  **P = 0.537   **P = 0.279 
 Allele    Allele   
 G/C 0.593/0.407 0.607/0.393  G/A 0.994/0.006 0.976/0.024
  ***P = 0.764   ***P = 0.083 
-759A>G Genotype   -32C>A Genotype   
(rs8178820) AA 46 (56.8) 86 (53.1) (rs8178822) CC 68 (84.0) 145 (88.4) 
 AG 27 (33.3) 67 (41.4)  CA 12 (14.8) 19 (11.6) 
 GG 8 (9.9) 9 (5.6)  AA 1 (1.2) 0 (0.0) 
 total 81 162  total 81 164 
  **P = 0.278   **P = 0.281 
 Allele    Allele   
 A/G 0.735/0.265 0.738/0.262  C/A 0.914/0.086 0.942/0.058
  ***P = 0.942   ***P = 0.265 
 
  
SNPs are numbered according to their positions relative to the first base of the start codon (ATG) 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 21. Single-site analysis of APOH promoter SNPs with carotid IMT 
SNP *P-value 
rs8178819 (-1219G>A) 0.113 
rs3760290 (-1190G>C) 0.366 
rs8178820 (-759A>G) 0.828 
rs3760292 (-643T>C) 0.244 
(-38G>A) 0.087 
rs8178822 (-32C>A) 0.628 
rs8178819 (-1219G>A) 0.634 
  
*Adjusted for age, HDL-C, LDL-C, cholesterol and triglycerides 
 
6.3.6 APOH promoter polymorphisms and the occurrence of antiphospholipid antibodies 
We categorized subjects into “APA-positive” and “APA-negative” groups. APA-positive group 
included participants positive for any of the following 3 antibodies; aCL (IgG and/or IgM), anti-
β2GPI (IgA and/or IgG and/or IgM) and LAC. APA-negative group contained individuals 
negative for all APA. None of the APOH promoter SNPs was found to have a significant 
association with the presence of APA in controls in multiple regression using dominant model 
(Table 14). However, in cases, the distribution of the -38G>A SNP differed significantly 
between APA-positive and APA-negative groups in both multiple regression (P = 4.57 x 10-4) 
and single-site analyses (P = 0.004). It is important to note that -38G>A is a relatively rare 
variant and was only detected in APA-positive patients (MAF = 0.027) but not in APA-negative 
patients. The significant difference in -38G>A genotype distribution was also observed when the 
comparison was subcategorized between aCL-positive vs. APA-negative (P = 0.018), LAC-
positive vs. APA-negative (P = 0.001) and anti-β2GPI-positive vs. APA-negative (P = 0.002) 
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cases using multiple regression under dominant model (data not shown). The genotype and allele 
frequency distribution of the seven APOH promoter SNPs (-1219G>A, -1190G>C, -759A>G, -
700C>A, -643T>C, -38G>A, -32C>A) between APA-positive group (subdivided into aCL-
positive, lac-positive, anti- β2GPI-positive and any APA-positive) vs. APA-negative groups are 
shown in Tables (22-49) separately for white cases and controls. No significant differences in the 
immunologic (aCL, LAC, anti-β2GPI and APA) parameters were observed for the APOH 
promoter -1219G>A, -1190G>C, -759A>G, -700C>A, -643T>C, and -32C>A SNPs in both 
groups. 
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Table 22. Distribution of -1219G>A SNP with anticardiolipin antibodies (aCL) in white cases 
and controls 
 
 
 
-1219G>A (rs8178819) SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
GG 74 (90.2) 188 (86.2) GG 106 (86.2) 242 (80.1) 
GA 7 (8.5) 30 (13.8) GA 16 (13.0) 56 (18.5) 
AA 1 (1.2) 0 (0.0) AA 1 (0.8) 4 (1.3) 
Total  82   218  Total 123   302   
**P = 0.143 **P = 0.384 
G 0.945  0.931   G 0.927  0.894   
A 0.055   0.069   A 0.073   0.106   
***P = 0.518 ***P = 0.115 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 74 (90.2) 121 (85.8) GG 106 (86.2) 163 (81.5) 
GA 7 (8.5) 20 (14.2) GA 16 (13.0) 35 (17.5) 
AA 1 (1.2) 0 (0.0) AA 1 (0.8) 2 (1.0) 
 Total 82   141  Total 123   200  
**P = 0.191 **P = 0.615 
G 0.945  0.929   G 0.927  0.903   
A 0.055   0.071   A 0.073   0.098   
***P = 0.494 ***P = 0.274 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 23. Distribution of -1219G>A SNP with lupus anticoagulant (lac) in white cases and 
controls 
 
-1219G>A (rs8178819) SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
GG 72 (87.8) 217 (86.1) GG 16 (76.2) 302 (83.0) 
GA 9 (11.0) 32 (12.7) GA 5 (23.8) 58 (15.9) 
AA 1 (1.2) 3 (1.2) AA 0 (0.0) 4 (1.1) 
Total  82   252  Total 21   364  
**P = 0.935 **P = 0.493 
G 0.933  0.925   G 0.881  0.909   
A 0.067   0.075   A 0.119   0.091   
***P = 0.715 ***P = 0.578 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 72 (87.8) 121 (85.8) GG 16 (76.2) 163 (81.5) 
GA 9 (11.0) 20 (14.2) GA 5 (23.8) 35 (17.5) 
AA 1 (1.2) 0 (0.0) AA 0 (0.0) 2 (1.0) 
 Total 82   141  Total 21   200  
**P = 0.386 **P = 0.633 
G 0.933  0.929   G 0.881  0.903   
A 0.067   0.071   A 0.119   0.098   
***P = 0.877 ***P = 0.679 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 24. Distribution of -1219G>A SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-1219G>A (rs8178819) SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
GG 90 (88.2) 172 (86.9) GG 62 (81.6) 304 (81.5) 
GA 12 (11.8) 25 (12.6) GA 13 (17.1) 64 (17.2) 
AA 0 (0.0) 1 (0.5) AA 1 (1.3) 5 (1.3) 
Total  102   198  Total 76   373  
**P = 0.905 **P = 1.000 
G 0.941  0.932   G 0.901  0.901   
A 0.059   0.068   A 0.099   0.099   
***P = 0.652 ***P = 0.985 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 90 (88.2) 121 (85.8) GG 62 (81.6) 163 (81.5) 
GA 12 (11.8) 20 (14.2) GA 13 (17.1) 35 (17.5) 
AA 0 (0.0) 0 (0.0) AA 1 (1.3) 2 (1.0) 
 Total 102   141  Total 76   200  
**P = 0.702 **P = 1.000 
G 0.941  0.929   G 0.901  0.903   
A 0.059   0.071   A 0.099   0.098   
***P = 0.590 ***P = 0.967 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 25. Distribution of -1219G>A SNP with APA-positive and APA-negative in white cases 
and controls 
 
-1219G>A (rs8178819) SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 145 (88.4) 121 (85.8) GG 154 (83.2) 163 (81.5) 
GA 17 (10.4) 20 (14.2) GA 29 (15.7) 35 (17.5) 
AA 2 (1.2) 0 (0.0) AA 2 (1.1) 2 (1.0) 
Total  164   141  Total 185   200  
**P = 0.293 **P = 0.880 
G 0.936  0.929   G 0.911  0.903   
A 0.064   0.071   A 0.089   0.098   
***P = 0.735 ***P = 0.692 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 26. Distribution of -1190G>C SNP with anticardiolipin antibodies (aCL) in white cases 
and controls 
 
-1190G>C (rs3760290) SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
GG 28 (34.2) 83 (37.7) GG 57 (45.6) 105 (34.9) 
GC 39 (47.6) 111 (50.5) GC 55 (44.0) 162 (53.8) 
CC 15 (18.3) 26 (11.8) CC 13 (10.4) 34 (11.3) 
Total  82   218  Total  125   302   
**P = 0.352 **P = 0.113  
G 0.579  0.630   G 0.676  0.618   
C 0.421   0.370   C 0.324   0.382   
***P = 0.263 ***P = 0.103 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 28 (34.2) 56 (39.7) GG 57 (45.6) 66 (33.2) 
GC 39 (47.6) 68 (48.2) GC 55 (44.0) 107 (53.8) 
CC 15 (18.3) 17 (12.1) CC 13 (10.4) 26 (13.1) 
Total  82   141  Total  125   200  
**P = 0.403 **P = 0.083 
G 0.579  0.638   G 0.676  0.601   
C 0.421   0.362   C 0.324   0.399   
***P = 0.219 ***P = 0.050 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 27. Distribution of -1190G>C SNP with lupus anticoagulant (lac) in white cases and 
controls 
 
-1190G>C (rs3760290) SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
GG 33 (39.8) 89 (35.3) GG 7 (31.8) 136 (37.4) 
GC 39 (47.0) 124 (49.2) GC 15 (68.2) 180 (49.5) 
CC 11 (13.3) 39 (15.5) CC 0 (0.0) 48 (13.2) 
Total  83   252  Total  22   302   
**P = 0.744 **P = 0.096  
G 0.633  0.599   G 0.659  0.621   
C 0.367   0.401   C 0.341   0.379   
***P = 0.442 ***P = 0.604 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 33 (39.8) 56 (39.7) GG 7 (31.8) 66 (33.2) 
GC 39 (47.0) 68 (48.2) GC 15 (68.2) 107 (53.8) 
CC 11 (13.3) 17 (12.1) CC 0 (0.0) 26 (13.1) 
Total  83   141  Total  22   199  
**P = 0.962 **P = 0.153 
G 0.633  0.638   G 0.659  0.601   
C 0.367   0.362   C 0.341   0.399   
***P = 0.903 ***P = 0.438 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 28. Distribution of -1190G>C SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-1190G>C (rs3760290) SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
GG 41 (39.8) 71 (35.7) GG 30 (39.5) 138 (39.5) 
GC 50 (48.5) 100 (50.3) GC 43 (56.6) 43 (56.6) 
CC 12 (11.7) 28 (14.1) CC 3 (4.0) 3 (4.0) 
Total  103   199  Total  76   374   
**P = 0.753 **P = 0.031 
G 0.641  0.608   G 0.678  0.614   
C 0.359   0.392   C 0.322   0.386   
***P = 0.429 ***P = 0.127 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 41 (39.8) 56 (39.7) GG 30 (39.5) 66 (33.2) 
GC 50 (48.5) 68 (48.2) GC 43 (56.6) 107 (53.8) 
CC 12 (11.7) 17 (12.1) CC 3 (4.0) 26 (13.1) 
Total  103   141  Total  76   199  
**P = 1.000 **P = 0.067 
G 0.641  0.638   G 0.678  0.601   
C 0.359   0.362   C 0.322   0.399   
***P = 0.955 ***P = 0.088 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 29. Distribution of -1190G>C SNP with APA-positive and APA-negative in white cases 
and controls 
 
-1190G>C (rs3760290) SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 57 (34.3) 56 (39.7) GG 78 (41.7) 66 (33.2) 
GC 83 (50.0) 68 (48.2) GC 93 (49.7) 107 (53.8) 
CC 26 (15.7) 17 (12.1) CC 16 (8.6) 26 (13.1) 
Total  166   141  Total  187   199  
**P = 0.521 **P = 0.138  
G 0.593  0.638   G 0.666  0.601   
C 0.407   0.362   C 0.334   0.399   
***P = 0.253 ***P = 0.059 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 30. Distribution of -759A>G SNP with anticardiolipin antibodies (aCL) in white cases and 
controls 
 
-759A>G (rs8178820) SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
AA 47 (58.0) 115 (52.5) AA 81 (64.8) 171 (56.6) 
AG 30 (37.0) 88 (40.2) AG 39 (31.2) 115 (38.1) 
GG 4 (4.9) 16 (7.3) GG 5 (4.0) 16 (5.3) 
Total  81   219  Total  125   302   
**P = 0.669 **P = 0.311 
A 0.765  0.726   A 0.804  0.757   
G 0.235   0.274   G 0.196   0.243   
***P = 0.319 ***P = 0.121 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
AA 47 (58.0) 76 (53.9) AA 81 (64.8) 111 (55.2) 
AG 30 (37.0) 54 (38.3) AG 39 (31.2) 78 (38.8) 
GG 4 (4.9) 11 (7.8) GG 5 (4.0) 12 (6.0) 
Total  81   141  Total  125   201  
**P = 0.737 **P = 0.249 
A 0.765  0.730   A 0.804  0.746   
G 0.235   0.270   G 0.196   0.254   
***P = 0.411 ***P = 0.082 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 31. Distribution of -759A>G SNP with lupus anticoagulant (lac) in white cases and 
controls 
 
-759A>G (rs8178820) SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
AA 48 (58.5) 133 (52.8) AA 11 (50.0) 212 (57.9) 
AG 27 (32.9) 98 (38.9) AG 11 (50.0) 132 (36.1) 
GG 7 (8.5) 21 (8.3) GG 0 (0.0) 22 (6.0) 
Total  82   252  Total  22   366   
**P = 0.626 **P = 0.366 
A 0.750  0.722   A 0.750  0.760   
G 0.250   0.278   G 0.250   0.240   
***P = 0.479 ***P = 0.887 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
AA 48 (58.5) 76 (53.9) AA 11 (50.0) 111 (55.2) 
AG 27 (32.9) 54 (38.3) AG 11 (50.0) 78 (38.8) 
GG 7 (8.5) 11 (7.8) GG 0 (0.0) 12 (6.0) 
Total  82   141  Total  22   201  
**P = 0.720 **P = 0.483 
A 0.750  0.730   A 0.750  0.746   
G 0.250   0.270   G 0.250   0.254   
***P = 0.649 ***P = 0.957 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 32. Distribution of -759A>G SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-759A>G (rs8178820) SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
AA 61 (60.4) 101 (50.8) AA 51 (67.1) 209 (55.7) 
AG 37 (36.6) 81 (40.7) AG 23 (30.3) 142 (37.9) 
GG 3 (3.0) 17 (8.5) GG 2 (2.6) 24 (6.4) 
Total  101   199  Total  76   374   
**P = 0.098 **P = 0.158 
A 0.787  0.711   A 0.822  0.747   
G 0.213   0.289   G 0.178   0.253   
***P = 0.038 ***P = 0.030 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
AA 61 (60.4) 76 (53.9) AA 51 (67.1) 111 (55.2) 
AG 37 (36.6) 54 (38.3) AG 23 (30.3) 78 (38.8) 
GG 3 (3.0) 11 (7.8) GG 2 (2.6) 12 (6.0) 
Total  101   141  Total  76   201  
**P = 0.242 **P = 0.180 
A 0.787  0.730   A 0.822  0.746   
G 0.213   0.270   G 0.178   0.254   
***P = 0.147 ***P = 0.044 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 33. Distribution of -759A>G SNP with APA-positive and APA-negative in white cases 
and controls 
 
-759A>G (rs8178820) SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
AA 88 (53.7) 76 (53.9) AA 118 (63.1) 111 (55.2) 
AG 65 (39.6) 54 (38.3) AG 62 (33.2) 78 (38.8) 
GG 11 (6.7) 11 (7.8) GG 7 (3.7) 12 (6.0) 
Total  164   141  Total  187   201  
**P = 0.935 **P = 0.240 
A 0.735  0.730   A 0.797  0.746   
G 0.265   0.270   G 0.203   0.254   
***P = 0.906 ***P = 0.093 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 34. Distribution of -700C>A SNP with anticardiolipin antibodies (aCL) in white cases and 
controls 
 
-700C>A (rs3760291) 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
CC 44 (54.3) 126 (57.5) CC 79 (63.7) 170 (56.3) 
CA 30 (37.0) 80 (36.5) CA 40 (32.3) 116 (38.4) 
AA 7 (8.6) 13 (5.9) AA 5 (4.0) 16 (5.3) 
Total  81   219  Total  124   302   
**P = 0.651 **P = 0.408  
C 0.728  0.758   C 0.798  0.755   
A 0.272   0.242   A 0.202   0.245   
***P = 0.465 ***P = 0.160 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 44 (54.3) 82 (58.2) CC 79 (63.7) 111 (55.2) 
CA 30 (37.0) 51 (36.2) CA 40 (32.3) 78 (38.8) 
AA 7 (8.6) 8 (5.7) AA 5 (4.0) 12 (6.0) 
Total  81   141  Total  124   201  
**P = 0.647 **P = 0.309 
C 0.728  0.762   C 0.798  0.746   
A 0.272   0.238   A 0.202   0.254   
***P = 0.431 ***P = 0.119 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 35. Distribution of -700C>A SNP with lupus anticoagulant (lac) in white cases and 
controls 
 
-700C>A (rs3760291) 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
CC 48 (58.5) 147 (58.3) CC 11 (50.0) 211 (57.8) 
CA 28 (34.2) 90 (35.7) CA 11 (50.0) 132 (36.2) 
AA 6 (7.3) 15 (6.0) AA 0 (0.0) 22 (6.0) 
Total  82   252  Total  22   365   
**P = 0.838 **P = 0.366  
C 0.756  0.756   C 0.750  0.759   
A 0.244   0.244   A 0.250   0.241   
***P = 0.880 ***P = 0.895 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 48 (58.5) 82 (58.2) CC 11 (50.0) 111 (55.2) 
CA 28 (34.2) 51 (36.2) CA 11 (50.0) 78 (38.8) 
AA 6 (7.3) 8 (5.7) AA 0 (0.0) 12 (6.0) 
Total  82   141  Total  22   201  
**P = 0.900 **P = 0.483 
C 0.756  0.762   C 0.750  0.746   
A 0.244   0.238   A 0.250   0.254   
***P = 0.881 ***P = 0.957 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 36. Distribution of -700C>A SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-700C>A (rs3760291) 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
CC 66 (65.4) 105 (52.8) CC 50 (65.8) 207 (55.4) 
CA 31 (30.7) 78 (39.2) CA 24 (31.6) 143 (38.2) 
AA 4 (4.0) 16 (8.0) AA 2 (2.6) 24 (6.4) 
Total  101   199  Total  76   374   
**P = 0.092 **P = 0.202 
C 0.807  0.724   C 0.816  0.745   
A 0.193   0.276   A 0.184   0.255   
***P = 0.020 ***P = 0.044 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 66 (65.4) 82 (58.2) CC 50 (65.8) 111 (55.2) 
CA 31 (30.7) 51 (36.2) CA 24 (31.6) 78 (38.8) 
AA 4 (4.0) 8 (5.7) AA 2 (2.6) 12 (6.0) 
Total  101   141  Total  76   201  
**P = 0.562 **P = 0.258 
C 0.807  0.762   C 0.816  0.746   
A 0.193   0.238   A 0.184   0.254   
***P = 0.236 ***P = 0.069 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 37. Distribution of -700C>A SNP with APA-positive and APA-negative in white cases 
and controls 
 
-700C>A (rs3760291) 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 92 (56.1) 82 (58.2) CC 116 (62.4) 111 (55.2) 
CA 59 (36.0) 51 (36.2) CA 63 (33.9) 78 (38.8) 
AA 13 (7.9) 8 (5.7) AA 7 (3.8) 12 (6.0) 
Total  164   141  Total  186   201  
**P = 0.757 **P = 0.288 
C 0.741  0.762   C 0.793  0.746   
A 0.259   0.238   A 0.207   0.254   
***P = 0.538 ***P = 0.122 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 38. Distribution of -643T>C SNP with anticardiolipin antibodies (aCL) in white cases and 
controls 
 
-643T>C (rs3760292) SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
TT 61 (75.3) 149 (67.7) TT 93 (74.4) 221 (73.2) 
TC 17 (21.0) 65 (29.6) TC 28 (22.4) 75 (24.8) 
CC 3 (3.7) 6 (2.7) CC 4 (3.2) 6 (2.0) 
Total  81   220  Total  125   302   
**P = 0.297 **P = 0.645  
T 0.858  0.825   T 0.856  0.856   
C 0.142   0.175   C 0.144   0.144   
***P = 0.315 ***P = 0.999 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
TT 61 (75.3) 98 (69.5) TT 93 (74.4) 154 (76.6) 
TC 17 (21.0) 38 (27.0) TC 28 (22.4) 44 (21.9) 
CC 3 (3.7) 5 (3.6) CC 4 (3.2) 3 (1.5) 
Total  81   141  Total  125   201  
**P = 0.591 **P = 0.587 
T 0.858  0.830   T 0.856  0.876   
C 0.142   0.170   C 0.144   0.124   
***P = 0.425 ***P = 0.478 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 39. Distribution of -643T>C SNP with lupus anticoagulant (lac) in white cases and 
controls 
 
-643T>C (rs3760292) SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
TT 56 (68.3) 177 (70.0) TT 15 (68.2) 277 (75.7) 
TC 23 (28.1) 64 (25.3) TC 7 (31.8) 81 (22.1) 
CC 3 (3.7) 12 (4.7) CC 0 (0.0) 8 (2.2) 
Total  82   252  Total  22   366   
**P = 0.844 **P = 0.568  
T 0.823  0.826   T 0.841  0.867   
C 0.177   0.174   C 0.159   0.133   
***P = 0.932 ***P = 0.638 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
TT 56 (68.3) 98 (69.5) TT 15 (68.2) 154 (76.6) 
TC 23 (28.1) 38 (27.0) TC 7 (31.8) 44 (21.9) 
CC 3 (3.7) 5 (3.6) CC 0 (0.0) 3 (1.5) 
Total  82   141  Total  22   201  
**P = 0.965 **P = 0.487 
T 0.823  0.830   T 0.841  0.876   
C 0.177   0.170   C 0.159   0.124   
***P = 0.859 ***P = 0.546 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 40. Distribution of -643T>C SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-643T>C (rs3760292) SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
TT 70 (68.6) 140 (70.4) TT 54 (71.1) 282 (75.2) 
TC 28 (27.5) 54 (27.1) TC 19 (25.0) 86 (22.9) 
CC 4 (3.9) 5 (2.5) CC 3 (4.0) 7 (1.9) 
Total  102   199  Total  76   375   
**P = 0.763 **P = 0.401 
T 0.824  0.839   T 0.836  0.867   
C 0.176   0.161   C 0.164   0.133   
***P = 0.629 ***P = 0.338 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
TT 70 (68.6) 98 (69.5) TT 54 (71.1) 154 (76.6) 
TC 28 (27.5) 38 (27.0) TC 19 (25.0) 44 (21.9) 
CC 4 (3.9) 5 (3.6) CC 3 (4.0) 3 (1.5) 
Total  102   141  Total  76   201  
**P = 1.000 **P = 0.319 
T 0.824  0.830   T 0.836  0.876   
C 0.176   0.170   C 0.164   0.124   
***P = 0.857 ***P = 0.242 
**Genotype frequencies were determined by fisher's exact test 
***Allele frequencies were determined by standard Z test of binomial proportion  
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Table 41. Distribution of -643T>C SNP with APA-positive and APA-negative in white cases 
and controls 
 
-643T>C (rs3760292) SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
TT 117 (70.9) 98 (69.5) TT 134 (71.7) 154 (76.6) 
TC 43 (26.1) 38 (27.0) TC 47 (25.1) 44 (21.9) 
CC 6 (3.0) 5 (3.6) CC 6 (3.2) 3 (1.5) 
Total  165   141  Total  187   201  
**P = 0.975 **P = 0.379 
T 0.839  0.830   T 0.842  0.876   
C 0.161   0.170   C 0.158   0.124   
***P = 0.750 ***P = 0.182 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 42. Distribution of -38G>A SNP with anticardiolipin antibodies (aCL) in white cases and 
controls 
 
-38G>A SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
GG 79 (96.3) 214 (97.3) GG 120 (96.0) 289 (95.7) 
GA 3 (3.7) 6 (2.7) GA 4 (3.2) 12 (4.0) 
AA 0 (0.0) 0 (0.0) AA 1 (0.8) 1 (0.3) 
Total  82   220  Total  125   302   
**P = 0.708 **P = 0.788  
G 0.982  0.986   G 0.976  0.977   
A 0.018   0.014   A 0.024   0.023   
***P = 0.694 ***P = 0.943 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 79 (96.3) 141 (100.0) GG 120 (96.0) 193 (76.6) 
GA 3 (3.7) 0 (0.0) GA 4 (3.2) 6 (21.9) 
AA 0 (30.0) 0 (0.0) AA 1 (0.8) 1 (1.5) 
Total  82   141  Total  125   200  
**P = 0.049  **P = 1.000 
G 0.982  1.000   G 0.976  0.980   
A 0.018   0.000   A 0.024   0.020   
***P = 0.080  ***P = 0.738 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 43. Distribution of -38G>A SNP with lupus anticoagulant (lac) in white cases and controls 
 
 
 
 
-38G>A SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
GG 78 (94.0) 247 (98.0) GG 20 (90.9) 351 (96.2) 
GA 5 (6.0) 5 (2.0) GA 2 (9.1) 12 (3.3) 
AA 0 (0.0) 0 (0.0) AA 0 (0.0) 2 (0.6) 
Total  83   252  Total  22   365   
**P = 0.072 **P = 0.277  
G 0.970  0.990   G 0.955  0.978   
A 0.030   0.010   A 0.045   0.022   
***P = 0.149 ***P = 0.460 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 78 (94.0) 141 (100.0) GG 20 (90.9) 193 (76.6) 
GA 5 (6.0) 0 (0.0) GA 2 (9.1) 6 (21.9) 
AA 0 (0.0) 0 (0.0) AA 0 (0.0) 1 (1.5) 
Total  83   141  Total  22   200  
**P = 0.006  **P = 0.264 
G 0.970  1.000   G 0.955  0.980   
A 0.030   0.000   A 0.045   0.020   
***P = 0.023  ***P = 0.429 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 44. Distribution of -38G>A SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-38G>A SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
GG 98 (95.2) 195 (98.0) GG 70 (92.1) 360 (96.0) 
GA 5 (4.9) 4 (2.0) GA 6 (7.9) 13 (3.5) 
AA 0 (0.0) 0 (0.0) AA 0 (0.0) 2 (10.5) 
Total  103   199  Total  76   375   
**P = 0.282 **P = 0.200  
G 0.976  0.990   G 0.961  0.867   
A 0.024   0.010   A 0.039   0.133   
***P = 0.229 ***P = 0.314 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 98 (95.2) 141 (100.0) GG 70 (92.1) 193 (76.6) 
GA 5 (4.9) 0 (0.0) GA 6 (7.9) 6 (21.9) 
AA 0 (0.0) 0 (0.0) AA 0 (0.0) 1 (1.5) 
Total  103   141  Total  76   200  
**P = 0.013  **P = 0.159 
G 0.976  1.000   G 0.961  0.980   
A 0.024   0.000   A 0.039   0.020   
***P = 0.024  ***P = 0.260 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 45. Distribution of -38G>A SNP with APA-positive and APA-negative in white cases and 
controls 
 
-38G>A SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
GG 157 (94.6) 141 (100.0) GG 178 (95.2) 193 (76.6) 
GA 9 (5.4) 0 (0.0) GA 48 (4.3) 6 (21.9) 
AA 0 (0.0) 0 (0.0) AA 1 (0.5) 1 (1.5) 
Total  166   141  Total  187   200  
**P = 0.004  **P = 0.795 
G 0.973  1.000   G 0.973  0.980   
A 0.027   0.000   A 0.027   0.020   
***P = 0.002  ***P = 0.536 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 46. Distribution of -32C>A SNP with anticardiolipin antibodies (aCL) in white cases and 
controls 
 
-32C>A (rs8178822) SNP 
White Cases White Controls 
  aCL Positive aCL Negative   aCL Positive aCL Negative 
  n (%) n (%)   n (%) n (%) 
CC 76 (92.7) 188 (85.5) CC 110 (88.0) 264 (87.4) 
CA 6 (7.3) 30 (13.6) CA 15 (12.0) 37 (12.3) 
AA 0 (0.0) 2 (0.9) AA 0 (0.0) 1 (0.3) 
Total  82   220  Total  125   302   
**P = 0.250 **P = 1.000 
C 0.963  0.923   C 0.940  0.935   
A 0.037   0.077   A 0.060   0.065   
***P = 0.036 ***P = 0.800 
White Cases White Controls 
  aCL Positive APA Negative   aCL Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 76 (92.7) 122 (86.5) CC 110 (88.0) 176 (88.0) 
CA 6 (7.3) 18 (12.8) CA 15 (12.0) 24 (12.0) 
AA 0 (0.0) 1 (0.7) AA 0 (0.0) 0 (0.0) 
Total  82   141  Total  125   200  
**P = 0.353 **P = 1.000 
C 0.963  0.929   C 0.940  0.940   
A 0.037   0.071   A 0.060   0.060   
***P = 0.105 ***P = 1.000 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 47. Distribution of -32C>A SNP with lupus anticoagulant (lac) in white cases and controls 
 
-32C>A (rs8178822) SNP 
White Cases White Controls 
  lac Positive lac Negative   lac Positive lac Negative 
  n (%) n (%)   n (%) n (%) 
CC 78 (94.0) 216 (85.7) CC 18 (81.8) 320 (87.7) 
CA 5 (6.0) 34 (13.5) CA 4 (18.2) 44 (12.1) 
AA 0 (0.0) 2 (0.8) AA 0 (0.0) 1 (0.3) 
Total  83   252  Total  22   365   
**P = 0.145 **P = 0.374  
C 0.970  0.925   C 0.909  0.937   
A 0.030   0.075   A 0.091   0.063   
***P = 0.011 ***P = 0.529 
White Cases White Controls 
  lac Positive APA Negative   lac Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 78 (94.0) 122 (86.5) CC 18 (81.8) 176 (88.0) 
CA 5 (6.0) 18 (12.8) CA 4 (18.2) 24 (12.0) 
AA 0 (0.0) 1 (0.7) AA 0 (0.0) 0 (0.0) 
Total  83   141  Total  22   200  
**P = 0.136 **P = 0.494 
C 0.970  0.929   C 0.909  0.940   
A 0.030   0.071   A 0.091   0.060   
***P = 0.044 ***P = 0.492 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 48. Distribution of -32C>A SNP with anti-β2-glycoprotein I (anti- β2GPI) in white cases 
and controls 
 
-32C>A (rs8178822) SNP 
White Cases White Controls 
  ß2GPI Positive ß2GPI Negative   ß2GPI Positive ß2GPI Negative 
  n (%) n (%)   n (%) n (%) 
CC 85 (82.5) 179 (90.0) CC 67 (88.2) 329 (87.7) 
CA 17 (16.5) 19 (9.6) CA 8 (10.5) 46 (12.3) 
AA 1 (1.0) 1 (0.5) AA 1 (1.3) 0 (0.0) 
Total  103   199  Total  76   375   
**P = 0.133 **P = 0.208  
C 0.908  0.947   C 0.934  0.939   
A 0.092   0.053   A 0.066   0.061   
***P = 0.087 ***P = 0.839 
White Cases White Controls 
  ß2GPI Positive APA Negative   ß2GPI Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 85 (82.5) 122 (86.5) CC 67 (88.2) 176 (88.0) 
CA 17 (16.5) 18 (12.8) CA 8 (10.5) 24 (12.0) 
AA 1 (1.0) 1 (0.7) AA 1 (1.3) 0 (0.0) 
Total  103   141  Total  76   200  
**P = 0.736 **P = 0.332 
C 0.908  0.929   C 0.934  0.940   
A 0.092   0.071   A 0.066   0.060   
***P = 0.400 ***P = 0.804 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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Table 49. Distribution of -32C>A SNP with APA-positive and APA-negative in white cases and 
controls 
 
-32C>A (rs8178822) SNP 
White Cases White Controls 
  APA Positive APA Negative   APA Positive APA Negative 
  n (%) n (%)   n (%) n (%) 
CC 146 (88.0) 122 (86.5) CC 162 (86.6) 176 (88.0) 
CA 19 (11.5) 18 (12.8) CA 24 (412.8) 24 (12.0) 
AA 1 (0.6) 1 (0.7) AA 1 (0.5) 0 (0.0) 
Total  166   141  Total  187   200  
**P = 0.865 **P = 0.757  
C 0.937  0.929   C 0.930  0.940   
A 0.063   0.071   A 0.070   0.060   
***P = 0.706 ***P = 0.591 
**Genotype frequencies were determined by fisher's exact test  
***Allele frequencies were determined by standard Z test of binomial proportion 
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6.4 GENETIC ASSOCIATION OF APOH PROMOTER SNPs WITH PLASMA β2GPI 
LEVELS 
The distribution of plasma β2GPI levels among the white SLE cases and controls is presented in 
Figure 52. Cases had slightly lower levels than controls (17.90 ± 4.15 vs. 18.72 ± 4.68; P = 0.05)                      
Hence all further analyses were done combining the subgroup of white SLE cases (n = 241) and 
controls (n = 206) that had information for plasma β2GPI levels. Stepwise regression analysis 
showed that age, BMI and ever smoking were the significant determinants of the plasma β2GPI 
levels. Adjusted mean plasma β2GPI levels ± SD among APOH promoter SNP genotypes are 
presented in Table 50. Only the -32C>A SNP was significant in both single-site (Table 51; P < 
0.001) and multiple regression analysis (P < 0.001) adjusted for the disease, age, BMI, ever 
smoking covariates. Mean plasma β2GPI levels were higher in homozygotes of the wild-type allele 
(18.62 ± 4.19) compared to the heterozygotes (16.24 ± 5.18) and homozygotes of less common 
allele (13.90 ± 0.00). Two coding polymorphisms, Cys306Gly and Trp316Ser, previously reported 
to be major regulators of plasma β2GPI levels [113], were included in both multiple regression and 
haplotype analyses along with all six APOH promoter SNPs. Our initial studies demonstrated that 
the -32C>A SNP is in moderately high LD with the codon 316 mutation (D' = 0.74, r2 = 0.63) 
[116]; therefore the Trp316Ser was excluded from multiple regression analysis. When all six 
APOH promoter SNPs and the coding Cys306Gly SNP were included in a multiple linear 
regression model adjusted for covariates (Table 52), the significant effect of -32C>A SNP 
remained (P < 0.001), consistent with single-site analysis and similarly also for the known coding 
Cys306Gly polymorphism (P < 0.001). The -32C>A and Cys306Gly SNPs accounted for 5.4% 
and 21.5% variation, respectively in plasma β2GPI levels (Table 52). Eight-site haplotype analysis 
identified a total of 11 haplotypes with a frequency of > 1% (Table 53) using the haplo.glm 
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function in the haplo.stats package in R program. Three haplotypes showed significant association 
with plasma β2GPI levels (P < 0.001). The haplotype (H5) harbored minor alleles for the -
1190G>C, -32C>A, and Trp316Ser SNPs. The other two significant haplotypes were 
predominantly defined by the minor alleles of the two coding polymorphisms, (H6: Cys306Gly; 
H10:Trp316Ser; respectively) that are already known to be major determinants of plasma β2GPI 
levels. Although the -32C>A SNP was significant in single-site analysis, the other haplotype (H7) 
defined by minor alleles only at -1190G>C and -32C>A SNPs and not for Trp316Ser did not show 
significant association, suggesting that the effect of the 1190G>C and -32C>A SNPs is dependent 
upon Trp316Ser polymorphism. None of the individual haplotypes harboring less common alleles 
for the -643T>C (H2 and H9) and -1219G>A SNPs (H4) that are found to be significantly decrease 
gene expression in vitro showed significant impact on plasma β2GPI levels. Three-site haplotype 
analysis (Table 54) with only the functionally relevant SNPs based on luciferase and EMSA data (-
1219G>A, -643T>C, and -32C>A) revealed one haplotype carrying -32A (freq: 0.075) to be 
significantly associated with decreased plasma β2GPI levels (P < 0.001). Another haplotype 
harboring the minor allele for -1219A (freq: 0.080) showed a significant albeit less pronounced 
association with plasma β2GPI levels (P = 0.046).  
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                                        White Cases                                        White Controls                        
Mean (mg/dL) ± SD                  17.90 ± 4.15                                            18.72 ± 4.68   
 
Figure 52. Box plot of plasma β2GPI levels in white cases and controls 
In this box-plot diagram, the horizontal line within each box represents the median. Horizontal 
lines outside the box represent the 10th and the 90th percentiles. 
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Table 50. Mean ± SD of plasma β2GPI levels of APOH promoter polymorphisms 
SNP
-1284C>G CC (n ) CG (n ) GG (n )
Mean ± SD 18.26 ± 4.41 24.19 ± NA NA ± NA
(446) (1) (0)
-1219G>A GG (n ) GA (n ) AA (n )
Mean ± SD 18.11 ± 4.43 19.04 ± 4.45 20.48 ± 2.80
(358) (81) (3)
-1190G>C GG (n ) GC (n ) CC (n )
Mean ± SD 18.75 ± 4.18 NA ± NA 17.83 ± 4.31
(141) (242) (62)
-759A>G AA (n ) AG (n ) GG (n )
Mean ± SD 18.22 ± 4.62 16.28 ± 4.08 18.49 ± 4.56
(241) (174) (30)
-700C>A CC (n ) CA (n ) AA (n )
Mean ± SD 18.00 ± 4.69 18.60 ± 4.01 19.09 ± 2.90 
(245) (169) (30)
-643T>C TT (n ) TC (n ) CC (n )
Mean ± SD 18.05 ± 4.33 18.92 ± 4.30 17.96 ± 6.52 
(332) (102) (10)
-38G>A GG (n ) GA (n ) AA (n )
Mean ± SD 18.20 ± 4.41 19.77 ± 4.39 NA ± NA
(426) (20) (0)
-32C>A CC (n ) CA (n ) AA (n )
Mean ± SD 18.62 ± 4.19 16.24 ± 5.18 13.90 ± NA 
(381) (64) (1)
Cys306Gly TT (n ) TG (n ) GG (n )
Mean ± SD 18.86 ± 3.80 12.87 ± 5.18 0.50 ± 0.42
(408) (37) (2)
Trp316Ser GG (n ) GC (n ) CC (n )
Mean ± SD 18.81 ± 4.03 14.16 ± 4.21 9.40 ± NA
(397) (47) (1)
P* - Adjusted for disease, age , bmi, ever smoking
            P * < 0.001
            P * < 0.001
            P * = 0.380
            P * = 0.2331
            P * = 0.296
            P * < 0.001
White Cases + Controls
            P * = 0.345
            P * = 0.830
            P * = 0.263
            P * = 0.218
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Table 51. Single-site analysis of plasma β2GPI levels of APOH promoter SNPs 
 
SNP P* - value 
Disease --- 
Age 0.232
BMI 0.051 
Smokever 0.991 
rs8178818 (-1284C>G) 0.218 
rs8178819 (-1219G>A) 0.263 
rs3760290 (-1190G>C) 0.345 
rs8178820 (-759A>G) 0.830 
rs3760291 (-700C>A) 0.380 
rs3760292 (-643T>C) 0.331 
(-38G>A) 0.296 
rs8178822 (-32C>A) <0.001
  
 P* - Adjusted for disease, age , bmi, ever smoking 
 
 
 
Table 52. Multiple regression * analysis of APOH SNPs for plasma β2GPI levels 
SNP P - value Adjusted R2 **    
Disease 0.176 0.003 
Age 0.129 0.004 
BMI 0.144 0.005 
Smokever 0.371 -0.006 
rs8178819 (-1219G>A) 0.441 --- 
rs3760290 (-1190G>C) 0.498 --- 
rs8178820 (-759A>G) 0.957 --- 
rs3760292 (-643T>C) 0.633 --- 
(-38G>A) 0.437 --- 
rs8178822 (-32C>A) <0.001 0.054 
rs1801689 (306T>G) <0.001 0.215 
 
*Adjusted for disease, age, BMI and ever smoking.  
**R2 was calculated only for covariates and significant P-values. 
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Table 53. Haplotype analysis of APOH SNPs for plasma β2GPI levels 
HAPLOTYPE** -1219G>A -1190G>C -759A>G -643T>C -38G>A -32C>A Cys306Gly Trp316Ser 
freq coef se P
base haplotype G G A T G C T G 0.384 - - -
H1 G C G T G C T G 0.156 -0.218 0.408 0.593
H2 G G A C G C T G 0.098 0.791 0.534 0.139
H3 G C A T G C T G 0.081 0.301 0.538 0.576
H4 A C G T G C T G 0.062 -0.046 0.675 0.946
H5 G C A T G A T C 0.042 -4.632 0.737 < 0.001
H6 G G A T G C G G 0.038 -5.439 0.739 < 0.001
H7 G C A T G A T G 0.023 -1.271 1.031 0.218
H8 G G A T A C T G 0.017 0.280 1.128 0.804
H9 G G G C G C T G 0.013 -0.097 1.255 0.938
H10 G C A T G C T C 0.013 -4.748 1.247 < 0.001
H11 G G G T G C T G 0.011 -0.727 1.453 0.617
rare haplotype * * *  * *  *  * * 0.062 -1.604 - 0.024
CASES + CONTROLS
*R software (haplostats package) for ß2GPI plasma levels, regression model included disease, age, BMI, 
smokever.  
**Only the haplotypes with more than 0.01 total frequencies are shown 
 
  Alleles found to decrease gene expression in vitro 
 
  Alleles found to be significantly associated with low plasma ß2GPI  levels in univariate analysis  
 
  Alleles found to decrease gene expression in vitro and also associated with  
    low plasma ß2GPI  levels in univariate analysis   
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Table 54. Three-site haplotype analysis of APOH promoter SNPs for plasma β2GPI levels 
Haplotype** -1219G>A 
(rs8178819)
-643T>C 
(rs3760292)
-32 C>A
(rs8178822)
Cases + Controls
freq coef se P
Base haplo G T C 0.712 --- --- ---
H1 G C C 0.120 0.576 0.455 0.206
H 2 A T C 0.080 1.170 0.585 0.046
H 3 G T A 0.075 -2.307 0.574 < 0.001
H 4 A C C 0.013 -1.562 1.472 0.289
 
• software (haplostats package) for β2GPI plasma levels, BMI 
• ** Only the haplotypes with more than 0.01 total frequencies are shown 
        Alleles found to decrease gene expression in vitro 
 
 
 158 
7.0  DISCUSSION 
The goals of this study were to i) clone and characterize 1,418 bp of the putative APOH promoter 
and to elucidate molecular mechanisms underlying the regulation of its expression, (ii) 
functionally characterize the SNPs as well as haplotypes present in the 1,418 bp fragment of the 
5´-flanking region of the APOH, (iii) understand the role of the APOH promoter SNPs in 
determining the genetic risk of SLE and its related phenotypes in a SLE-case control cohort, and 
(iv) examine the influence of APOH promoter genetic polymorphisms on gene expression and 
plasma β2GPI levels. 
7.1 CHARACTERIZATION OF THE APOH  PROMOTER 
In order to assess basal, proximal promoter activity in the 5′-flanking region, a series of 5' 
deletions fused to the luciferase gene were constructed (see Figure 23) and transfected into COS-
1 and HepG2 cells. The ability of the 5′-flanking region of APOH to function as a promoter was 
assessed by its capacity to drive the expression of a luciferase reporter gene. The wild-type (-
1,375/+43) construct was defined by a 1,418 bp genomic DNA fragment of APOH 5′-flanking 
region fused to a promoterless firefly luciferase gene of the pGL3-basic vector (see Figure 21). A 
series of five truncated 5′-flanking APOH deletion mutant constructs, differing in approximately 
200 bp, were generated with the 3′ end always terminating +43bp from the translation start site. 
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The 5′ ends began at bases -815/+43 (deletion mutant 1), -575/+43 (deletion mutant 2), -325/+43 
(deletion mutant 3), -166/+43 (deletion mutant 4), -65/+43 (deletion mutant 5).  
To provide insights into mechanisms that control basal APOH expression, our 5′- serial 
deletion analysis results suggest that 166 bp region upstream to the translation start site (ATG) is 
the minimum proximal promoter that consists of functional domains critical for basal APOH 
transcriptional activity. Starting with the wild-type (-1,375 bp upstream ATG), successive 
deletions extending to nt -325 (deletion mutants 1-3) enhanced promoter activity in COS-1 cells 
while a slightly different pattern, deletion mutant 1 was lower in expression as compared to wild-
type, deletion mutants 2 and 3 were observed in HepG2 cell line.  This slight difference in 
expression can be explained based on tissue-specific factors that play a key role in driving APOH 
expression. For both cell lines, deletion mutant 3 (-325/+43) was associated with highest 
promoter activity. No statistical significant differences were seen between wild-type and deletion 
mutants 1-3, that was consistent for both cell types. A deletion extending to nt -166 resulted in a 
slight to moderate reduction in activity while deletion of another 100 nt (deletion mutant 5 -
66/+43) decreased promoter activity by more than ~60% in COS-1 cells and even more 
pronounced in HepG2 cells (~98%). Therefore, functional characterization of the APOH 5′ – 
flanking region revealed that sequences between nt -166 and -66 are likely to contain elements 
that participate in recruiting components of the core APOH transcription machinery.  
Consistent with the earlier report by Wang and Chiang (2004) [83], our results 
demonstrate that ~160 bp upstream of the translation start site contains all the necessary elements 
to confer basal hepatic-specific expression of APOH. In the previous study of Wang and Chiang 
(2004) [83], a 4.1-kb genomic fragment of the 5′-flanking untranslated region of APOH was 
cloned and functionally characterized by transient transfection assays in the human hepatoma 
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cell lines (HepG2 and Huh7 cells). Serial deletion analyses revealed the region between -197 to 
+7 to show strong basal promoter activity in hepatoma cells and identified two critical cis-acting 
elements, an atypical TATA box (TATTA) located between nt -97 and -92 and HNF-1α at 
position between nt -65 and -51 for cell-specific regulation of APOH expression. Neither of the 
two elements was able to initiate transcription by itself indicating that both TATTA sequence 
and the HNF-1 element are necessary for APOH transcription. The nucleotide numbering used in 
the prior study (Wang and Chiang, 2004) [83] starts at the transcription start site 21 bp upstream 
of the ATG codon; the thymidine residue at this precise position is designated +1. This differs 
from the current study, wherein, the APOH fragments are numbered relative to the translation 
start codon ATG. Therefore, in order to do a comparative analysis between the present study vs. 
the previous one, the APOH deletion mutants used in the present study were numbered based on 
the method used in the Wang and Chiang paper, (Table 55 and Figure 53). 
 
Table 55. Numbering of APOH 5´deletion fragments for comparative analysis 
 Numbering based on translation start site (ATG 
codon) (This study) 
Numbering based on transcription start site 21 bp 
upstream of ATG codon (Wang and Chiang, 2004) 
APOH deletion mutant 1 (-815/+43) APOH deletion mutant 1 (-794/+64) 
APOH deletion mutant 2 (-575/+43) APOH deletion mutant 2 (-554/+64) 
APOH deletion mutant 3 (-325/+43) APOH deletion mutant 3 (-304/+64) 
APOH deletion mutant 4 (-166/+43) APOH deletion mutant 4 (-145/+64) 
APOH deletion mutant 5 (-65/+43) APOH deletion mutant 5 (-44/+64) 
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 Del = deletion; Mut = mutant 
TATTA HNF-1?
Transcription start site (21
bp upstream of ATG)
Translation start site 
ATGT(+1)
 Del mut 2Del mut 1 Del mut 3 Del mut 4 Del mut 5
+64-44-145-304-554-794 -77-197- 280- 364 - 477-616
APOH 5´ Del mutants in current study
APOH 5´ Del mutants in the study by Wang and Chiang (2004)
-51-65-92-97
+7
  
Figure 53. Comparison analysis of APOH 5´deletion fragments 
Fragments are numbered from the thymidine (T) residue positioned at transcription start site 21 
bp upstream of the translaton start site (ATG). 
 
 
The smallest APOH 5´deletion mutant used in this study lacked both the cis-elements 
(TATTA and HNF-1α; red circle, Figure 53), whereas, the smallest deletion mutant used in the 
previous study (Wang and Chiang, 2004) [83] lacked only the TATTA element (green circle, 
Figure 53). Despite this difference between fragments, our study replicates the key findings from 
the prior study (Figure 54) in which the smallest 5´deletion mutant almost completely abolished 
luciferase activity by ~98% (present study) and ~91% (Wang and Chiang, 2004) [83] in HepG2 
cells, emphasizing the vital role of the TATTA cis-element in APOH transcription. 
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Figure 54. APOH 5´deletion analysis  
From Wang and Chiang, 2004, [83]. Luciferase (LUC) reporter gene driven by the human 
APOH promoter and the relative luciferase activities. The 5´-ends of these constructs were 
numbered in base pairs relative to the β2 -GPI transcription start site, and the putative cis-
elements are indicated at the top. (A) The reporter constructs containing sequentially deleted 5´-
flanking fragments were cloned and transiently transfected into Huh7 and HepG2 cells. Results 
are expressed as the means ± S.D. for at least two independent experiments performed in 
triplicate. 
 
 
Potential liver-specific transcription factor–binding sites within the 5'-flanking DNA 
sequence of the human APOH were identified by using MatInspector program from Genomatrix 
software (http://www.genomatix.de/index.html); [184] which locates matches by comparing 
DNA sequences with weighted matrix descriptions of functional binding sites, based on the 
TRANSFAC database (http://www.biobase.de). The results of these searches have been 
compiled, and the putative sites for transcription factors are displayed in Figures 55 and 56 and 
Table 56. 
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AGTGGCAGCA CACTCTTCTT ATCATGGAAC ACAATGTTCA TTAGGATCGT 50
                                                                                    V$CEBP 
                             79---------------93   99- 
AATTTAAGAA TCATCTGCCT GACAGATGGA GATTTCTCAA GCTGATG (-1284C>G) TGT 100 
      V$NR2F, V$NF1F,  V$FKHD,  O$VTBP                  O$INRE 
-------------------------------------137 139-------149 
CTCAGGGAAT TTTAGACCTC TGGATATAAA CCAAGATCAC CCAAATGAGA 150 
                                  V$CLOX 
               V$HNF1 165----------------------------- 
       159-----------------175 
GCAAGC GAG GTTATTTATT CAGAGCTTGC TATAG AAGG GAGGCAGCCA 200 
V$HNF1
G G (-1219G>A; 1190G>C) 
, V$CLOX, V$NF1F, V$HNF6 
------------------------------------------238     250- 
TTAACAGTTG TGTTTGGCAG AGACTCAAAG TCAAAGTCAG ACAGAGGAGT 250 
       O$VTBP          
----------------266                 286--------------- 
GGGAAAGCTT TATAATAGAA AAAAGGAAAG GCTTCAGGTG TGCTCCAAC 0 
V$CLOX
G 30 (-1076G>A) 
 
------308                                      345----
GATTGTTGGT ATGGGGAGGA GGAAGGAAA CTAACTAGAA GTGAGGTGTC 350 
     
       V$CLOX
 
 T (-1055T>G) 
 
------------------367                           398--- 
CATGTGATTG GTTAGAGAAA TATGTTTGGA TTTCTCTGGT TGGCCTTAAG 400 
     V$CLOX 
-----------------420 
 
TTGGGCCAAC TGCTATAGAG GTTGTAGGTT TGGCTTTCTA GACCTGTTGC 450 
        V$RXRF, V$PERO, V$NR2F, V$FKHD, O$VTBP, O$VTBP,   
453--------------------------------------------------- 
TACAGATGTG TGGGTCAGAG TTCTGTTTTC ACATATGGCC TGGCTATTGT 500 
  O$PTBP, O$PTBP 
---------------514 
 
CCATTTATAT ATCCTTTTTT TTTTTTTTAG AGCAAATGAT GTAGAAGAGA 550 
                    V$EKLF 
           564----------------580 
 
ACTAGGGAAT CAAAGACAAC CCCCCTTCCG AACCCTCTCA AGCAACAACA 600 
 
TCAGCACTGG CCCATT T TATCCTACTC AAG TTTTT TTTCTTCTTC 650 
                V$CLOX
ATC TT (-759A>G; -742delT) 
, V$HNF6, V$CLOX 
           662--------------------------689 
 
GAGTCCCAAG TTGTTAATTT CAAAT TT TTCAAATTCC TGAAACAGAT 700 CAA (-700C>A) 
                                V$CLOX, V$NR2F, V$CLOX, 
                            727----------------------- 
CTAGAAACCT GTCTAGACAG ATCCAAGACA TA AAGAAT GGATGAGG  750 
V$RXRF
TT AG (-643T>C; -627A>C) 
, V$CLOX, V$PARF, V$CEBP                V$RXRF 
--------------------------775           788---------- 
 
GACTTTGTAT TGATCTGACG TAAGAGAAGA TAGAGAATTC AAGG GCT 800 
       V$NR2F
ATA (-581A>C) 
 
--------------814 
 
CTAAGGTCCT AACTGGAGCT ATAGGAGCTT GCAAGAGAGG ATGTTGAGCT 850 
 
CAGTTTGTAG GGAATTAAAG TTGTAAGTGC CTCCTGGAAG ACATTCTTTG 900 
                             O$VTBP,  
 
Figure 55. (Continued Below) 
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                              O$VTBP, 
                      922----------------------------- 
TAATTATACA TCTGAAAACT GGAACATCAT TTTAGAGAGG TGGAGACTGA 950 
             V$NR2F, O$VTBP, V$FKHD 
--------------------------------------986 
GAACAGAGAG TAGGTGTTTG TCCAAAGTTT ATATGCCAAG GCTGTGAGTG 1000 
 
AAACAGGAGC TTCGA (-363C>T) TCTTT TGGTGTTCCA TCTACAACAT ACACAAAACA 1050 
                                   V$FKHD 
                         1077-----------------1093 
 
AAAGATGGAG AATGAGAAGT CCAGGCAACC CCGGAAACAA CAAGTTTCTG 1100 
          V$CLOX, V$CLOX                   V$FKHD 
  1104----------------------1128    1135-------------- 
TCAAAAGCAA TAATGAACTG TTTTGTGCCA TTAACAAAAA CGTTATGAAG 1150 
                 V$PARF, V$PARF, V$CEBP 
-1151         1166------------------1183       1196--- 
ACAGAAACCA TCTCCCAAAG ATTTCATAAC AGAGCCACAT AAGTGGAAAG 1200 
V$HNF1, V$HNF1 
--------------1214 
TAAATGATTA AAGAATGTGG GTCTCAGAGT TCCATTCAAA TCATGATACT 1250 
                       V$NR2F                  V$HNF1, 
      V$FKHD 1261------------------1285  1289--------- 
1253--------------1269 
TTATCTTCTA TTTACAAAGA TAAAAGTACA CCAGAAAATG GTTAATGTTT 1300 
V$FKHD, O$VTBP 
--------1308 
AAGCGCTTTC ATATTTGGCT CTGTCTTTTT AGCAGAC  AAC ACTTTG 1350 
                              V$CLOX
GAA C (-38G>A; -32C>A) 
 
                      1371-------------------1393 
GTAGTGCCAG TGTGACTCAT CCACAATGAT TTCTCCAGTG CTCATCTTGT 1400 
 
TCTCGAGTTT TCTCTGCC 1418 
 
Figure 55. Liver-specific transcription factor binding sites for the APOH promoter 
As determined by the TRANSFAC and Matinspector databases. The start of the coding  
region (ATG) is highlighted in green. 
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Two critical cis-factors for APOH basal transcription [hepatic nuclear factor1 (HNF1) and 
vertebrate TATA binding factor (VTBP)] 
 
Figure 56. Schematic graphical representation of liver-specific transcription factors 
From MatInspecter, Genomatix 
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Table 56. MatInspector output for liver-specific transcription factors of APOH promoter  
 Family Further Information Start pos. End pos. Strand Sequence
V$CEBP Ccaat/Enhancer Binding Protein 79 93 - cagcttgaGAAAtct
V$NR2F Nuclear receptor subfamily 2 factors 99 123 - tccagaggtctAAAAttccctgaga
V$NF1F Nuclear factor 1 116 136 - atcTTGGtttatatccagagg
V$FKHD Fork head domain factors 120 136 + tggataTAAAccaagat
O$VTBP Vertebrate TATA binding protein factor 121 137 + ggataTAAAccaagatc
O$INRE Core promoter initiator elements 139 149 - tcTCATttggg
V$HNF1 Hepatic Nuclear Factor 1 159 175 + gGTTAtttattcagagc
V$CLOX CLOX and CLOX homology (CDP) factors 165 187 + ttattcagagcttgctATAGgaa
V$HNF1 Hepatic Nuclear Factor 1 189 205 - tGTTAatggctgcctcc
V$CLOX CLOX and CLOX homology (CDP) factors 194 216 - ccaaacacaactgttaATGGctg
V$NF1F Nuclear factor 1 210 230 - actttgagtctctGCCAaaca
V$HNF6 Onecut homeodomain factor HNF6 222 238 + actcaaagTCAAagtca
O$VTBP Vertebrate TATA binding protein factor 250 266 - tattaTAAAgctttccc
V$CLOX CLOX and CLOX homology (CDP) factors 286 308 - ccaaCAATccgttggagcacacc
V$CLOX CLOX and CLOX homology (CDP) factors 345 367 - tctctaacCAATcacatggacac
V$CLOX CLOX and CLOX homology (CDP) factors 398 420 + agttgggccaactgctATAGagg
V$RXRF RXR heterodimer binding sites 453 477 + agatgtgtgggtcagaGTTCtgttt
V$PERO Peroxisome proliferator-activated receptor 454 476 + gatgtgtgggtcagAGTTctgtt
V$NR2F Nuclear receptor subfamily 2 factors 455 479 + atgtgtgggtcagAGTTctgttttc
V$FKHD Fork head domain factors 468 484 - tatgtgaaAACAgaact
O$VTBP Vertebrate TATA binding protein factor 495 511 - atataTAAAtggacaat
O$VTBP Vertebrate TATA binding protein factor 497 513 - ggataTATAaatggaca
O$PTBP Plant TATA binding protein factor 498 512 - gataTATAaatggac
O$PTBP Plant TATA binding protein factor 500 514 - aggaTATAtaaatgg
V$EKLF Basic and erythroid krueppel like factors 564 580 - tcggaaGGGGggttgtc
V$CLOX CLOX and CLOX homology (CDP) factors 662 684 - ttgaaaattGATTtgaaattaac
V$HNF6 Onecut homeodomain factor HNF6 666 682 + atttcaaaTCAAttttc
V$CLOX CLOX and CLOX homology (CDP) factors 667 689 + tttcaaATCAattttcaaattcc
V$CLOX CLOX and CLOX homology (CDP) factors 727 749 - ctcctcATCCattcttaatatgt
V$NR2F Nuclear receptor subfamily 2 factors 742 766 - cagatcaatacAAAGtcctcctcat
V$CLOX CLOX and CLOX homology (CDP) factors 747 769 - cgtcagATCAatacaaagtcctc
V$RXRF RXR heterodimer binding sites 751 775 - ctcttaCGTCagatcaatacaaagt
V$CLOX CLOX and CLOX homology (CDP) factors 752 774 + ctttgtattGATCtgacgtaaga
V$PARF PAR/bZIP family 760 776 + tgatctgacGTAAgaga
V$CEBP Ccaat/Enhancer Binding Protein 761 775 + gatctgacGTAAgag
V$RXRF RXR heterodimer binding sites 788 812 + tcaaggataGCTCtaaggtcctaac
V$NR2F Nuclear receptor subfamily 2 factors 790 814 + aaggatagctctaAGGTcctaactg
O$VTBP Vertebrate TATA binding protein factor 922 938 - ctctcTAAAatgatgtt
V$NR2F Nuclear receptor subfamily 2 factors 962 986 + ggtgtttgtcCAAAgtttatatgcc
O$VTBP Vertebrate TATA binding protein factor 969 985 - gcataTAAActttggac
V$FKHD Fork head domain factors 970 986 - ggcataTAAActttgga
V$FKHD Fork head domain factors 1077 1093 + accccggaAACAacaag
V$CLOX CLOX and CLOX homology (CDP) factors 1104 1126 - cacaaaacagttcattATTGctt
V$CLOX CLOX and CLOX homology (CDP) factors 1106 1128 + gcaaTAATgaactgttttgtgcc
V$FKHD Fork head domain factors 1135 1151 - gtcttcATAAcgttttt
V$PARF PAR/bZIP family 1166 1182 + aaagaTTTCataacaga
V$PARF PAR/bZIP family 1167 1183 - ctctgTTATgaaatctt
V$CEBP Ccaat/Enhancer Binding Protein 1168 1182 - tctgttatGAAAtct
V$HNF1 Hepatic Nuclear Factor 1 1196 1212 - cTTTAatcatttacttt
V$HNF1 Hepatic Nuclear Factor 1 1198 1214 + agtAAATgattaaagaa
V$FKHD Fork head domain factors 1253 1269 - tctttgtaAATAgaaga
V$NR2F Nuclear receptor subfamily 2 factors 1261 1285 + ttacaaagataAAAGtacaccagaa
V$HNF1 Hepatic Nuclear Factor 1 1289 1305 + gGTTAatgtttaagcgc
V$FKHD Fork head domain factors 1290 1306 - agcgctTAAAcattaac
O$VTBP Vertebrate TATA binding protein factor 1292 1308 + taatgttTAAGcgcttt
V$CLOX CLOX and CLOX homology (CDP) factors 1371 1393 - tgagcactggagaaATCAttgtg
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7.2 FUNCTIONAL CHARACTERIZATION OF APOH PROMOTER SNPS 
SNPs that are located within coding regions and result in a change in the peptide sequence may 
be classified as 'damaging' or 'altering' if predicted to be in structurally or functionally important 
sites of the three dimensional structure of the protein. However, it is less straightforward to 
predict the functional importance of SNPs within regulatory regions (regulatory SNPs or rSNPs), 
such as promoters, enhancers, and silencers [185]. Allelic differences in expression of genes due 
to common polymorphisms in 5' regulatory regions could equally elucidate gene function as the 
examination of non-synonymous SNPs in coding regions [186]. As many as 35% of promoter 
SNPs may be of functional significance [163]. There are numerous examples of rSNPs 
associated with disease susceptibility, including hypercholesterolemia, hyperbilirubinemia, 
myocardial infarction, acute lung injury , and asthma [185]. 
In this study we “functionally” validated SNPs in the APOH promoter based on two 
experimental approaches (reporter assays and EMSA). For this purpose, we tested 12 SNPs 
located within the 1,418 bp of the 5'-flanking region of APOH for allele-specific regulatory 
effects on expression of the luciferase reporter gene and by EMSA for SNPs within TFBS, which 
could potentially influence the kinetics of binding affinity. 
Potential regulatory activities (promoter, enhancer or silencer) of a putative regulatory 
sequence, and the effect of a particular change caused by alleles of the APOH promoter SNPs, 
were studied using dual-luciferase reporter gene assays (Promega). Fragments of DNA carrying 
alleles of the APOH promoter SNPs were cloned into a promoter-less pGL-3 basic reporter gene 
vector carrying a weak promoter. Different allelic constructs, together with a control plasmid 
(pRL_TK; Renilla luciferase) used for normalization of the efficiency of transfection, were 
transiently transfected into COS-1 cell lines. The level of reporter gene expression was evaluated 
 168 
for both alleles of the SNPs and compared with the expression of the empty promoterless pGL3-
basic vector. An increase or decrease in reporter gene expression caused by one of the alleles 
will help demonstrate that the allele is affecting the activity of the regulatory elements in the 
promoter region. Out of the 12 SNPs examined three SNPs at positions −1219A, −643C and -
32A showed a significantly stronger reduction of luciferase expression (~50%, ~40% and ~36%, 
respectively) than the wildtype -1219G, -643T, and -32C alleles in COS-1 cells. Although, the 
5´- serial deletion of APOH promoter identified the basal transcriptional activity restricted to the 
regions ~160 bp upstream of ATG codon, one cannot exclude the possibility of the functional 
roles of the -643T>C and -1219G>A SNPs as part of the extended APOH promoter 
transcriptional machinery. The -32C>A SNP is a part of the core APOH promoter region (-166 
bp upstream from ATG) identified in this study and has been previously shown to play a key role 
in the transcription initiation process by serving as a site for the binding of transcription factor II 
D TFIID factor [115]. 
To confirm our hypothesis that the APOH promoter SNPs are  involved in binding with a 
transcription factor, we constructed wild type and mutant type oligos for each SNP and examined 
their binding with nuclear extracts of HepG2 cells. Our EMSA results for five of the SNPs 
examined (-1284C>G, -1219G>A, -1190G>C, -643T>C and -1076G>A) showed binding of 
transcription factor(s) for both wild-type and mutant-type oligos for all SNPs with no differential 
binding for the two alleles.  
In silico analysis (Figure 57) using MatInspector program from genomatrix for the 
prediction of liver-specific TFBS was done for two of the potentially “functional” SNPs, -
1219G>A and -643T>C SNPs that showed both a significant effect in the dual-luciferase assay, 
as well as positive binding to TFs in EMSA using HepG2 nuclear cell extracts. For the -
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1219G>A SNP, the results indicated the binding of an important liver-enriched transcription 
factor, HNF1, adjacent to the polymorphic site which could explain for the functional relevance 
of this SNP. HNF1 plays a prominent role in regulating genes that are expressed in hepatocytes 
[187]. The -643T>C SNP region binds to CLOX and CLOX homology CCAAT displacement 
protein (CDP) factors, that have been previously reported as transcriptional repressors [188]. 
This could probably explain the decrease in reporter gene expression seen by variant allele at this 
SNP.  
EMSA results previously reported by Mehdi et al. (2003) [116] have revealed that the  -
32C>A SNP disrupts the binding of crude mouse hepatic nuclear extracts and purified TFIID, 
which is part of the RNA polymerase II preinitiation complex, indicating its functional role in the 
transcriptional regulation of APOH promoter. However, in silico analysis using MatInspector 
program for liver-specific factors did not identify any liver-specific transcription factor to bind to 
the region including the -32C>A SNP; which is also consistent to what is reported in the 
previous study by Wang and Chiang (2004) [83]. 
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-1219G>A (HNF1-hepatic nuclear factor1)
 
 
 
 
 
                                                -643T>C (CLOX and CLOX homology CCAAT displacement 
protein (CDP) factors; CDP cut-like homeodomain protein, transcriptional repressor) 
 
Figure 57. MatInspector predictions for the potentially “functional” APOH promoter SNPs 
Hepatic nuclear factor1    
          
CLOX and CLOX homology CCAAT displacement protein (CDP) factors 
 
Vertebrate TATA binding factor 
 
 Fork head domain factors 
 
 
By combining in silico and experimental approaches, this study provides evidence that 
the polymorphic sites at positions -1219G>A and -643T>C in addition to the previously reported  
-32C>A SNP [116] in the APOH promoter may be functionally important.  
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7.3 ASSOCIATION OF APOH PROMOTER SNPS WITH SLE AND SLE-RELATED     
PHENOTYPES 
Because of the important role of β2GPI in the production of APA and the observation that β2GPI-
mediated immune response in patients with autoimmune diseases may lead to atherosclerosis 
[127], it is important to understand the role of APOH genetic variation in relation to autoimmune 
diseases and associated premature CVD. A priori, one might expect that genetic variation in 
elements which control APOH expression (promoter region) can be associated with the disease 
risk. Promoter sequences are potential sources of polymorphisms affecting gene expression and 
phenotypic variation [163]. Promoter variants may potentially alter the affinities of existing 
protein-DNA interactions or recruit new proteins to bind to the DNA, altering the specificity and 
kinetics of the transcription process. To our knowledge, this is the first study to evaluate the role 
of APOH promoter SNPs in relation to SLE and related phenotypes, including lupus nephritis 
and subclinical CVD. 
Numerous epidemiological studies have implicated differences in gender, race, 
ethnic/national origin on SLE incidence and prevalence [35]. Studies of racial tendencies showed 
that SLE is more frequent in more frequent in African Americans than in Caucasians in USA 
[32]. SLE occurrence is three to four times higher among African-American women compared to 
Caucasian women. Given the ethnic differences, this study examined the APOH promoter SNPs 
for racial differences between the white (n =799) and black (n = 90) population-based registry of 
SLE patients in Pittsburgh area. The genotypes of two APOH SNPs (-759A>G and -700C>A), in 
strong LD, significantly differed for both genotype and allele frequency distribution between the 
two ancestry groups.  
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Our study revealed a significant association for the -643T>C SNP with SLE risk in the 
Pittsburgh sample (P = 0.014). However, this association was not confirmed in a second 
relatively small sample from Chicago (P = 0.919). The significance level decreased in the 
combined Pittsburgh + Chicago sample (P = 0.025) compared to the Pittsburgh sample despite 
increase in the sample size and power. This suggests that either the effect of the -643T>C SNP 
on SLE risk is small, which is difficult to reproduce in all samples or this association is due to 
chance. The latter assumption was confirmed in the haplotype analysis where one haplotype that 
carried the defining -643C allele (H3 haplotype in Table 16) was not associated with SLE risk. 
On the other hand, our six-site haplotype analysis yielded a significant difference in overall 
haplotype distribution between SLE cases and controls (P = 0.009). The haplotype (H7 
haplotype) with the most striking difference between cases and controls (P = 1.21 x 10-5) had a 
frequency of less than 2% in the total sample suggesting that only a small number of individuals 
were predicted to carry this haplotype. Notably, while no example of this haplotype was 
observed in 888 control chromosomes based on EH program, 4.5% of the patients carried this 
haplotype. H7 haplotype was not defined by a particular allele, although it carried the minor 
alleles for three APOH promoter SNPs (-643T>C, -1190G>C and -759A>G).  The minor alleles 
at these three SNPs do not appear to be causative, as the presence of the -643C allele in H3 
haplotype alone or the presence of the -1190C and -759G alleles together in H2 and H5 
haplotypes did not demonstrate significant association. It appears that the simultaneous presence 
of these three alleles affect the risk of SLE in an additive fashion as demonstrated by the H7 
haplotype. The apparently additive effects of these alleles were also obvious in the gene 
expression assay where the H7 haplotype was associated with greatest effect on luciferase 
activity. Alternatively, the unique H7 haplotype may be a marker for a functional variant present 
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in APOH or a nearby gene. Sequencing of the individuals who carry the haplotype H7 may help 
to identify putative functional variant(s).  
The -643T>C SNP showed convincing association with the presence of carotid plaque 
among SLE patients as it was found to be associated in two independent samples from Pittsburgh 
and Chicago. In the combined Pittsburgh + Chicago SLE sample the association was more 
significant than observed in individual samples from each site (adjusted OR = 0.35, P = 0.002). 
The accumulation of oxLDL is believed to initiate the process of atherosclerosis and β2GPI is 
known to inhibit the uptake of oxLDL by macrophages in vitro while it promotes the influx of 
oxLDL in the presence of APA. Several lines of evidence suggest that autoimmune vascular 
inflammation and oxidative stress may promote the formation of oxLDL/ β2GPI complexes in 
the arterial wall as seen in SLE and APS patients (Matsuura et al. 2006). Since many SLE 
patients are positive for APA, it is likely that low β2GPI expression associated with the -643C 
allele may retard the influx of oxLDL to macrophages in the presence of APA and thus provide 
protection against plaque formation (Figure 58). Alternatively, there may be another mechanism 
underlying the effect of -643C allele on carotid plaque formation or it may simply be in strong 
LD with another variant, especially given that another APOH promoter variant (-32A allele), 
which is also associated with low APOH expression, was associated with increased risk for 
carotid plaque after adjusting for covariates (OR = 2.63, P = 0.031). Additional studies in large 
data sets may help to delineate the role of APOH promoter SNPs in relation to carotid plaque 
formation. 
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 Figure 58. Proposed mechanism of APOH -643T>C SNP and carotid plaque protection 
Renal disease is a major cause of morbidity in SLE patients. Some studies reported an 
increased production of APA in patients with Lupus nephritis, including anti-β2GPI and anti-
oxLDL [157, 189, 190]. We found that -1219G>A SNP may potentially affect the lupus nephritis 
risk both in single-site (P = 0.019) and in multiple regression (P = 0.014) with a age-adjusted OR 
= 0.36, P = 0.016 and this effect seems to be independent from APA occurrence given that this 
SNP did not show significant association with any of the APA examined in our sample. Rather, 
we found significant association of the -38G>A SNP with the occurrence of APA (P = 4.57 x 10-
4), aCL (P = 0.018), LAC (P = 0.001) and anti-β2GPI (P = 0.002) in SLE cases but not in 
controls using multiple regression under dominant model. It is possible that the -38G>A SNP 
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may be interacting with other factors that are involved in SLE etiopathogenesis to show its effect 
on APA in an autoimmune background. It is reasonable to expect that some factors would 
specifically show their effects on APA in association with disease status, thus contributing to the 
increased prevalence of APA in patients with autoimmune diseases as compared to the general 
population. Alternatively, the APOH variants may have modest effects on the occurrence of APA 
which may be difficult to reproduce in all samples. Finally, given the very low MAF of -38G>A 
SNP, we cannot exclude the possibility of its spurious association. 
The power for most of the examined SNPs in this study was adequate to detect SLE 
disease- related risk. For four SNPs (-1190G>C, -759 A>G, - 700C>A, -643T>C), we had 80% 
power to detect ORs between 1.50 and 1.55. For the -1219G>A and -32C>A SNPs, we had 80% 
power to detect an OR of 1.61 and 1.75, respectively. The power for the less common SNPs (-
1284C>G and -38G>A) with MAF < 0.05 was low. 
 
7.4 ASSOCIATION OF APOH PROMOTER SNPS WITH PLASMA Β2GPI LEVELS 
The regulatory promoter and expression of APOH at both the transcriptional and translational 
levels have not been fully characterized. The purpose of this study, in addition to, characterizing 
the basal APOH promoter and its functional variants, was also to establish the links between 
APOH promoter activity, gene expression and plasma β2GPI levels that were available for a 
subgroup of the Pittsburgh white population (SLE cases, n = 241; and controls, n = 206). Since 
there was no observed difference between SLE patients and control subjects concerning both the 
mean and the distribution of the plasma β2GPI levels, all analyses were done using the pooled 
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data combining both SLE patients and control subjects adjusted for disease status, age, BMI, 
smoking covariates. In univariate analysis, only the previously reported -32C>A APOH promoter 
SNP showed a significant effect after adjustment for covariates. None of the other APOH 
promoter SNPs used in this study had a significant effect on plasma β2GPI levels. Using genetic 
association analysis and conventional genotype-phenotype analysis this study suggests a role for 
the -643T>C polymorphism in protection from formation of carotid plaque and therefore 
autoimmune-mediated atherosclerosis in SLE patients and also for the -1219G>A SNP having a 
moderate effect on lupus nephritis.  Functional role for the two SNPs was established using 
promoter reporter technology and EMSA. Having demonstrated that the two polymorphisms do 
have a functional effect on gene expression, there are legitimate grounds to question whether 
these polymorphisms could have an effect on plasma β2GPI levels. Although in vitro luciferase 
assays measuring promoter activity suggest that the two polymorphisms show an effect on gene 
expression, this may not entirely be a true reflection of the complexity of regulation that occurs 
in vivo. The regulation of human gene expression is a critical, highly coordinated, and complex 
process. The core promoter is generally within 50 bp of the transcription start site (TSS), where 
the preinitiation complex forms and the general transcription machinery assembles. The extended 
promoter can contain specific regulatory sequences that control spatial and temporal expression 
of the downstream gene. The transcription machinery, which consists of interconnected co-
regulatory protein complexes in a regulatory network, is responsible for mRNA synthesis from a 
given promoter. Control of gene regulation could occur at various stages, including level of 
transcription, post-transcriptional regulation, alternative splicing, translation, post-translational 
modifications and secretion of β2GPI, all of which may have an effect on the quantitative 
measure of plasma β2GPI levels. Alternatively, it is also possible that a change in promoter 
 177 
activity does not necessarily results in a quantitative change at protein level. Whether the APOH 
promoter SNPs (-643T>C and -1219G>A) could influence the promoter activity by either the 
former or latter methods is beyond the scope of in vitro experiments. Further studies will be 
needed to explore the mechanism for these associations. APOH promoter SNPs explain a small 
proportion of the variance in APOH expression, thus the ability of these SNPs to influence 
plasma β2GPI levels may be obscured by the strong effects of other factors (other genetic loci 
which are in strong LD with the promoter SNPs  and other regulatory factors that affect in vivo 
gene expression) in aggregate. However, given the reporter gene expression data on promoter 
activity and EMSA results indicating the binding to transcription factors , there is clearly a 
functional effect of the two polymorphisms on APOH regulation that are worthy of further 
investigation.  
Haplotype analysis including APOH promoter SNPs and previously known coding SNPs 
affecting plasma β2GPI levels (Cys306Gly and Trp316Ser) gave us no new insights into 
determining the genetic basis of plasma β2GPI levels. The significant haplotypes were defined 
predominantly by the minor alleles at the coding SNPs, which are already known to have an 
effect. Consistent with the univariate data, none of the haplotypes defined by the minor alleles at 
APOH promoter SNPs reached significance. Although the -32C>A SNP was significant in the 
univariate analysis, the individual haplotype (H7) harboring the minor allele -32A was not 
significant, indicating that the effect of the -32C>A SNP is dependent upon the presence of the 
Trp316Ser coding SNP, which is in strong LD with the -32C>A SNP as shown in haplotype 
(H5). Three-site haplotype analysis with only the APOH promoter functionally relevant SNPs (-
643T>C, -1219G>A and -32C>A) showed a highly significant effect for haplotype (H3) defined 
by the -32A allele and also a moderate effect for the -1219A allele (H2). Another questionable 
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mechanism for the lack of association of APOH promoter SNPs on plasma β2GPI levels in this 
study is the modified capture-ELISA method that was used to determine the plasma β2GPI 
levels, wherein, the analyzed antibodies could have been targeted against only a small number of 
the antigenic sites in β2GPI.  
Therefore, given both the limitation of the method and also the small sample size, further 
studies are warranted in larger cohorts using improvised methods (antibody titers are measured 
against other/additional β2GPI) that will help better to delineate the molecular basis of plasma 
β2GPI levels. 
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8.0  CONCLUSIONS 
The present study has shown that the APOH promoter is characterized by the presence of two 
key cis-elements (atypical TATTA box and hepatic nuclear factor 1 (HNF-1). Although further 
studies are required to better define the molecular mechanisms controlling the specific 
expression of the APOH, our findings are in agreement with a previous study (Wang and Chiang, 
2004) [83]suggesting that the region encompassing ~160 bp upstream of the ATG codon contain 
all the elements necessary to confer the basal tissue-specific transcriptional regulation of the 
APOH.  
In vitro evidence revealed functional relevance for three of the APOH promoter SNPs at 
positions -1219G>A, -643T>C and -32C>A that resulted in lower promoter activity (51%, 40% 
and 37%, respectively) as compared to the respective wild-type alleles. This conclusion was 
further supported by using EMSA that demonstrated HepG2 nuclear protein(s) bind to the 
elements located in the regions of the three SNPs (-1219G>A, -643T>C and -32C>A ) of the 
APOH promoter. Competition assays reflected on the relative stability and specificity of the 
formed DNA-protein complex. 
We present evidence that individual APOH promoter SNPs as well as haplotypes may be 
involved in the etiology of SLE and especially the risk for autoimmune-mediated CVD.  Our 
results merit further investigation of APOH in independent large SLE case-control samples with 
subclinical phenotype information. 
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Except the -32C>A SNP, none of the APOH promoter SNPs showed a significant effect 
on plasma β2GPI levels in univariate analysis. Three-site haplotype analysis (-643T>C, -
1219G>A and -32C>A SNPs) showed a highly significant effect for haplotype defined by the -
32A allele and also a moderate effect for the -1219A allele. Molecular characterization of the 
APOH promoter SNP haplotypes will help to further delineate the molecular basis of plasma 
β2GPI levels and to understand the functional role of APOH in various pathological pathways, 
thereby, contributing to future therapeutic strategies. Further confirmation, in additional studies 
and in-depth molecular experiments, are needed to determine the functional basis for these 
effects. 
 
 
 
 
 
 
 181 
9.0  PUBLIC HEALTH SIGNIFICANCE  
With cardiovascular-related disorders accounting for the highest mortality rates in the world, 
affecting the quantity and quality of life of patients and creating an economic burden of 
prolonged therapeutic intervention, there is great significance in understanding the cellular and 
molecular alterations that influence the progression of these pathologies. The turn of the 21st 
century is considered in medicine to mark the beginning of a “Golden Age” of American 
cardiovascular medicine and health. Despite the pharmacological and technological advances, 
CVD is still by far the leading cause of death and disability in the United States. There still 
remain several challenges in understanding the CVD epidemic burden.  
Given the strong evidence for genetic factors in affecting SLE susceptibility and high 
mortality rates of CVD seen in SLE patients, identifying genetic variants will benefit patients 
through improved clinical management and help develop better preventive strategies.  
This is an                important study that provides evidence for individual APOH promoter SNPs as 
well ashaplotypes may be involved in the etiology of SLE and especially the risk for 
autoimmune-mediated CVD. Systemic inflammation serves as a pivotal link between 
cardiovascular events and autoimmune diseases such as SLE and APS. One of the highlights 
of this research is the significant association of an APOH promoter variant -643T>C with 
autoimmune-mediated atherosclerosis. This study provides a mechanistic framework to 
better understand the pathogenesis involved in autoimmune-mediated atherosclerosis that will
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DLGLQVXEVWDQWLDWLQJWKHcurrent existing knowledge about the CVD epidemic. The clinical benefits 
of this knowledge willhelp in formulating newer therapeutic strategies using anti-inflammatory 
drugs that will allow for a better control of inflammation, individual risk assessment and treatment 
that may decrease the adverse consequences of accelerated atherosclerosis in this SLE patient 
population. 
To gain a better understanding in the molecular mechanisms controlling the 
transcriptional regulation of human APOH expression that will help to delineate the molecular 
and functional role of β2GPI implicated in several physiologic pathways, including lipid 
metabolism, coagulation, and the production of antiphospholipid antibodies, this study focuses 
on the functional characterization of APOH promoter variants and its putative cis-regulatory 
elements present in the cloned 1.4-kb genomic fragment of the 5´-flanking region of human 
APOH.  
The primary impetus of this research project is to stimulate more and better research 
directed towards the illumination of the molecular and functional role of β2GPI in normal health 
and in the pathogenesis of autoimmune diseases such as SLE. 
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